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ABSTRACT 
 
Chapter 1 provides a brief introduction to colorectal cancer (CRC), methods of detection, photodynamic 
therapy (PDT), and EGFR as an attractive targeting strategy for imaging CRC. 
Chapter 2 details the synthesis of ten peptide sequences for targeting EGFR receptors at the site of CRC, as 
a collaborative work with Dr. Seetharama Jois. This chapter also investigates the efficacy of these peptides 
for EGFR.  
Chapter 3 offers the first synthetic strategy for developing BODIPY-peptide conjugates via amide linkages. 
All conjugates were optimized for the best reaction conditions and good yields were observed. Each 
conjugate was subjected to photophysical, SPR, and characterization studies. Cell studies obtained by Mrs. 
Zehua Zhou suggesting the conjugate bearing the hydrophobic peptide sequence had a greater cellular 
uptake then compared to conjugates containing a charged peptide sequence.  
Chapter 4 details the conjugation strategy via NCS- chemistry. NCS-BODIPY dyes were conjugated to two 
pegylated peptides. These conjugates were synthesized in 30 minutes with excellent yields. Tests 
administered by Mrs. Zehua Zhou determined the conjugates to have low dark and phototoxicity to human 
carcinoma HEp2 cells over-expressing EGFR, and to be taken up in to cells efficiently. 
 
Chapter 5 discusses the conjugation of BODIPY dyes and peptides via click chemistry to build peptide-
BODIPY conjugates with cyclic or linear peptide sequences. The conjugates were synthesized efficiently 
in 24 hours with great yields and minimal side products were observed. Preliminary cell studies suggest 
conjugates bearing mono-styryl group were  
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CHAPTER 1.  Introduction to methods of targeting Colorectal Cancer for In Vivo Imaging 
1.1 Colorectal Cancer (CRC) 
 
 
 Cancer remains one of the most challenging ailments to cure in the world due to its genetic 
variability, effects, and symptoms. Colorectal cancer (CRC), also known as colon cancer, rectal cancer, or 
bowel cancer, is the third most common cancer diagnosed in both men and women when reviewed 
separately in the United States.1 In 2017, The American Cancer Society (ACS) estimated that there would 
be 95,520 new cases of colon cancer, and 39,910 new cases of rectal cancer. CRC is expected to cause 
nearly 50,260 deaths in the year 2017. Commonly, the lifetime risk of developing CRC is about 1 in 22.1 
However, the ratio of obtaining CRC is marginally lower in women than in men. Recent studies have 
suggested that CRC age specificity is now rising as previously seen with patients who were born around 
the 1890s.2 These studies suggest a probability of births occurring in 1990 doubling the amount of patients 
who will be affected by colon cancer and quadrupling those affected by rectal cancer.2  
Over time, many simple life factors have been associated with colorectal cancer. Research ties diet, 
weight, and exercise together to compare against colorectal cancer risk. The results show that the 
correlations are strongly matched when compared to other cancers.3 Generally, if you are a person who is 
heavily overweight or obese the risk factors for developing CRC are greater, with the odds leading in men 
over women. People, who are lethargic throughout the day, prefer a meal with considerable amounts of red 
meat, and prefer meat cooked at high temperatures have a greater chance in developing CRC.4 ACS suggests 
the more active you are, having a diet high in vegetables, fruit and whole grains, the better your chances 
are at prevention of CRC.5  
 The mortality rate from CRC has continually decreased in both men and women for over 20 years. 
There is a sum of likely reasons for this such as an increase in dieting, exercising, and changed lifestyle 
may be the cause, however, the most important reason is due to screening.5 As seen with dieting, people 
who use tobacco products and indulge in frequent alcoholic beverages are at an increased risk for colorectal 
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cancer.5 All these factors are adaptable and can be altered to reduce the risks of obtaining CRC, however 
certain factors are inescapable and affect people every day. 
 Factors such as old age amplifies your chances of obtaining CRC, however certain diseases and 
syndromes have been known to lead to CRC. Diseases such as Crohn’s disease or inherited syndromes such 
as Lynch syndrome have shown increased connection to CRC.6 In fact, inherited syndromes have shown to 
make up 5 to 10 percent of the population living with CRC.5 Like any other cancer or disease having a 
family history of adenomatous polyps, or CRC, puts you at a higher risk of development, however early 
screening can aid in treatment and longevity.   
 Patients that are partaking in early screening are aiding in the fight against CRC. Polyps are being 
found by screening, and removed before they can develop into cancers.7 Early screening is also permitting 
more CRCs to be discovered earlier when the disease is easier to cure and free from metastatic behavior. In 
addition, treatment for CRC has enhanced over the last several years. As a result, there are now more than 
1 million survivors of CRC in the United States.1  
 Generally, CRC occurs when cells that line the colon or rectum become abnormal and grow in 
extreme measures (Figure 1). The colon, is a connection that extends six feet long that connects the small 
intestine directly to the rectum. The colon is a highly functional portion of the body in which waste is 
managed and water removal occurs to store the stool in a dry form. The stool is then removed from the 
colon once or twice a day and passed down to the rectum to be excreted from the body. The rectum is much 
smaller in size averaging around eight inches, and is also a connection similar to the colon extending from 
the colon to the anus. The rectum has a unique job of primarily collecting dried stool from the colon, 
notifying the body that there is waste that is ready to be removed, and to act as a holding area of collected 
stool until removal. The colon and rectum collectively makeup the large intestine, and cancer formation in 
either is termed “colorectal cancer” or CRC.  
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Figure 1. Progression of polyp to cancer in CRC.8 
 The evolution of uncontrolled cell growth in the colon or rectum, can be either benign or 
malignant.7 Benign CRC contains cancer cells that are not invasive to surrounding environments. The 
surrounding normal tissue and cells are not poisoned by the tumors, and will not spread to other parts of the 
body.9 Malignant CRC is a more severe case, as the tumor is transportable, and will spread to bordering 
tissues and may move around the body causing more tumor sites to occur and ultimately becoming more 
deadly.  
 Interestingly in CRC the majority of cancers ascend in the colon where the fluid separation takes 
place, however development of cancer in the rectum may still appear. Furthermore, CRC has been known 
to be a quiet tumor and not producing any noticeable indications until the cancer is large in size.10 
 The characteristic polyps of CRC usually develop to include a stalk that allows for protrusion from 
the surface of the inner colon.11 These polyps begin as a non-cancerous or benign growth but may later 
ripen into malignant cancer. CRC polyps progress into two main categories of hyperplastic polyps and 
adenomas or adenocarcinomas. Hyperplastic polyps are of less risk as they are typically benign, however 
if located on the right side of the body and of large size should be removed completely.12 Typically most 
CRCs are adenocarcinomas, which tend to begin in cells that make and release mucus and other fluids.13 
Normal Colon 
Small Early 
Polyp 
Growing Pre-Cancerous 
Large 
Cancerous 
Polyps 
Metastatic Cancer 
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Adenocarcinomas are of higher risk, as they will develop more often in size, quantity, and tend to be pre-
cancerous in comparison to hyperplastic polyps. 
  Cancer is typically diagnosed in stages that are dependent solely on the degree or amount of cancer 
found throughout the body. In particular, CRC stages of cancer are diagnosed based on the depth of the 
cancer in the interior lining, if the surrounding tissue is infected, and if the cancer has reached nearby lymph 
nodes.14 CRC can be diagnosed from two phases clinical and pathological. In the clinical phase, stage 
determination is based on findings from physical exams, biopsies, and imaging tests. In the pathological 
phase, the results from clinical findings are combined with necessary surgery to determine the stage of 
cancer.15  
 In colorectal cancer, there are five stages (Figure 2). Stage 0 indicated that the cancer is in its 
earliest state. Stage 0 is also known as carcinoma in situ and has not yet grown beyond the inner layer of 
the intestine.15 The next stage is stage I, where the cancer has protruded through the mucosa or inner layer 
but has not passed the submucosa. Stage II is broken down into three portions A, B, and C. In stage IIA, 
the cancer has cultivated through the lining both mucosa and submucosa, but has not grown out of the 
outermost lining. In stage IIB, the cancer has grown through the outermost lining, but has not traveled to 
nearby organs. Stage IIC is indicative that the cancer has attached to nearby organs but has not travelled to 
nearby lymph nodes. Like stage II, stage III is broken down into three portions A, B, C. The stages are 
similar to stage II cancer, however IIIA includes spreading from 1 to 3 nearby lymph nodes or the fat 
surrounding the nodes, but not toward distant sites. In IIIB spreading is advanced from 3 to 6 nodes and no 
distant sites. Finally, stage IIIC indicates the cancer has advanced to 7 or more sites and no distant sites.   
Stage IV is broken down into only two portions A and B, and interestingly enough, may or may not protrude 
through the wall of the colon or rectum as well as to other lymph nodes.15 In stage IVA, there is a present 
distinction of spreading to one distant organ, normally lung or liver, or a distant set of lymph nodes. In stage 
IVB, the progression will have advanced as seen in IVA however there may also slight spreading to the 
abdominal cavity.15  
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 Among these five stages, stage IV is the most dangerous due to the metastatic cells spreading 
through the lymphatic system to other parts of the body. A dangerous mechanism due to the extent of the 
organs the lymphatic system can reach. Finding a method to detect these polyps at earlier stages such as 
stage 0 or stage I is of extreme importance in aiding in the fight for survivors against CRC.  
  
1.2 Methods for Detecting Colorectal Cancer 
 
  
 Although CRC is considered a “silent cancer” by providing minimal symptoms of issues, physical 
exams and past family medical history serves as a great foundation for screening as well as various other 
tools. Presently, several assessments have been advanced to notice CRC sooner, so that it is more operable. 
There are a limited amount of tests that can be rendered as a method to prevent the progress of polyps and 
adenomas.1 The United States has directed a group of experts, U.S. Preventive Services Task Force 
(USPSTF), to coordinate and suggest the best methods of screening for cancers such as CRC.5 USPSTF 
advocates high-sensitivity fecal occult blood tests (FOBT), stool DNA test (FIT-DNA), sigmoidoscopy, 
virtual colonoscopy, and optical or standard colonoscopy as the most effective methods for detecting CRC.5 
   
Metastaic Progression 
The cancer spreading to 
other organs.  
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1.2.1 High-Sensitivity Fecal Occult Blood Test (FOBT) 
 
High-Sensitivity Fecal Occult Blood Test (FOBT) is a non-invasive screening technique that is 
performed annually. A typical FOBT consists of collection of stool samples that are then analyzed and 
inspected for blood particles.16 Polyps and CRC may lead to evidence of patients bearing blood in their 
stool, thus the patient will then collect their stool and bring the sample in to a primary care physician to 
determine the result. There are two types of FOBTs that can be performed: Guaiac FOBT (gFOBT) and 
fecal immunochemical test (FIT or IFOBT).7, 16  
Blood samples are analyzed by gFOBT and determined by the detection of heme in the collected 
sample. The chemical used during investigation of samples can also detect heme from other sources such 
as digested foods, requiring patients to maintain a certain diet before analysis in order to prevent test 
interference.12, 17 Though gFOBT is the government-approved method, and the most widely used FOBT 
method in the US, FIT provides a method that is more specific to patients.   
Unlike gFOBT, FIT maintains specificity by utilizing antibodies as the measure to detect human 
hemoglobin protein. Patients who are able to acquire FIT testing are not required to maintain diets 
restricting the consumption of certain foods.15, 18 Subsequently gFOBT has become extremely convenient 
for patients by allowing simple at-home tests as well as being cost efficient for patients who are considered 
“at risk age” for developing CRC.19 The problem with gFOBT testing is that the specificity of the test for 
CRC is not as sensitive as seen with IFOBT. Other issues such as hemorrhoids can lead to fecal bleeding 
and may be detected in gFOBT samples. FOBT has become a vital point of detection of CRC for patients 
over the age of 50 who maintain 1 or 2 screening tests per year; however, if positive identification is 
obtained, patients will still need to undergo a colonoscopy to determine the stage of the cancer.  
1.2.2 Stool DNA Test  
This test is very similar to the FIT as it is an immunochemical test that detects any blood that may 
be in the stool. This time, however, nine other DNA biomarkers are also detected.20 These biomarkers 
provide information in regard to three genes that are associated with precancerous adenomas. Patients 
collect samples and have them mailed off to a laboratory that uses a computer to perform diagnosis. The 
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computerized testing confers either a positive or negative result. Although this test is more sensitive than 
IFOBT due to the three genes, the specificity comes at a price, yielding more false positive results than seen 
with IFOBT.19 
1.2.3 Sigmoidoscopy 
Sigmoidoscopy requires the use of a sigmoidoscope, a lighted flexible tube that bears a lens that 
allows physicians to view inside of the rectum and sigmoid colon as well as a tool for biopsing tissue. In 
order to perform the test, doctors insert the tube through the anus into the rectum after the colon has been 
pumped with air to expand it. This expansion is important for viewing abnormal growths. The colon, in 
particular the lower colon, is cleared of stool before the test is performed. To prepare for sigmoidoscopy, 
patients are not sedated making this test less extensive than others.  
Sigmoidoscopy has its disadvantages, where abnormalities growing in the upper part of the colon 
are normally missed during testing.21 This is due to the lower part of the colon being the highest view of 
range. The test also requires patients to need their lower bowel cleansed prior to testing. As seen with 
FOBT, if any abnormal results are detected, further measures, such as colonoscopy, and are still necessary. 
Sigmoidoscopy could also result in patients incurring small tears in the lining of the colon during testing 
leading to post screening bleeding as an unwanted side effect. 
1.2.4 Standard Colonoscopy 
In a standard or normal colonoscopy, the entire colon and rectum are investigated using a 
colonoscope, which is quite similar to a sigmoidoscope. The colonoscope is a small flexible tube that is 
also lighted with a lens and equipped with a tool for removing any necessary tissue. The process of 
colonoscopy also parallels sigmoidoscopy where the colonoscope is inserted through the anus into the 
rectum and the colon that is filled with air for viewing more clearly. Colonoscopy screening is extremely 
beneficial as any abnormalities found throughout the entire colon and rectum can be removed right away, 
unlike with sigmoidoscopy. However, with this method, the entire colon and rectum must be cleansed 
before requiring patients to undergo sedation.22  This process tends to be painful for patients, but it is well 
suited for diagnosing and removal of adenomas.  
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1.2.5 Virtual Colonoscopy 
 Virtual colonoscopy is a form of computed tomography that requires a special X-ray scanner that 
produces several pictures of the colon and rectum from the exterior of the body. A computer is used in order 
to assemble all of the pictures into a detailed image of the colon and rectum. Virtual colonoscopy has several 
benefits: 1) The detailed images show polyps and abnormalities; 2) Does not require sedation; 3) Procedure 
is less invasive compared to normal colonoscopy.23-24 As seen with normal colonoscopy, the entire colon 
and rectum must be cleansed and pumped with air for viewing. Ideally, the specificity and sensitivity are 
parallel to those seen in normal colonoscopy, and the risk of tearing or complications are much lower with 
virtual colonoscopy. However, the biggest downfall is that unlike with normal colonoscopy, if 
abnormalities are found in the screening, they cannot be removed in situ.25 A standard method of 
colonoscopy must be performed to remove them.  
1.2.6 Confocal Laser Endomicroscopy (CLE)  
  Confocal Laser Endomicroscopy (CLE) has become a renewed area of interest in colonoscopy. 
CLE is a technique for acquiring high-resolution optical images with depth selectivity during an ongoing 
endoscopy, upgrading detection from colonoscopy procedures.26  Investigation of the in vivo 
microarchitecture is desirable in targeting distinct areas for biopsies, allowing for an in depth, real-time 
look at the biological environment of the patient.27  
 Probe-based CLE, a specialization of CLE, has brought much attention to the benefits of 
endomicroscopy, where it allows real-time in vivo scanning of mucosal surfaces during standard 
endoscopy.28 Fluorescence cystoscopy (i.e. photodynamic diagnosis) and narrow band imaging are 
additional endoscope-based optical imaging modalities that can be combined with CLE to achieve 
multimodal and multidirectional imaging of various cancer types.29 
 Compared to other methods of colonoscopy, CLE provides a method of acheiving better spatial 
resolution. The laser light is emitted on colorectal tissue at the mucosal surface deeper levels of the tissue, 
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and multiple images are compiled to reveal detailed information regarding the tissue imaged. Clinical trials 
have suggested CLE to aslo be an effective method of imaging cancer tissue such as CRC. One study 
obtained results of CLE that expressed a change in a particular polyp with 97.4% sensitivity, 99.4% 
specificity, and 99.2% accuracy.30 Other imaging agents, such as cresyl violet blue, acrivlavin, and 
fluorescein tend to stain cells in a nonselective manner permitting normal and cancerous cells to appear 
colored (Figure 3).31 These dyes also exhibit poor water solubility, lower quantum yields, and emit at lower 
wavelengths that are not close to the NIR-range, providing an intense amount of interference and feedback. 
 
 
Figure 3. Common imaging agents used in CLE. 
1.3 Photodynamic Therapy as a method of treatment for CRC 
 
Photodynamic Therapy (PDT) is identified as a method of administering photosensitizers, followed 
by activation with a specific wavelength of light to produce reactive oxygen species (ROS). 32-33 ROS then 
goes on to cause oxidative damage to proliferating cancer cells that results in cell death through apoptosis 
or necrosis.34-36 PDT is a very selective process due to its reactivity being based solely on the irradiation of 
the photosensitizer and biochemistry of tumor cells. Thus, providing cell death only in the affected area 
where the photosensitizer is localized.  
In order to enhance cancer treatment in the 1950s, a fluorescent marker, porfimer sodium 
(Photofrin®) was designed to enhance the amount of dye accumulated in tumor cells.37 Over time, porfimer 
sodium became the first drug to receive approval for treatment during PDT by the FDA. Porfimer sodium 
is a hematoporphyrin derivative, and has been used to treat patients for over two decades. Porfimer sodium 
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is the most commonly used PS for PDT; however, some patients tend to suffer from side effects in particular 
sunlight that may cause severe sunburn.38 Porfimer sodium is considered a “first generation” photosensitizer 
that has been used in the treatment of cancerous and precancerous lesions due to its safe and effective 
treatment. Although it is approved, porfimer sodium still lacks attributes necessary for ultimate treatment: 
such as isolation of one compound, limited tissue penetration, and poor distribution ratios.39 
In the past twenty years PDT has been an area of increased interest for since the advance studies 
into porfimer sodium versus its counterparts (such as surgery, chemotherapy, and radiotherapy). However, 
the setbacks of porfimer sodium turned scientists’ attention to creating photosensitizers that conquered 
issues surrounding chemical distinction, enhanced photophysical properties, and enriched tumor selectivity. 
To aid in photophysical tuning, researchers worked on inducing a bathochromic shift in photosensitizers in 
the near-IR region of the electromagnetic spectrum. This region allows PDT to have decreased background 
interference during treatment and sharpens the accuracy of therapy. These compounds became known as 
the “second generation” photosensitizers. These photosensitizers consisted of new macrocycles, such as 
phthalocyanines, porphyrins, chlorins, and naphthalocyanines (Figure 4). These compounds could be 
isolated and purified versus the previous hematoporphyrin.  
 
    Figure 4. Macrocycles commonly used as photosensitizers. 
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Although second generation photosensitizers refreshed the face of PDT, issues regarding tumor 
selectivity were still a remarkable challenge. Avoiding destruction of surrounding healthy tissue was 
inevitable due to its low enhanced permeability and retention (EPR) effect.40-41 To tackle tumor selectivity 
and cellular uptake issues, investigators focused on the design of photosensitizers. The center of most 
investigations relied heavily on the option to focus on the light delivery and the amount of photosensitizer 
absorbed by the tumor cells. Photosensitizers are capable of localizing in tumor cells more than they would 
in normal cells, however the possibility remains of healthy cell uptake.  To enhance tumor selectivity, data 
suggested using devices that were able to improve tumor accrual, biomolecules with selectivity precedence 
for tumor sites,42 or overexpression on the surface of tumor tissue. These photosensitizers were denoted as 
“third generation photosensitizers.” 
 Photosensitizers conjugated to various biomolecules create promising selectivity for PDT. 
Approaches to increase specific accumulation of photosensitizers at the target site recently involve the use 
of various designs some of which including polymer conjugated photosensitizers, encapsulated 
photosensitizers in different carriers.43 Although these methods provide an increased selectivity, they were 
not effective enough to allow restricted selectivity and neglect neighboring healthy tissue. Through covalent 
linkage, several biomolecules were chosen for selectivity enhancement. Several studies have investigated 
the ability of photosensitizer conjugations to biomolecules such as antibodies,44 sugars,45 
oligonucleotides,46 proteins,47 hormones,48 and metabolites.49  
1.4 Epidermal Growth Factor Receptor 
 
 Epidermal growth factor receptors (EGFRs) are ligand-stimulated cell-surface receptors that play 
a crucial role in the regulation of cellular functions, comprising cell proliferation and survival.50-53 The 
receptor EGFR is a single polypeptide backbone chain that is considered a transmembrane glycoprotein 
consisting of 1186 amino acid residues, and it has proven to be an integral piece in ruling an effective 
treatment for cancers including CRC. The receptor tyrosine kinase group that EGFR belongs to is known 
as the ErbB family. The ErbB family consists of four members: EGFR, ErbB2/HER2, ErbB3/HER3, and 
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ErbB4/HER4 .54 At maturity, each ErbB receptor includes: an extracellular ligand-binding region, a single 
transmembrane (TM) domain, and an intracellular tyrosine kinase domain that is bordered by regulatory 
regions.55 Each member of the ErbB family plays a critical role as proteins involved in carcinogenesis as 
the membrane protein expression is upregulated.56 
 
Figure 5. Crystal Structure of EGF localized in the binding pocket of EGFR.57 
 
Receptor activation of ErbB occurs during the binding of the receptor and its specific ligand (Figure 
5). ErbB has over 12 different growth factors including epidermal growth factor and transforming growth 
factor α (TGFα). The growth factor EGF consists of 53 amino acid residues that stimulates cell growth, 
proliferation, and differentiation by binding to EGFR with high affinity.58 Strong mitogenic and neo-
angiogenic activity that causes this overexpression of EGFR is all due to the EGF ligand.59-61 This excessive 
expression of the EGFR greatly improves receptor targeting and is a growing area in cancer studies.  
Activated first by binding of growth factor ligands in eukaryotic cells, EGFR undergoes 
dimerization, then stimulates its inherent protein-tyrosine kinase activity, thereby catalyzing the 
phosphorylation of tyrosine residues.62-63 Growth factor binding induces homo- and/or heterodimerization 
of the receptor, leading to trans-autophosphorylation and subsequent activation of SH2 domain-dependent 
downstream signaling pathways as seen in Figure 6.55 
EGF Ligand 
Epidermal Growth 
Factor Receptor 
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Figure 6. Binding of EGF to EGFR.64 
98% of colon cancers have had an identification of EGFR, and are amply over-expressed on small 
cancers including non-small cell lung cancer (NSCLC), breast, head and neck (SCCHN), gastric colorectal, 
esophageal, prostate, bladder, renal, pancreatic, and ovarian cancers.59, 62This overexpression of EGFR is 
considered a mutation that may cause uninhibited cell proliferation and has therefore been associated with 
cancer.63 The cause of this overexpression is a result of mutations occurring during the binding of EGFR to 
one of its endogenous ligands, EGF, as represented in Figure 5. Over the past two decades, as a result of 
mirroring the native ligand EGF,65 several different practices have been advanced for targeting EGFR,51 
containing FDA-approved anti-EGFR antibody cetuximab,66-68 single-chain anti-EGFR ScFvEGFR,69 anti-
EGFR affibody,70-71 accessible small peptides,59, 62, 72-77 and non-peptidic tyrosine kinase inhibitors.78  
The discovery of EGFR’s importance to CRC and other cancers has led to the discovery of peptide 
ligands, with high specificity for the receptor.  Among these ligands, those containing short sequences are 
particularly attractive for EGFR-targeting due to a variety of reasons, mainly their low cost, readily 
availability, low immunogenicity, moderately fast diffusion rates, ease of alteration, as well as their easiness 
of conjugation to various molecules. Computer-based design and screen phage display libraries were used 
to identify two peptides (Figure 7), LARLLT (designated “D4” or EGFR-L1) and YHWYGYTPQNVI 
(designated “GE11” or EGFR-L2). These peptides have established particularly efficient binding to the 
extracellular domain of EGFR over-expressed on cancers cells. This binding has been established in vivo 
in cell lines such as SKBR-3 and BT-474 cells, and in vitro in nude mice with A431 tumors.59, 62, 73-77, 79-80 
EGF and EGFR activity at the Cell Surface  
Signaling Dimer Induced Dimerization Monomer  
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Moreover, determination of successful binding of these peptides to EGFR through the extracellular domain 
has been detected via computational studies.59, 62, 76 Two prominent binding sides were identified: EGFR-
L1 binds to EGFR away from the binding pocket, while EGFR-L2 binds to the EGF binding pocket. 
 
Figure 7. Structures of EGFR-L1 and EGFR-L2  
1.5 BODIPY Dyes and Applications to In Vivo Imaging 
 
1.5.1 Introduction to BODIPY Dyes 
 
4,4-Difluoro-4-bora-3a,4a-diaza-s-indacenes, commonly known as BODIPYs are a group of small 
fluorescent dyes. BODIPY dyes were first synthesized by Treibs and Kreuzer in 1968 for use in their 
angiographic studies.81 Conversely, BODIPY dyes did not gain extensive appreciation until the 1980s.81
 
Today, BODIPY dyes have been extremely useful to scientists due to their versatility and stability as a 
fluorophore, as they inherently present exceptional photophysical properties.82  
 
Structurally, BODIPY dyes possess a conjugated framework of Π-electrons, and are numbered 
using the indacene system (Figure 8). This framework is named dipyrromethene, and it is complexed with 
a boron difluoride salt.83 The complexation of the boron difluoride salt and dipyrromethene is restricting in 
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structure causing minimal flexibility of the compound. This limited flexibility leads the dye to exhibit high 
fluorescence quantum yields.84 
  
Figure 8. BODIPY core structure following the indacene numbering system. 
The BODIPY core C-8 is termed the “meso-position,” while positions -1, -2, -6, and -7 are termed 
the “β-positions.” The “α-“ positions are at C-3 and C-5.84 BODIPY dyes are not only small cyclic UV-Vis 
absorbing molecules (507 nm), they emit in the Vis (520 nm), possess high quantum yields, and have 
reduced aggregation in aqueous media. BODIPYs are stable in physiological conditions, various pH, 
solvent, and polarity values.  The BODIPY core can be functionalized to induce bathochromic (red) shifts 
in the optical spectrum, useful for bioimaging.84-85 This alteration of the BODIPY core permits the 
opportunity for fluorescence tuning and introduction of water-soluble moieties, therefore these small 
molecules are useful in labeling proteins and DNA.82, 86 
Normal absorption spectra of a BODIPY dye showcases a narrow and intense band due to S0-S1 
(π-π*) transitions with a λ max between 500-525 nm, a shoulder peak is observed at high energy centered 
around 480 ± 5 nm assigned to the 0-1 vibrational transition, and finally a very broad absorption band 
around 375 ± 5 nm is attributed to the S0-S2 (π-π*) transition as a quite weak peak. Ideally, 
phosphorescence is a rare occurrence in BODIPY-based dyes due to negligible triplet energy state and a 
slow rate of intersystem crossing (except for one report due to heavy-atom effect of diiodoBODIPY).87 To 
aid in increasing bathochromic shifts of the absorption bands into the NIR region, simplistic derivatives of 
the BODIPY core are desired. The photophysical characteristics of altered BODIPYs vary with respect to 
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the number, nature, as well as the position of the attached substituents.88 Additionally, the emission behavior 
of BODIPY fluorophores are vastly dependent on the steric interactions between their components and 
intramolecular rotations of the BODIPY scaffold.89 Ever-growing success of BODIPY dyes has inspired a 
large amount of investigations into the design, synthetic modifications, and spectroscopic/photophysical 
characterization of these bright small molecule fluorophores.  
Current developments in various fields of science, have powered the creation of new fluorophores 
that can be excited to emit within the red or near-infrared (NIR) region of the spectrum.88 This is in part 
attributed to the “biological window” (700-900 nm) of the spectrum involving minimal obstruction from 
endogenous chromophores, optimum penetration of tissue, and minimal damage to cells.90-93 Current 
fluorophores can no longer work as mono-functional entities, whereas fluoropores are now called to be 
more flexible in the scope in which they are used. There are several classes of nonradioactive fluorophores 
that are used to date. For instance, the FDA approved fluorescein and rhodamine platforms, however 
BODIPY dyes have acquired much attention due to its platform versatility in synthesis and it’s smaller 
framework.82  
1.5.2 The Early Years of BODIPY Dyes  
 
Treibs and Kreuzer were the first to synthesize a BODIPY dye, and ironically, the synthesis 
happened by accident. The group reacted 2,4-dimethylpyrrole with acetic anhydride in the presence of 
BF3.OEt2 to create a green fluorescent BODIPY dye. The received dye was kindly denoted as “porphyrins 
little sister” and utilized as a tunable laser dye.83 This iconic reaction afforded a mixture of mono- and di-
acetylated BODIPY fluorophores. However in 1968, Treibs and Kreuzer’s worked pioneered the field of 
BODIPY dyes and revealed that the 2,6-positions on BODIPY chromophore are highly electron deficient, 
i.e. susceptible to electrophilic substitution reactions. 81 Throughout the mid- ‘90s studies have continually 
surfaced on the future applications of BODIPY dyes and the wondrous optical properties that can be easily 
tuned to meet a cascade of desired products. Methodology studies have suggested the synthesis of BODIPY 
dyes that entail bathochromic shifts and the use of BODIPYs as light-emitting devices,94 drug delivery 
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devices,95 fluorescent switchesy,96and pH switches,97 solar cells,98 and for labeling biomolecules for 
imaging. 99 
Founders of Life Technologies Inc., previously known as Molecular Probes, Haugland and Kang 
were heavy contributors to the world of BODIPY dyes in 1993.100-102  Haugland and Kang were able to 
design various derivatives of BODIPYs ready for biomolecule conjugation or conjugated ready for testing. 
These findings helped the scientists to create over 80 Unites States patents and become the largest 
commercial supplier of BODIPY dyes and bioconjugates.100-102  
1.5.3 BODIPY Synthetic Strategies 
 
Typical methodology for BODIPY dyes is devised from pyrrole moieties that interact with 
electrophilic carbonyl compounds to create the desired dipyrromethene. This dipyrromethene is then 
complexed with a BF2 source by deprotonating with a non-nucleophilic base such as a bulky secondary or 
tertiary amine to afford the BODIPY dye. The yields for these reactions are typically modest however 
reproducible.  
1.5.3.1 Symmetric BODIPY Synthesis 
Synthesis of symmetric BODIPY dyes can allow for substitution at either position, however the 
most visited synthesis happens where the meso- or 8-position of the core is substituted. The symmetric 
synthesis is commonly prepared by acid-catalyzed condensation of pyrroles with acid chlorides, anhydrides 
or aldehydes to install the dipyrromethene (or dipyrromethanes from aldehydes which are subsequently 
oxidized). The corresponding dipyrromethene is then complexed using boron trifluoro-diethyl etherate in 
the presence of a bulky base that is non-nucleophilic, normally a tertiary amine base (Scheme 1). In order 
to prevent any polymerization of pyrrolic units, the pyrroles have to be protected by implications of 
substitution at the C-2 position.103  
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Scheme 1. General scheme of symmetric BODIPY synthesis. 
This platform allows for the installation of various BODIPY dyes that can be further functionalized 
to meet several application measures. The apparent diversity of meso- substitution has developed a platform 
for building fluorophores that are capable of multiple purposes, such as labeling with biomolecules. 
BODIPY dyes with substituents at the meso-position may possess improved stability when compared to 
their meso-unsubstituted counterparts.  
One common route for synthesis of symmetric BODIPY dyes is through the condensation of an 
aryl aldehyde that is combined with an excess (2 equiv.) of an α-free pyrrole. Like the previous method, the 
corresponding dipyrromethane that is created must be oxidized to the dipyrromethene followed by 
complexation. Oxidation normally occurs when using an agent such as DDQ (2,3,-dichloro-5,6, dicyano-
p-benzoquinone) or p-chloranil. The downfall of using oxidizing agents is the amount of side products that 
can be formed during dipyrromethene formation. These side products tend to be very difficult to remove 
through chromatography. However, the resulting complexed BODIPY provides an aryl moiety at the 8-
position (Scheme 2).  
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Scheme 2. Methodology for the synthesis of symmetrical BODIPY via condensation of pyrroles with an 
activated carbonyl source. 
 
Another method of installing meso- substituted symmetrical BODIPY dyes is the condensation of 
acid chloride with free pyrroles. The condensation of acid chloride is quite different than that of aryl 
aldehyde as the synthesis goes straight to a dipyrromethene by passing the need for oxidizing agents. 
Elimination of the oxidizing agent aids in freeing the reaction of the byproducts associated with the 
oxidation yielding more of the desired compound (Scheme 2).  
Symmetric BODIPY dyes unsubstituted at the meso-position are obtainable, and can be created by 
self-condensation of a desired pyrrole bearing a carbonyl and an α-free pyrrole. However the use of an acid 
catalyst is necessary such as p-toluenesulfonic acid, Montmorillonite clay, and more recently phosphorous 
oxychloride.104-106 This acidic environment aids in creating the carbonyl cation that is needed to condense 
with the second equivalent of α-free pyrrole. The combination of these two portions creates the desired 
dipyrromethene that is later complexed. 
1.5.3.2 Unsymmetrical BODIPY Synthesis  
To synthesize the asymmetric BODIPY, the MacDonald coupling approach usually attains dyes, 
substituted or unsubstituted at the meso-position. The condensation of two different pyrroles as seen in 
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Woods and coworkers; where pyrrole-2-carbaldehyde and an α-free pyrrole were condensed under an acidic 
catalyzed environment leading to the desired BODIPY dye. 107 The use of electron-deficient pyrroles tends 
to lead to the undesired product of a symmetric BODIPY, however, the use of electron rich pyrroles leads 
to the high yielding unsymmetrical product. After the acid condensation is complete, the anticipated 
dipyrromethene is generally isolated in its salt form sub sequent complexation with BF3.OEt2 affords the 
required BODIPY dye (Scheme 3). Unsymmetrical BODIPY dyes have a great advantage as the possibility 
to attach different functional moieties on the BODIPY scaffold for further derivatizing or bio-conjugation 
is endless.  
 
Scheme 3. Generic synthesis of unsymmetrical BODIPY dyes 
1.5.4 BODIPY Dyes and Biolabeling 
 
Fluorophores that are equipped to visualize and investigate the functions of biological materials 
such as proteins, enzymes, and living cells are highly desired. The necessity of a fluorescent molecule that 
is easily tuned to the desired labeled fluorescent probe has delivered BODIPY dyes to the foreground of 
fluorescent markers. The smaller size of the BODIPY core when compared to other fluorescent entities 
such as porphyrins is significant in allowing the dye to form bioconjugates without alteration of the 
components of the targeting molecule. Several reports have observed synthesis of bioconjugation between 
BODIPY dyes and targeting components such as amino acids and proteins.108 To prepare conjugates, motifs 
are established via BODIPY dyes to connect the two. A more frequently used component is carboxylic 
acids, sulphonic acids, PEG moieties, polysaccharides, and oligonucleotides.81, 83  
In recent years, BODIPY dyes have been shown to attach to extracellular proteins and DNA to 
create probes that are able to engage in living cells as labeling moieties. Some reports to date have observed 
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promising results in both single and two photon microscopy of living tissue.109 Groups such as Wolfbeis 
and coworkers110 suggested that biomolecules were conjugated to items such as sugars, amino acids, and 
nucleotides via a copper-free and copper-mediated cycloaddition. These BODIPY fluorophores bearing 
clickable alkynyl groups were created for labeling azide modified surface glycans of Chinese hamster ovary 
(CHO) cells. In the same manner, Vicente et al.111 also suggested the conjugation of clickable BODIPY 
dyes to azide bearing carbohydrates and PEG linkers. These conjugates bearing either one or two styryl 
groups were tested in HEp2 cells, to determine their affinity.111 Zhang and coworkers also aid in 
development of BODIPY bioconjugates by developing a C-C linkage between a tryptophan amino acid 
and the BODIPY dye spacer-free. The fluorescent antimicrobial peptides remain intact while 
incorporating a fluorogenic amino acid that has no effect on the specificity of the peptide sequence. The 
peptide sequence is still able to provide real-time imaging of fungal infection and enhance the 
fluorescence in hydrophobic microenvironments. 
 Although conjugation measures have proceeded, drawbacks still remain for bioconjugation of 
BODIPY dyes.112 Of these drawbacks, in particular, relatively low wavelength absorption and emission 
maxima (around 500 nm),113 small Stokes shifts, poor aqueous solubility,  and lack of functional groups for 
conjugation to biological materials are of urgent concern.114 These apparent drawbacks limit the scope of 
BODIPY fluorophores for various biomedical and bioanalytical applications, and require additional steps 
to achieve the desired fluorophore. Many of these problems are under attack in various research groups. 
The BODIPY core itself is essentially electron-rich and can be conveniently amended at various positions 
to analogues that span the entire visible spectrum and beyond. 
 
1.6 Research Focus 
 
Despite the varied developments released in BODIPY methodology, there is definitely more work 
to be done. The synthesis of BODIPY derivatives that exhibit bathochromic shifts in the NIR region and 
beneficial conjugation to various target biomolecules, represent an established challenge in the BODIPY 
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biomarker world. For instance, BODIPY bioconjugates that not only emit in the NIR but also possess a 
water-solubilizing moiety in the presence of targeting modules that are suitable for in vivo imaging are very 
few reports in literature.  Current methods for CRC diagnosis, including different types of colonoscopy and 
radiography, have relatively low sensitivity for detection of small adenomas (< 5 mm) in the early stages 
of CRC, when it usually causes no outward symptoms in patients.115 Therefore, the molecular targeting of 
EGFR over-expressed in CRC cells, especially during the early stages of cancer, is a valuable tool in CRC 
diagnosis and treatment.116 Conscious of these issues, endeavors in the synthesis, characterization and in 
vitro evaluations of novel BODIPY bioconjugates will be discussed in the next chapters. 
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CHAPTER 2. Design and Synthetic Strategies for Peptides that Target EGFR 
2.1 Introduction to EGFR-L1 and EGFR-L2 
 
Several studies have suggested various replacements for EGFR’s endogenous ligands. 
Replacements such as antibodies, proteins, and peptides are often considered when searching for targeting 
tools of EGFR. Of the aforementioned list of possibilities, peptides have shown prominent interest among 
the community because they are readily diffusible, have low immunogenicity, and are easy to incorporate 
into imaging devices.1 
To improve current detection methods for CRC two peptides were developed by Li and Song to 
target EGFR with high binding affinity.2-3 Li and Song investigation included two expenditures towards 
prominent EGFR selectivity. One method employed was the use of computer-aided designs that were 
screened against an X-ray crystal structure of EGFR in silico and tested through in vitro and in vivo studies.3 
As a result EGFR-L1 (LARLLT) a six-member amino acid sequence was selected (Figure 1). Screening 
phage display libraries discovered a second peptide. The resulting enriched phage clone gave an encoding 
of amino acids YHWYGYTPQNVI, also known as EGFR-L2 (Figure 2).2 
 
Figure 1. Peptide ligand structure EGFR-L1 (LARLLT). 
Peptides are compounds comprised of several amino acids that are connected through amide bonds. 
Peptides in particular are an extremely striking source due to their relative small size, low immunogenicity, 
ease of conjugation, comparative ease of synthesis, ready availability, and more importantly high binding 
affinity.4 
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Figure 2. Peptide ligand structure EGFR-L2 (YHWYGYTPQNVI). 
The efficient cell penetration of peptides, selective binding ability, and low toxic behavior makes 
peptides a focal point in areas such as in vivo imaging and photosensitizer-biomolecule conjugation for 
PDT. Peptides are easily modified to use for imaging.5  
Peptides found through screening of phage display peptide libraries, or virtual peptide libraries as 
seen in Li and Song’s work behave as an antagonist for the targeted receptor.2-3 Peptide targeting is an 
extreme benefit for in vivo studies especially in certain tumor cases such as glioblastomas. Peptide 
application is a growing area with endless possibilities. Select peptides have been developed to act as 
ligands for different receptors or cell lines. This essential application is advantageous as it provides a way 
to selectively target specific receptor sites. Developing imaging probes based upon peptides as the targeting 
molecule will ensure the final receptor destination is met.  
2.2 Results and Discussion 
 
Peptide chemistry is a valuable asset of organic chemistry that employs the conjugation of multiple 
amino acids via an amide linkage or peptide bond. Peptides are synthesized by the union of a free carboxyl 
group of one amino acid to the amino group of another amino acid molecule. Peptides are normally 
translated from left to right. The beginning of a peptide sequence is normally the N-terminus or where the 
amino acid has a free or protected amino group. The C-terminus is where the carboxyl group is normally 
located (Figure 3). To develop the functionality of the C-terminus specific resin supports are chosen in solid 
phase peptide synthesis (SPPS), and initial amino acids are chosen for solution phase peptide synthesis. 
Due to the opportunity of side reactions, protecting groups are usually necessary.6 While peptides are read 
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from N-ternimus to C-terminus, synthesizing peptide sequences tend to begin at the C-terminus or carboxyl 
end of the peptide, and proceeds toward the N-terminus.  
 
Figure 3. Glycine Amino Acid termini. 
In peptide chemistry the use of coupling agents and coupling additives are the most efficient routes. 
To date the most commonly used coupling agents vary, however they all fall under three types: 
carbodiimides, phosphonium, and aminiums (Table 1).7-10 Over time carbodiimides have been used as 
activators in SPPS, and have remained relevant. However in current years coupling agents phosphonium 
and aminium reagents have attracted more interest (Table 1). Each class of coupling agents has distinct 
methods of creating the amide bond, however in the presence of additives they work together to minimize 
the amount of racemization that may occur. An example of a suitable coupling additive used to date is 
hydroxybenzotriazole (HOBT) and its clorinated counterpart (Cl-HOBT) which together fall under the class 
of OBt active esters.  
SPPS has become a favorite method for producing peptide sequences particularly sequences that consist of 
4 or more amino acids. The method first discovered by Merrifield11, provides ease of removal of side 
products by rinsing after coupling, and the simplicity of addition of amino acids.11 Normally, when 
synthesizing peptides by SPPS Fmoc protecting methods are usually applied.11 Fmoc chemistry allows for 
successful conjugation of amino acids through the C-terminus to N-terminus. A Fmoc-Pal-PEG resin is 
used to yield an amide at the C-terminus when synthesizing peptides EGFR-L1 and EGFR-L2. To complete 
the desired sequences, the amino acids were selected purchased from AAPTEC. These amino acids were 
chosen with certain side chain protecting groups to prevent alternative reactions from occurring.  
 
H2N
O
OH
C-Terminus
N-Terminus
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2.2.1 BT-SPPS of EGFR-L1 and EGFR-L2 
EGFR-L1 and EGFR-L2 were synthesized using two techniques of SPPS, Microwave SPPS (MW-
SPPS) and Bench-top or Normal phase SPPS (BT-SPPS). In both methods a Fmoc-Pal-PEG resin was then 
allowed to swell in dimethylformamide (DMF). Resin expansion is particularly important, as it will allow 
for maximum coverage of resin beads for amino acids to follow.  
Table 1: Solid Phase Peptide Synthesis (SPPS) Common Coupling Agents 
Coupling Class Structures 
Carbodiimide 
  
Aminium 
 
Phosphonium 
 
 
After expanding the resin beads, a wash cycle with DMF, the first amino acid is allowed to double 
couple. Double coupling is a procedure where the first amino acid of each sequence is introduced to the 
resin beads in the presence of coupling agents TBTU and additive HOBT in a DIEA/DMF solution. After 
this addition is complete and drained, the same amino acid under identical conditions is added to the resin 
beads and repeated coupling occurs.  
After completion of double coupling the first amino acid is then deprotected of the Fmoc protection 
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group using a piperidine/DMF solution. The resulting free amine is then coupled to the next amino acid of 
each sequence under the same coupling conditions. This cycle is continued until all desired amino acids are 
coupled to the resin 12-14 (Scheme 1). 
  
Scheme 1. Generic double coupling procedure. 
 
For BT-SPPS methods deprotecting the Fmoc group took 15 min, and the coupling of each amino 
acid took around three hours (Scheme 2).  
OMe
NH
PEG
NH2
OO
O
OMe
NH
PEG
N
H
OO
O
H
N
Fmoc
O OMe
NH
PEG
N
H
OO
O
H
N
O
FmocHN
O
OH
HOBT, TBTU
1st Coupling
FmocHN
O
OH
HOBT, TBTU
2nd Coupling
Fmoc
1. DMF Rinse
2. 20% Piperidine/ DMF 25 min
OMe
NH
PEG
N
H
OO
O
NH2
O
 39   
 
 
Scheme 2. BT-SPPS of EGFR-L1. The same steps occur for synthesis of EGFR-L2. 
2.2.2 MW-SPPS Synthesis of EGFR-L1 and EGFR-L2 
In solid phase peptide synthesis (SPPS), there are many polar and ionic species present that can be 
rapidly heated by use of microwave energy. Ideal conditions for microwave coupling include polar solvents, 
the peptide framework or resin, the terminal amine group (if coupling through C-terminus), bases for 
deprotection, and polar/ionic activators such as TBTU.15 The increase in temperature is beneficial to SPPS 
as well, as this can aid the reaction by disruption of chain aggregation due to intra- and interchain 
association and allow for easier access to the growing end of the chain.15 
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In MW-SPPS, we used microwave-assisted chemistry to achieve deprotection of Fmoc groups, as 
well as for coupling each amino acid in the sequence used in BT-SPPS. To deprotect the Fmoc group, the 
solid support is suspended in piperidine/DMF solution for 30 seconds, followed by removal of the solution. 
The resin was then covered in piperidine/DMF solution for only five minutes, and then allowed to cool to 
room temperature for five minutes. To couple amino acids to the resin, the same mixture was created as for 
the BT-SPPS method, but the reaction was run for 20 minutes and then continued until completion of 
sequences (Scheme 3). Completed peptide sequences can then be cleaved from the resin to perform solution 
phase conjugation to the fluorophore, or left on the resin to perform solid support conjugation. 
Both methods’ products were deprotected at the last amino acid.  Rinsed with DMF and DCM to 
ensure all free by products and reaction conditions are removed. The dry resin beads are then introduced 
into cleavage conditions using a trifluoroacetic acid (TFA) cocktail. The TFA cocktail contains a mixture 
of TFA, H2O, phenol, and Tris (94/2.5/2.5/1). Each method product was then precipitated out of solution 
using cold anhydrous diethyl ether. The precipitate in diethyl ether is centrifuged and the supernatant was 
decanted and new diethyl ether is added. 
This procedure was repeated three times. The final time the residual peptides were dissolved in a 
water/acetonitrile (ACN) mixture 90:10 ratio. The solution was then frozen by liquid nitrogen and 
lypholized where the frozen solution is brought to a solid form. The free peptides were then purified using 
reverse phase HPLC. 
MW-SPPS at first glance is the most efficient method due to its rapid production time. EGFR-L1 
and EGFR-L2 can be completed in a fraction of the time using MW-SPPS. However when looking closely 
at the percent yields of each method, MW-SPPS does not provide a substantial difference in yields, however 
the reactions are extremely faster. The yields were comparable to each other regardless of the methods. 
From this comparison, however, MW-SPPS showcases a method that is faster, easier, and comparable to 
the traditional method of synthesizing peptides as seen in Table 2.  
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Scheme 3. MW-SPPS synthesis of EGFR-L1. The same steps occur for synthesis of EGFR-L2. 
 
Table 2: Comparison of BT-SPPS and MW-SPPS of EGFR-L1 and EGFR-L2 
Name Abbreviation Synthesis Method Molecular 
Weight 
% 
Yield 
EGFR-L1 2-1 Synthesizer16  685.39 g/mol 48 
EGFR-L1 2-1 Bench-top 685.39 g/mol 35 
EGFR-L1 2-1 Microwave 685.39 g/mol 43 
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Table  cont'd 
Name Abbreviation Synthesis Method Molecular 
Weight 
% Yield 
EGFR-L2 2-2 Synthesizer16 1538.73 g/mol 37 
EGFR-L2 2-2 Bench-top 1538.73 g/mol 39 
EGFR-L2-
Gly 
2-3 Bench-top 1595.75 g/mol 44 
 
2.3 Derivatives of EGFR-L1 and EGFR-L2  
 
 
The EGFR-L2 (2-2) sequence was initially modified to EGFR-L2-Glycine (2-3) to account for the 
steric hindrance at the N-Terminus foreseen for future conjugations with fluorophores. The tyrosine of the 
last amino acid has a bulky side chain that could possibly cause extreme issues when conjugating with 
BODIPY dyes for completion of probe structure (Figure 4).   
 
Figure 4. Peptide ligand structure 2-3. (GYHWYGYTPQNVI). 
The yields in Table 2 obtained for the addition of glycine via BT-SPPS for synthesis of peptide 2-3, revealed 
an increase in percent yield compared to the yield obtained for peptide 2-2. Due to the error in coupling, 
the additional amino acid was completed using BT-SPPS under normal Fmoc conditions. The completed 
sequence was purified as seen previously with peptides 2-1 and 2-2.   
O
N
H
OH
O
H
N
N
H
N
O
N
H
NH
O
H
N
OH
O
N
H
O
H
N
OH
O
N
H
HO
O
N
O
NH
O
NH2
O
H
N
O
NH2
O
N
H
O
H
N NH2
H2N
O
 43   
 
Current studies suggest that peptides as targeting agents conjugated to fluorophores require linkers 
or spacers to ensure the affinity for binding is remained. Choosing a linker there are various points to 
consider, finding linkers that can aid the entire probe in solubility while still providing space between each 
portion is an essential benefit. Polyethylene glycol (PEG) is often sought after due to its capabilities of 
performing as a linker. PEG groups offer improved water solubility to molecules, as well as a decrease 
aggregation due to extension of the molecules conformation.17-19 PEG groups come in various chain lengths, 
and are easily tunable for attaching to different compounds. Ideally a PEG group that is transformed to 
mimic an amino acid is desirable. Terminating the PEG group with an amino group at one end and 
carboxylic acid at the other are beneficial aspects. To complete the linker Fmoc-NH-PEG3-propionic acid  
(PEG3) was chosen from AAPTEC, as it possessed each component necessary, and protects the amino 
group using the same Fmoc chemistry applied during peptide synthesis (Figure 5).  
 
 
Figure 5. Structure of Fmoc- NH-PEG3-Propionic acid (PEG3).   
BT-SPPS was used to couple peptides EGFR-L1 and EGFR-L2 to PEG3.  PEG3 was introduced to 
the resin beads containing peptides in the presence of coupling agents TBTU and additive HOBT in a 
DIEA/DMF solution as previously described. Although PEG3  resembles an amino acid because of 
terminus, a double coupling was performed to ensure maximum attachment of PEG3 (Scheme 4).  
The Fmoc groups were removed from PEG3-EGFR-L1 and PEG3-EGFR-L2 as described 
previously, and the sequences cleaved from resin beads to reveal the white fluffy crude peptides 2-4 and 2-
5.  Each pegylated peptide was purified using RP-HPLC in good yields (Table 3). 
Although peptides have sustained properties as targeting molecules various drawbacks exist to date. 
One persistent boundary is the inherent low chemical stability peptides exhibit. 20-21 
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Table 3: Results of BT-SPPS of Pegylated peptides 2-4 and 2-5  
Name Abbreviation Molecular Weight  % Yield 
PEG3-EGFR-L1 2-4 888.59 g/mol 38 
PEG3-EGFR-L2 2-5 1798.867 g/mol 39 
 
Peptides tend to be extremely susceptible to enzymatic cleavage, which allows the molecules to 
break down into smaller portions upon cleavage in vivo. The free termini of peptides allow possibilities of 
degradation as well.22-23 This nagging attribute limits the scope of peptides unless stability modulations are 
performed.  To counter act these issues several efforts are possible such as termini modifications, 
cyclization of peptides, and substituting L-amino acids for D-amino acids (Figure 6).  24-27 
Altering the peptide sequence to enhance stability is essential, however the most viable point is to 
not alter the receptor-binding affinity of the peptide after enhancement, hence, and some studies have 
suggested using a linker to avoid these issues.   
 
Figure 6. L-amino acid configuration and D-amino acid confirmation of Lysine.   
A top of stability, maintaining binding affinity, the ease of access should also be considered when 
developing alternative sequences. Determining which sequence to tackle was based on previous studies that 
suggest that EGFR-L1 would be a better suite.4 Peptides 2-1 and 2-3 were both conjugated to 
Phthalocyanines (Pc) via a small PEG linker (Figure 7). The Pc-EGFR-L1 conjugate was found to have 
enhanced water solubility and higher targeting for EGFR versus Pc-EGFR-L2-Gly, which showed lower 
solubility due to the more hydrophobic peptide sequence.  
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Scheme 4. BT-SPPS of peptide 2-4. (The same steps occur for synthesis of peptide 2-5). 
The EGFR-L1 conjugate exhibited a 17-fold higher accumulation in EGFR overexpressing cells 
over EGFR-L2 conjugate.  The Pc-EGFR-L1 conjugates increased cellular uptake was thought to be due to 
the arginine charge side chain providing an enhanced solubility for the entire conjugate.  Due to the multiple 
highlights of EGFR-L1 such as the ease of synthesis, the smaller backbone structure, and enhanced 
solubility this sequence was chosen for modification. 
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Figure 7. Pc-Peptide Conjugates previously investigated.4 
Several modifications were considered to enhance the stability of EGFR-L1 sequence (Table 4), 
and examined for effectiveness. EGFR-L1 N-terminus was first investigated to determine if altering would 
increase the stability. 
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Table 4: Derivatives of EGFR-L1 obtained by BT-SPPS 
Peptide 
sequence 
Abbrev. Structure Molecular 
 Weight 
% 
Yield 
 
tllral-CONH2 2-6 
 
685.47 
g/mol 
40 
KLARLLT- 
CONH2 
2-7 
 
813.57 
g/mol 
39 
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O
NH
O
N
H
HN
NH2H2N
O
H
N
O
N
H
O
H2N
HO
NH2
 47   
 
 
Peptide 2-1 is synthesized with a Leucine amino acid as the final addition to the sequence. However 
adding an additional amino acid could possibly change the activity of the peptide sequence, as well as 
provide increase stability for conjugation. Increasing the distance of attachment for fluorophores could act 
as a small linker or extend the confirmation as seen with PEG linkers. Two amino acids were considered in 
this approach Lysine (Lys) (Figure 6) and Glycine (Gly) (Figure 3). Each sequence was synthesized by BT-
Table cont’d  
Peptide sequence Abbrev. Structure Molecular 
 Weight 
% 
Yield 
 
GLARLLT- 
CONH2 
2-8 
 
742.49 
g/mol 
37 
K(N3)LARLLT-
CONH2 
2-9 
 
839.56 
g/mol 
59 
cyclo[KLARLLT] cycloL1.1 
 
796.61 
g/mol 
- 
Cyclo[K(N3)larllt] cycloL1.2 
 
822.62 
g/mol 
- 
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SPPS and purified by RP-HPLC. The yields of each sequence were comparable to those achieved with 
EGFR-L1 (Table 4).  
The second endeavor to aid stability was synthesizing EGFR-L1 with D-amino acids. D-amino 
acids have been shown to withhold their integrity under enzymatic cleavage allowing peptide sequences to 
reach their target goal. D-amino acids are observed in multiple peptides that are naturally synthesized in 
animal cells.28-30 These D-amino acids are formed when a posttranslational alteration occurs from L-amino 
acids into D-amino acids. Studies have also shown that peptides that are partially made up of D-amino acids 
exhibit a higher degree of stability to enzymatic cleavage over sequences that are fully designed with L-
amino acids. 25, 31-32 
To synthesize EGFR-L1 with D-amino acid a retroinverso of EGFR-L1 must be considered. 
Retroinverso peptides are synthesized by taking the normal LARLLT sequence of EGFR-L1 replacing them 
with D-amino acids respectively, however a reverse order of D-amino acids addition to the resin must be 
performed (Figure 9). Using a retroinverso-EGFR-L1 (tllarl) may result in retention of the biological 
activity of the EGFR-L1 sequence, but allows for an enhanced biological stability. 
Synthesis of 2-6 was performed on PAL-PEG-PS resin beads under BT-SPPS Fmoc chemistry as 
described previously.  The resulting peptide were purified by RP-HPLC and confirmed by MALDI-TOF.  
 
Figure 9. Structure of retroinverso peptide sequence (tllarl). 
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Scheme 5. Synthesis of peptide 2-8. The same steps occur for synthesis of peptide 2-7. 
The final modification considered to enhance the metabolic state of peptide 2-1 was to cyclize the 
backbone of the EGFR-L1 sequence. A current study in Dr. Seetharama Jois, our collaborator, suggests that 
the linear peptides may exhibit random or flexible structure in solution. However, in the presence of our 
peptide 2-1 the definition of the structure may obtain a folded firm structure. Docking studies of the 
sequence with EGFR were performed and several low energy docked structures were analyzed and 
determined to indeed acquire a folded structure in the presence of the receptor. With this information, and 
to increase the peptide stability, a cyclized derivative of 2-1 was considered. 
The preferred method to cyclize was head to tail cyclization due to the counter method involving 
an acid sensitive disulfide bridge. Although a more difficult feat, head to tail cyclization provides a more 
stable peptide backbone structure. However, head to tail cyclization of 2-1 would result in a cyclic structure 
without an N or C-termini. EGFR-L1 sequence does not include a free amine on the side chain thus 
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removing all necessary components for conjugation. Therefore a lysine residue was introduced in the 
peptide sequence at the N-terminus. The side chain of Lys can be used for subsequent conjugation to a 
fluorophore via amide bond formation. The cyclization was performed under the direction of collaborators 
in the Agriculture building headed by Dr. Gauthier and coworkers. The cyclic sequence was synthesized 
using standard Fmoc peptide chemistry protocol using chlorotrityl chloride (CTC) as the resin.33  
The degree of loading was determined by coupling of the first amino acid (Leu) to the resin for one 
hour in the prescence of HCTU as the coupling agent.  After coupling was complete the Fmoc group was 
removed via 20% piperdine in DMF. The resin bearing Leu was then “capped” using DCM/MeOH/DIPEA 
(80:15:5).  Followed by washing of the resin using DMF and DCM, and drying under vaccuo overnight. 
The substitution level of the resin was determined by a quantitative Fmoc test wear UV analysis were 
acquired at 466nm. After acquisition of the substitution level the synthesis of the linear sequence of 
Cyclo.L1.1 [KLARLLT] was performed in the same manner. To ensure the head to tail cyclization 
proceeded the side chains remained protected therefore a different cocktail was necessary for cleavage. The 
side chain protected peptides were cleaved from the resin with 5 mL of 1% TFA in DCM for 5 min.  The 
cleavage conditions were repeated on the resin 10 times.   The cleavage solutions were combined and 
concentrated in vacuo.  The residue was dissolved in a 1:1 ratio of water and acetonitrile mixture containing 
0.05% TFA frozen and lyophilized to yield white solids.  To cyclize the white solid was taken up in DMF 
in a 2 mM solution. To this solution HATU and DIPEA were added.  The mixture was allowed to stir for 3 
hours after which time the peptides were concentrated to remove as much DMF overnight.  Protecting 
groups were then removed by dissolving the oil in a second cleavage cocktail consisting of TFA/water/TIPS 
(96:2:2) for two and a half hours.  The resulting mixture was then subjected to cold diethyl ether and 
centrifuged to precipitate out the crude cyclized peptide. The pellet was then removed from the old diethyl 
ether and resuspended in fresh cold diethyl ether and centrifuged. This process was repeated five times. 
After the final ether wash, the peptide pellet was dissolved in a minimal amount of water containing 0.1% 
TFA, frozen and lyophilized.   
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In considering potential conjugation measures of the peptide sequences for future conjugation to 
BODIPY fluorophores, an azido group at the lysine side chain was also considered for the cyclic sequence 
and linear sequence of EGFR-L1. This small measure would allow the peptides to be suitable for 
conjugation via “click” chemistry without any further modifications performed. To complete the 
modification lysine amino acids bearing azide moieties, Fmoc-Lys(N3)-OH, at the side chain was chosen 
from Anaspec, as it possessed the desired functionalities, and protects the amino group using the same 
Fmoc chemistry applied during peptide synthesis (Figure 10).  
 
Figure 10. Structure of Fmoc-Lys(N3)-OH. 
Dr. Gautier performed the cyclic peptide bearing the azide as the side chain for the lysine amino 
acid, however the sequence was not able to cyclize as the sequence K(N3)LARLLT and required the 
incorporation of d amino acids for all AA included except the azio bearing lysine. The final sequence 
confirmed was cycloL1.2 [K(N3)larllt]. This was a very interesting observation by far as the initial cyclic 
peptide cycloL1.1 was cyclized with no issues, however the azide moiety may have provided a steric 
interaction with the side chains of the other amino acids in the L-configuration requiring an alleviation of 
stress, and the D-configuration possibly aided in this manner. The linear sequence K(N3)LARLLT (2-9) 
was performed as achieved previously via BT-SPPS and was purified via HPLC analysis of the crude fluffy 
peptide received.  The pure peptide was then characterized with MS,1H-NMR, and HSQC NMR. 
 
2.4 Characterization of Peptides 
2.4.1 Determination of Peptide Sequencing 
To ensure all sequences are as expected various characterization techniques exist. One important 
technique is the use of MALDI-TOF MSMS. MALDI-MSMS provides a method that is robust in nature 
but easy to use to determine the sequencing of peptides. Fragmentations are developed in three ion types 
for sequences a, b, and y. These ions are selectively used to determine the sequence. The first ions a and b 
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are generated from the N-terminus of a peptide and the y ion is generated from the C-terminus. A suitable 
amount of fragments from either terminus should be observed, however preferably b and y ions are expected 
for peptide sequences.34 Parent peptides EGFR-L1 and EGFR-L2 sequences were first investigated to 
ensure the methods of synthesis were accurate and the expected fragmentations were recognized. EGFR-
L1 showed more fragmentations associated with b ions followed by only a few ions associated with the y 
ions (Figure 11). This shows that the fragmentation appears to extend from the amino terminus to the c-
terminus.  
  
Figure 11. MALDI-TOF-TOF (MSMS)  spectrum of 2-1. 
 
Peptide 2-1 MALDI-TOF MSMS spectra is indicative of the fragmentation pattern favoring the 
loss of amino acids from the N-terminus. The ions associated with this spectra reveal the preference of b 
ions with only one a ion present and three y ions.  The overall amount of b and y ions were good indicators 
of the desired peptide 2-1 sequence was formed. 
 
 
    1  2  3  4  5  6  
a  L-A-R-L-L-T 
b  L-A-R-L-L-T 
 L-A-R-L-L-T     y 
 
b2 
184.82 
b3 
341.82 
b4 
454.62 
b5 
567.27 y5 
572.37 
y4 
501.35 
y4-NH3 
484.43 
b4-NH3 
437.05 
b3-NH3 
324.31 
a5 
539.42 
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Figure 12. MALDI-TOF-TOF (MSMS)  spectrum of 2-3. 
 
Peptide 2-3 MALDI-TOF MSMS spectra indicates the same fragmentation noted in peptide 2-1 
more fragmentations associated with b ions followed by y ions as preferred. However with peptide 2-3 
more a ions were present then those noted with peptide 2-1 (Figure 12).  Both peptides prefer fragmentation 
from the amino or N-terminus than the C-terminus. Each parent peptide and derivative of peptide 2-1 was 
then explored for binding efficacy.  
 
2.4.2 Spatial Plasmon Resonance (SPR) of Peptides 
 
Another insightful tool for determining the efficacy of peptide sequences is Surface Plasmon 
Resonance (SPR). SPR is an intricate tool that can be used to characterize the affinity of two ligands for 
one another.35-36 SPR is essential for this manner as it can aid in finding binding constants. The target 
receptor extracellular domain of EGFR was immobilized on a CM5 sensor chip and used as the bait ligand. 
Through a microfluidic system of 10 uL/min, each peptide was used as the prey ligand and passed through 
the chip to determine the protein peptide interaction.  The association and dissociation rates are measured 
in response units at a function of time.37  
	
                                         1  2  3   4   5   6  7  8  9 10 11 12 13 
a    G-Y-H-W-Y-G-Y-T-P-Q-N-V-I 
b    G-Y-H-W-Y-G-Y-T-P-Q-N-V-I 
   I-V-N-Q-P-T-Y-G-Y-W-H-Y-G    y 
 
 
b12	
1466.742	
	b10	
1253.619	
	
b7	
927.366	
	
b6	
764.350	
	
b5	
707.241	
	
b4	
544.278	
	
b3	
358.036	
	
y11	
1376.697	
	
y5	
569.235	
	
b8	
1028.334	
	
a3	
330.349	
	
a4	
516.316	
	
a3	
679.385	
	
y6	
670.814	
	
a7	
899.186	
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SPR of all peptides were performed in a concentration manner of varying concentrations from 0 μM to 200 
μM and sensograms were attained at each concentration. Parent peptides 2-1 (Figure 13) and 2-3 (Figure 
14) showed similar results as seen before.  
 
Figure 13. SPR sensogram of EGFR-L1. 
As previously reported2, 38 peptide 2-1  showed an affinity for  EGFR . A linear increase in binding 
via response units from .25 μM to 200 μM. There was no evidence of non-specific binding at any 
concentration indicating the benefit of using EGFR-L1 for its specificity. The Kd value determined for 2-1 
was in the nanmolar range (Table 5). 
Peptide 2-3 also possesed a linear increase in the association and dissasociationa of the peptide to 
EGFR in a concentration manner. This concentration difference was investigated from .25 μM to 200 μM. 
However the binding constant value determined for 2-3 was in the micromolar range proving that the 
charged sequence EGFR-L1 acquires a better affinity for EGFR. All peptides binding efficacy was studied 
via SPR and the results can be found in Table 5.  
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Figure 14. SPR sensoogram of EGFR-L2-Gly. 
All peptide deritivate 2-4 to 2-9 and cyclic peptides cycloL1.1 and cycloL1.2 were also 
investigated. Surprisingly retroinverso peptide 2-6 showed no binding although previous studies suggested 
possible increased binding affinity.39 Of the other peptides pegylated peptides 2-4 and 2-5 showed an 
increased binding affinity for EGFR over their parent peptides with a greater binding constant. While 
Peptide 2-6 showed a decrease in affinity. Of the peptide derivatives 2-7 shows the strongest binding affinity 
for EGFR this may be due to the additional positive charged exhibited by inserting the Lys amino acid in 
the sequence. Comparing the results of Peptide 2-7 and 2-9 the azido group added in peptide 2-9 showed 
to have a negative affect on binding to EGFR. 
 
This notion was also confirmed with cyclic peptides cycloL1.1 and cycloL1.2. Peptide cycloL1.1 
showed to have a better affinity over its azido counterpart. Previous computational studies have shown that 
EGFR-L1 binds to EGFR in an open or closed confirmation.40 The immobilized EGFR did not have the 
endogenous ligand EGF bound to the receptor thus the receptor is thought to maintain mostly a closed 
confirmation. 
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2.5 Conclusions 
 
Peptides have proven to be essential targeting molecules for imaging agents, and seven potential 
EGFR ligands were developed and tested.  EGFR-L1 and EGFR-L2 were synthesized by SPPS in two 
fashions, bench-top and microwave. Each method utilized Fmoc chemistry as the standard and provided 
comparable yields. MW-SPPS provided a faster method that maintained simiilar, and efficiency to BT-
SPPS. EGFR-L2 sequence was initially modified to EGFR-L2-Gly due to the possible steric hindrance at 
the N-Terminus and potential increase in stability. Both peptide sequences EGFR-L1 and EGFR-L2 were 
conjugated to 3-PEG linkers to aid in solubility and to potentially provide probe development spacing 
between peptide ligands and fluorophore. EGFR-L1 was modified to aid in stabilizing the sequence to 
minimize the amount of enzymatic cleavage seen in in vivo studies. Peptide derivatives 2-1 to 2-9 were 
synthesized in good yields and tested for binding affinities by SPR. Peptide 2-6 showed no binding affinity 
for the EGFR receptor while 2-8 and 2-9 displayed good affinity for the receptor. CycloL1.1 showed great 
Table 5: KD Values of All Ppeitdes 
Compound Molecular Weight KD Value 
(nM) 
2-1 685.39 g/mol 6.55  
2-3 1595.75 g/mol 
 
2-4 888.59 g/mol 3.29  
2-5 1798.867 g/mol 3.61  
2-6 685.47 g/mol 29.1  
2-7 813.57 g/mol 2.41  
2-8 742.49 g/mol 18.2 
2-9 839.56 g/mol 120.7  
cycloL1.1 796.61 g/mol 1.75 
cycloL1.2 822.62 g/mol 64,870 
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binding affinity for EGFR while cycloL1.2 showed a decrease affinity for EGFR similar to the efficacy 
observed with peptide 2-9. Of all EGFR-L1 derivatives synthesized and characterized by SPR 2-7 provided 
the best binding affinity. All peptides have been characterized and their sequences confirmed using 
MALDI-TOF. 
2.6 Experimental  
 
2.6.1 General Information 
All solvents and reagents used in the synthesis of peptides were performed with reagents purchased 
from Sigma Aldrich peptide synthesis grade. Required amino acids and resin were purchased from either 
Anaspec, AAPPTec or Applied Biosystems.  
2.6.2 General Procedure for Synthesis for Linear Peptide Sequences 
Peptide sequences were prepared on a 0.2 mmol scale following standard Fmoc Chemistry. A 4-
fold excess of the L-Fmoc protected amino acids or D-Fmoc protected amino acids were coupled using 
TBTU/HOBT as the activating agent and coupling additive. The peptide sequences prepared using this 
methodology are found in Table 4. After the final amino acid is added a final Fmoc deprotection was 
performed using 20% piperdine in DMF for 10 minutes and released from the resin beads followed by a 
second addition for 15 minutes. This was trailed by washing the resin beads with DMF five times and then 
with DCM five times. The resin beads were then allowed to dry overnight under high vacuum. Cleavage 
from resin: Following drying of resin beads a cleavage cocktail consisting of TFA (94%), Water (2.5%), 
Liquid Phenol (2.5%), and Triisopropylsilane (1%) is added to the resin for 3 hours. The cocktail was then 
released into cold anhydrous ethyl ether, and centrifuged. The supernatant was decanted away, and repeated 
three times. The pellet is then dissolved in water and acetonitrile (90/10). The solution is then frozen and 
lypholized. Reverse-phase HPLC analysis was performed with a Waters 2545 Quaternary Gradient Module 
(Waters, USA), Waters Sample Injector, and 2489 UV/Visible Detector, which are controlled by Waters 
Empower 2 software (Waters, USA).  Separations were completed on an X-Bridge BEH300 Prep C18 (5 
μm, 10 x 250 mm) with a X-Bridge BEH300 Prep Guard cartridge 300 Å (5 μm 10 x 10 mm) at a 4 mL/min 
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flow rate with UV detection for peptides 220 nm using a stepwise gradient. The solvent system for peptide 
purification consisted of milpure water and HPLC grade acetonitrile with 0.1% TFA. Mass Specta were 
acquired using Bruker Ultraflex Extreme MALDI Tandem TOF Mass Spectometer with α-cyano-4-
hydroxycinnamic acid (CHCA) was used for the matrix. Fractions of HPLC purity (> 95%) with the 
anticipated mass were combined and lyophilized.   
2.6.3 General Procedure for Synthesis for Cyclic Peptide Sequences 
Cyclic peptides were prepared using 1.2mmol/g of CTC resin was placed in a polypropylene 
reaction vessel including a polypropylene frit.  The resin was swollen with dry DCM (10 mL/gram of resin) 
for 30 minutes after which the solvent was drained.  Fmoc-Leu-OH (297 mg, 0.84 mmol, 0.7 equivalents) 
was dissolved in dry DCM and DIEA (3.5 equiv) was added.  The amino acid solution was added to the 
resin and shaken for 1 hour.  After this time, the resin was drained and washed with DMF. Unreacted sites 
on the resin were capped with DCM/MeOH/DIEA (80:15:5) twice for 15 minutes.  The resin was washed 
again with DMF (5 x 30 sec) followed by DCM. After drying the resin under vacuum overnight, the 
substitution level of the resin was determined by a quantitative Fmoc test or UV test. After the substitution 
level was determined (usually about 0.5 mmol/g), the Fmoc-Leu-CTC resin was deprotected using 20% 
piperidine in DMF  and washed with DMF followed by DCM.  The H-Leu-CTC resin was dried under 
vacuum and then stored at 4ºC.  The Cyclo.L1.1 and Cyclo.L1.2 were prepared on a Tribute peptide 
synthesizer (Protein Technologies, Tucson, AZ) utilizing a standard Fmoc peptide chemistry protocol on a  
.1 mmol scale using the previously loaded H-Leu-CTC and H-(d)Leu-CTC resins, respectively.  Side-chain 
functionalities were protected with tert-butyl (Thr), NG-2,2,4,6,7-pentamethyldihydrobenzofuran-5-
sulfonyl (Arg) and tert-butyloxycarbonyl (Lys).  In the case of peptide Cyclo.L1.2, Fmoc-Lys(N3)-OH was 
used. Five fold excess of Fmoc-amino acids and HCTU, in the presence of 10 equivalents of DIEA were 
used for each of the coupling steps (10 min) with DMF as the solvent.  After the synthesis of each sequence 
was complete, the final Fmoc groups are removed using 20% piperidine in DMF for 15 minutes.  The resin 
from each synthesis was washed with DMF and DCM. The side chain protected peptides were cleaved from 
the resin with 5 mL of 1% TFA in DCM for 5 min.  The cleavage reactions were repeated for a total of 10 
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times.  The cleavage solutions for each respective peptide were combined and concentrated under vacuum.  
The residues were dissolved in water:acetonitrile containing 0.05% TFA (1:1, 20 mL), frozen and 
lyophilized to yield white solids.  The peptides were dissolved in DMF to yield 2 mM solutions after which 
HATU (2.5 equivalents) and DIEA (5 equivalents) were added.  The cyclization reactions were stirred for 
3 hours, and then the peptides were placed under high vacuum to remove the DMF (usually overnight) to 
yield an oil.  Protecting groups were removed from the peptides using TFA/water/TIPS (3 mL, 96:2:2) for 
2.5 hours.  Cold diethyl ether was then added to the peptide solutions to precipitate the crude cyclized 
peptides.  The peptides were centrifuged for 10 minutes (10,000 rpm) and the ether layers decanted.  Fresh 
cold diethyl ether was added, and the pelleted peptides were resuspended.  The peptides were centrifuged 
again, and the procedure was repeated 5 times for each peptide.  After the final ether wash, the peptide 
pellets were dissolved in a minimal amount of water containing 0.1% TFA, frozen and lyophilized.  HPLC 
analysis was performed with a Waters 616 pump, Waters 2707 Autosampler, and 996 Photodiode Assay 
Detector which are controlled by Waters Empower 2 software. The separation was performed on an Agilent 
Zorbax 300 SB-C18 (5 um, 4.6 x 250 mm) with an Agilent guard column Zorbax 300 SB-C18 (5 um, 4.6 
x 12.5 mm).  Elution was done with a linear 5% to 55% gradient of solvent B (0.1% TFA in acetonitrile) 
into A (0.1% TFA in water) over 50 min at a 1 mL/min flow rate with UV detection at 215 nm.  Preparative 
HPLC runs were performed with a Waters prep LC Controller, Waters Sample Injector, and 2489 
UV/Visible Detector that are controlled by Waters Empower 2 software. The separation was performed on 
a Agilent Zorbax 300SB-C18 PrepHT column (7 um, 21.2× 250 mm) with Zorbax 300SB-C18 PrepHT 
guard column (7 um 21.2 × 10 mm) using a linear 5% to 55% gradient of solvent B (0.1% TFA in 
acetonitrile) into A (0.1% TFA in water) over 50 min at a 20 mL/min flow rate with UV detection at 215 
nm.  Fractions of high (>95%) HPLC purity with the expected mass were combined and lyophilized 
followed by high resolution mass spectra of each peptide.  
2-1: Peptide Sequence:LARLLT-CONH2  1H NMR (500 MHz, DMSO-d6, 308K): δ 8.65 (d, J= 7.40 Hz, 
2H), 8.10 (d, J = 7.9 Hz, 4H), 7.91 (d, J = 8.1 Hz, 2H), 7.52 (t, J = 5.8 Hz, 1H), 7.44 (d, J = 8.5 Hz, 2H), 
7.09 (d, J = 9.0 Hz, 3H), 4.41 (t, J = 7.2 Hz, 2H), 4.33 (t, J = 7.8 Hz, 3H), 4.27 (d, J = 7.1 Hz, 1H),  4.07 
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(dd, J = 8.4 Hz, 2H), 4.02 (s, 1H), 3.80 (s, 1H), 1.74 (m, 9H), 1.51 (m, 8H), 1.24 (d, J = 6.7 Hz, 5H), 1.00 
(d, J = 6.3 Hz, 3H), 0.87 (m, 18H). MS(MALDI-TOF): m/z 685.390 . Calc’d. for C31H61N10O7+ 685.891. 
2-3: Peptide Sequence: GYHWYGYTPQNVI-CONH2. 1H NMR (500 MHz, DMSO-d6) δ 9.13 (d, J = 
20.0 Hz, 5H), 8.45 (m, 3H), 8.20 (t, J = 9.6 Hz, 2H), 8.04 (m, 4H), 7.90 (t, J = 10.5 Hz, 3H), 7.66 (d, J = 
9.0 Hz, 2H), 7.55 (d, J = 7.9 Hz, 3H), 7.38 (d, J = 10.7 Hz, 1H), 7.29 (d, J = 8.2 Hz, 1H), 7.16 (d, J = 23.0 
Hz, 3H), 7.08 (s, 1H), 6.98 (m, 9H), 6.74 (s, 2H), 6.62 (m, 6H), 4.55 (m, 5H), 4.39 (m, 4H), 4.12 (m, 5H), 
3.89 (m, 1H), 2.12 (t, J = 7.6 Hz, 2H), 2.02 (m, 4H), 1.88 (m, 4H), 1.75 (d, J = 18.1 Hz, 5H), 1.43 (m, 3H), 
1.24 (s, 4H), 1.10 (s, 5H), 0.81 (m, 18H). MS(MALDI-TOF): m/z calcd for C77H101N19O19 [M+H]+ 
1595.752; found 1596.697. 
2-4: Peptide Sequence:3PEG-LARLLT-CONH2. 1H NMR (500 MHz, DMSO) δ 8.13 (d, J = 7.4 Hz, 2H), 
8.00 (dd, J = 19.6, 7.7 Hz, 2H), 7.93 (d, J = 8.1 Hz, 1H), 7.78 (s, 2H), 7.57 (t, J = 5.4 Hz, 1H), 7.38 (d, J = 
8.5 Hz, 1H), 7.05 (d, J = 20.9 Hz, 3H), 4.28(m, 5H), 4.05 (m, 3H), 3.57 (m, 16H), 3.10 (m, 2H), 2.98 (dd, 
J = 10.5, 5.2 Hz, 2H), 1.64 (m, 4H), 1.49 (m, 10H), 1.20 (d, J = 7.0 Hz, 4H), 1.00 (d, J = 6.2 Hz, 3H), 0.87 
(m, 18H). MS(MALDI-TOF): m/z calcd for C40H78N11O11  [M]+ 888.588; found 888.542. 
2-5: Peptide Sequence:3PEG-GYHWYGYTPQNVI-CONH2. 1H NMR (500 MHz, DMSO) δ 13.96 (s, 
1H), 10.72 (s, 1H), 9.12 (s, 3H), 8.89 (s, 1H), 8.07 (m, 6H), 7.68 (m, 4H), 7.40 (s, 1H), 7.30 (d, J = 7.9 Hz, 
1H), 7.20 (m, 3H), 7.01 (m, 9H), 6.75 (s, 1H), 6.61 (m, 5H), 4.73 (m, 8H), 4.42 (m, 5H), 4.16 (m, 3H), 4.08 
(m, 2H), 3.91 (m, 3H), 3.70 (m, 4H), 3.58 (m, 16H), 2.91 (m, 5H), 2.65 (m, 3H), 2.37 (m, 2H), 2.06 (m, 
7H), 1.90 (d, J = 15.3 Hz, 3H), 1.74 (m, 2H), 1.43 (m, 2H), 1.25 (s, 3H), 1.10 (m, 4H), 0.84 (m, 10H). 
MS(MALDI-TOF): m/z calcd for C86H119N20O23 [M+H]+ 1799.876; found m/z 1799.972. 
2-6: Peptide Sequence: tllarl-CONH2. 1H NMR (500 MHz, DMSO-d6, 308K) δ 8.53 (d, J = 8.0 Hz, 1H), 
8.19 (d, J = 7.9 Hz, 1H), 8.09 (s, 3H), 7.93 (dd, J = 10.8 Hz, 2H), 7.78 (d, J = 8.3 Hz, 1H), 7.54 (t, J = 5.7 
Hz, 1H), 7.26 (s, 2H), 6.96 (s, 2H), 4.40 (m, 1H), 4.24 (m, 4H), 3.78 (t, J = 6.8 Hz, 1H), 3.58 (s, 1H), 3.09 
(q, J = 6.5 Hz, 3H), 1.63 (m, 5H), 1.47 (m, 9H),  1.21 (d, J = 7.1 Hz, 4H),  1.14 (d, J = 6.3 Hz, 3H), .88 (m, 
18H). MS(MALDI-TOF): m/z 685.361. Calc’d for C31H61N10O7+ 685.891. 
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2-7: Peptide Sequence: GLARLLT-CONH2. 1H NMR (500 MHz, DMSO-d6, 308K): δ 8.44 (d, J = 8.3 
Hz, 1H), 8.30 (d, J = 7.2 Hz, 1H), 8.13 (d, J = 8.0 Hz, 2H), 7.93 (m, 4H), 7.43 (d, J = 8.5 Hz, 2H), 7.08 (d, 
J = 13.4 Hz, 3H), 4.43 (m, 1H), 4.28 (m, 4H), 4.04 (m, 3H),  3.84 (d, J = 5.6 Hz, 1H), 3.08 (q, J = 6.5 Hz, 
2H), 1.60 (m, 5H), 1.47 (m, 10H), 1.20 (d, J = 7.1 Hz, 3H),  0.99 (d, J = 6.3 Hz, 4H),  0.86 (m, 18H). 
MS(MALDI-TOF): m/z 742.991. Calc’d. for C33H64N11O8+ 742.493.   
 
2-8: Peptide Sequence: KLARLLT-CONH2.  1H NMR (500 MHz, DMSO-d6, 308K) δ 8.49 (s, 1H), 8.25 
(d, J = 7.3 Hz, 1H), 8.14 (d, J = 7.8 Hz, 4H), 7.92 (m, 3H), 7.52 (d, J = 5.5 Hz, 1H), 7.44 (d, J = 8.6 Hz, 
2H), 7.08 (d, J = 9.8 Hz, 2H), 4.39 (q, J = 7.1 Hz, 2H),  4.29 (m, 5H),  4.07 (m, 2H), 3.78 (s, 1H), 3.08 (d, 
J = 7.2 Hz, 4H),  2.75 (t, J = 7.8 Hz, 2H), 1.64 (m, 6H), 1.48 (m, 10H), 1.22 (m, 6H), 0.99 (d, J = 6.3 Hz, 
4H), 0.86 (m, 18H). MS (MALDI-TOF): m/z [M+H] 814.0550. Calc’d. for C37H73N12O8+ 813.567.  
2-9: Peptide Sequence:K(N3)LARLLT-CONH2. 1H NMR (500 MHz, DMSO-d6 308K) δ 8.45 (d, J = 8.2 
Hz, 1H), 8.17 (d, J = 7.2 Hz, 1H), 8.06 (s, 4H), 7.91 (dd, J = 14.7 Hz, 3H), 7.43 (d, J = 11.0 Hz, 2H), 7.08 
(d, J = 12.7 Hz, 2H),  4.88 (t, J = 5.3 Hz, 1H),  4.34 (m, 6H),  4.06 (m, 3H),  3.79 (s, 1H),  3.09 (q, J = 6.5 
Hz, 2H),  1.66 (m, 6H),  1.49 (m, 11H),  1.37 (t, J = 7.5 Hz, 2H),  1.20 (d, J = 7.1 Hz, 4H),  1.00 (d, J = 6.3 
Hz, 4H),  0.87 (m, 18H). MS (MALDI-TOF): m/z 839.4219. Calc’d. for C37H71N14O8+ 839.558.  
Cyclo.L1.1 Peptide sequence: Cyclo(KLARLLT). 1H NMR (500 MHz, DMSO-d6) δ 8.51 (d, J = 8.9 Hz, 
1H), 8.43 (d, J = 5.6 Hz, 1H), 8.30 (d, J = 7.4 Hz, 1H), 8.10 (s, 1H), 7.78 (t, J = 9.6 Hz, 2H), 4.32 (m, 2H), 
4.22 (m, 6H), 4.03 (q, J = 7.3 Hz, 1H), 3.91 (m, 1H), 2.93 (d, J = 50.6 Hz, 6H), 2.77 (t, J = 8.4 Hz, 1H), 
1.78 (m, 5H), 1.58 (m, 12H), 1.29 (d, J = 7.2 Hz, 4H), 1.09 (d, J = 6.3 Hz, 1H), 1.03 (d, J = 6.4 Hz, 4H), 
0.97 (d, J = 6.6 Hz, 4H), 0.90 (m, 18H). MS (MALDI-TOF): m/z 796.609. Calc’d. for C37H70N11O8+ 796.540. 
Cyclo.L1.2. Peptide sequence: Cyclo (K(N3)larllt). 1H NMR (500 MHz, DMSO-d6) δ 8.23 (dd, J = 21.2, 
7.5 Hz, 1H), 8.07 (d, J = 37.3 Hz, 1H), 7.91 (d, J = 9.3 Hz, 2H), 7.53 (t, J = 5.4 Hz, 1H), 4.35 (m, 4H), 4.16 
(q, J = 7.3 Hz, 2H), 4.09 (dd, J = 9.8, 5.4 Hz, 3H), 4.01 (m, 4H), 3.94 (d, J = 7.9 Hz, 1H), 1.77 (m, 7H), 
1.53 (m, 6H), 1.56 – 1.50 (m, 11H), 1.35 (d, J = 7.3 Hz, 4H), 1.07 (d, J = 5.9 Hz, 4H), 0.87 (m, 18H). ). 
MS (MALDI-TOF): m/z 822.616. Calc’d. for C37H68N13O8+ 822.530. 
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2.6.4 SPR Methods 
Surface Plasmon Resonance was performed using Biacore X100 from GE Health Sciences. Pure 
recombinant protein EGFR was obtained from Leinco Technologies (St. Louis, MO). HBS-EP+ buffer and 
100 mM glycine at pH 4, 4.5, 5, 5.5 were purchased from GE Health Science. The extracellular domain of 
EGFR protein was immobilized on a CM5 sensor chip (GE Healthcare Biosciences) at a rate of 10 μL/min 
using a normal amine coupling procedure. The carboxyl groups on the CM5 chip were activated using a 
solution containing 0.2 M N-ethyl N-(dimethylaminopropyl) carbodiimide (EDC) and 0.05 M N-
hydroxysuccinimide (NHS) (35μL solution, with a flow rate of 5 μL/min). The running buffer for peptides 
was HBS-EP+ buffer was diluted 10 times to contain 0.01 M HEPES, 0.15 M NaCl, 3mM EDTA, and 
0.005% surfactant P20 at pH 7.5. Peptides were dissolved in buffer were used as analyte. The running buffer 
for conjugates and BODIPY was HBS-EP+ buffer was diluted 10 times to contain 0.01 M HEPES, 0.15 M 
NaCl, 3mM EDTA,  0.005% surfactant P20 at pH 7.5, but brought to a 4% DMSO concentration. SPR 
sensograms were obtained and the association and dissociation rates were obtained from 0 to 200 μM 
concentrations.  
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CHAPTER 3. Design and Synthetic Strageties for BODIPY-Peptidic 
Conjugates for Diagnosis of CRC via Peptide Linkages 
3.1  Introduction 
 
Visualizing the integrity of cells, especially cancerous cells, has become a technique of 
interest. Integration of labeling entities such as peptides, proteins, or DNA with non-radioactive 
fluorescent labels is a widely applicable area for understanding the cellular mechanisms.1 In this 
instance BODIPY dyes are attractive and promising for labeling with fluorescence and have 
progressed as highly sought after entities for biomarker labeling.2  
Recent advantages in the synthesis of BODIPY fluorophores have yielded a multitude of 
BODIPY conjugates readily available commercially. Companies such as Invitrogen, in particular, 
have designed various BODIPY fluorophores that cover the full visible spectrum, and have 
functionalization for conjugation to various sources such as proteins, lipids, polysaccharides, and 
peptides, which are available and ready to partake in labeling experiments.3-5 However, 
disadvantages to these commercially available probes are apparent due to their small Stokes shifts; 
moreover, the readily available conjugates are exceptionally expensive and unsuitable for standard 
bioconjugation procedures on small or large scales. As a result, conquering the most important 
challenge of BODIPY probe development includes developing a fluorophore equipped with 
functional groups ready to covalently link BODIPY dyes to biomolecules.6-7  
Developing an efficient method for attaching BODIPY dyes and peptides together insists 
that a clear position for attachment be present. In peptide synthesis, the most evident attachment 
point is revealed during the last deprotection of the Fmoc group yielding a free amino group at the 
N-terminus of the sequence. This reactive amino group can undergo a variety of transformations, 
however, the most common method is amidation. The free amino group of the peptide sequence 
can react in the presence of coupling agents and base with a carboxylic BODIPY dye to return the 
desired amide derived conjugate.  
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The simplicity of amino group formation for peptide sequence is important, as carboxylic 
BODIPY dyes are not as easily developed. There are various methods that exist to create carboxylic 
BODIPY dyes at either the meso, 2,6-, or 3.5- position.  Among these methods, introduction of the 
carboxyl moiety is most often seen via 2,6-8-9 or 3.5- positions10-11,
 
on the BODIPY core through  
asymmetrical dye formation. The synthesis of asymmetrical dyes is usually created from the 
condensation of two different pyrroles with one pyrrole bearing a carboxyl group. The condensation 
of mixed pyrroles is more challenging as removal of side products tends to be lengthy.12-13 This 
difficulty in purification can lead to percent yields being extremely low, and tedious for future 
bioconjugation steps.14-15
 
Past synthetic approaches to achieve carboxylic BODIPY dyes involved 
protection/deprotection steps that caused potential issues for the BODIPY core.16  Protecting the 
carboxylic acid as an ester normally requires the use of basic conditions to remove the ester and 
reveal the necessary carboxylic acid. However, the core of the BODIPY dye is particularly unstable 
under basic conditions.6, 17-19 Although favoring methods to remove esters under aqueous acidic 
conditions exist, to date yields for the corresponding BODIPY dye have the potential of yielding 
low yields due to removal of the BF2 chelation unit. Consequently, carboxylic BODIPYs with easier 
and more convenient syntheses are significant for their practical applications. Due to the 
photophysical attractiveness of BODIPYs, synthesizing the necessary carboxylic BODIPY that is 
formed in minimal steps and high yielding is desirable for creating a fluorescent probe that is 
capable of in vivo imaging of CRC.  
In 2009, a method for carboxylic BODIPY formation that bypassed the need for mixed 
pyrrole was revealed. Peng and coworkers developed a cascade of syntheses that eliminated the 
formation of protected carboxyl groups, asymmetrical dyes, and released the necessary acid in a 
two-step one pot reaction.20 The synthetic strategy investigated the condensation of pyrrole entities 
with various anhydrides to determine the efficacy for carboxyl BODIPY formation. In these 
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reactions, the first step involves reacting a pyrrolic moiety with an anhydride to create the 
dipyrromethene structure, followed by complexation of the molecule with boron trifluoro 
diethyletherate to form the full BODIPY structure with a free carboxyl chain in  21-25% yields 
(Scheme 1).20 
 
Scheme 1. Peng and coworkers’ one pot two-step synthesis of carboxylic BODIPYs.20 
Peng’s efforts revealed a method to achieve the desired BODIPY core bearing a free 
carboxylic acid, and the dismissal of the normal harsh conditions, long reaction times, and varied 
steps were reduced to a one-pot, two-step reaction under reflux. In order to prepare a carboxylic 
BODIPY core under moderate conditions to pair with the peptides designed in Chapter 2, the 
methods mentioned above were further explored.  The performance of the new probes is studied 
for determination of the photophysical and in vitro properties. 
3.2  Results and Discussion 
 
3.2.1 Carboxylic BODIPY Dyes 
 
Peng et al. investigation’s contained synthesis of carboxylic BODIPYs by way of 
condensation of pyrroles and carboxylic anhydrides to form the necessary carboxyl 
dipyrromethene. Following the dipyrromethene formation, the BODIPY core is developed by 
coordination with BF3OEt2. The key step in this reaction was reported as the formation of the 
carboxyl dipyrromethene, or step one (Scheme 2). The conditions during the condensation were 
noted to be of great success under anhydrous conditions, thus molecular sieves are applied to rid 
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the reaction of the water produced during the dipyrromethene construction. Dehydration of the 
ensuing water produced allows the reaction to bypass dipyrromethane, an unstable intermediate, 
and form the dipyrromethene in situ.  
 
Scheme 2. Peng and coworkers’ pivotal step in the synthesis of carboxylic BODIPYs.20 
To replicate Peng’s reactions, glutaric anhydride (3-1) and phthalic anhydride (3-2) were 
used for the dicarboxylic anhydrides. Compounds 3-1 and 3-2 were condensed with 2,4-
dimethylpyrrole under inert conditions to yield the corresponding dipyrromethene. This 
condensation is done in the presence of an acid catalyst BF3OEt2 in tetrahydrofuran (THF) over 
the course of eight hours to promote the formation of the dipyrromethene by coordinating to the 
anhydride inserting a partial positive charge and ensuring the pyrroles nucleophilic behavior. The 
resulting dipyrromethene was then deprotonated under basic conditions using triethylamine (TEA) 
the following dipyrromethene is then complexed with boron trifluoride etherate (BF3OEt2) to form 
carboxylic BODIPY compounds 3-3 and 3-4 in four hours (Scheme 3).  
Purifications of these BODIPY dyes were performed on these compounds using two 
different systems deemed by Peng et al. BODIPY 3-3 and 3-4 was purified by silica gel column 
chromatography using a hexane, ethyl acetate (EtOAc), acetic acid (HOAc) mixture 80:40:1; and 
hexane, ethyl acetate, methanol (MeOH) mixture 100:30:3  respectively. Purification of these 
compounds proved to be quite strenuous as thin layer chromatography (TLC) showed several 
impurities and column chromatography was equally inefficient, and a pure product was only 
achieved in trace amounts as shown by mass spectrometry. Separation of the crude mixture proved 
difficult due to numerous impurities near impossible to remove.  
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Scheme 3. Synthesis of carboxylic BODIPYs 3-3 and 3-4 using conventional heating methods.30 
In an attempt to improve the carboxylic BODIPY yields, microwave-assistance (MW) was 
applied as seen in SPPS. Previously MW provided cleaner reaction efforts at a fraction of the time 
seen in conventional bench-top synthesis of peptides in Chapter 2. In BODIPY synthesis, we 
speculated that the homogeneous and speedy heating would result in substantial accelerations in 
the key step (i.e. dipyrromethene development.) The enhanced heating of the reaction mixture 
would allow for ideal conditions that are often neglected in normal heating measures such as reflux. 
21 
Irradiating the reaction mixture under microwave conditions produces an efficient 
thorough internal heating over the entire solution based on dielectric properties. The extent of the 
energy transferred is dependent on the dielectric properties of the molecules in the mixture. 
Compounds  or solvents with high dielectric constants tend to absorb microwave energy, whereas 
less polar substances absorb poorly.22 Therefore, reactions performed in MW can manufacture high 
yields while diminishing the quantity of side-products.21 
The same constituents used before, 2,4-dimethylpyrrole, compounds 3-1 and 3-2 were 
subjected to condensation, however this time, using MW conditions to form the dipyrromethene 
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core, and then cooled to room temperature before subjecting each reaction to complexation in the 
microwave to form BODIPYs 3-3 and 3-4 (Scheme 4).   
 
Scheme 4. Synthesis of carboxylic BODIPYs 3-3 and 3-4 using microwave-assistance. 
 As assumed, TLC analysis of each compound showed fewer impurities, and column 
purification was indeed successful. Carboxylic BODIPY 3-3 initially was not produced in 
reasonable yield, which we believed was partially due to the solvent used, tetrahydrofuran (THF). 
THF is not a good microwave solvent as it does not absorb the microwave radiation as well as other 
solvents, and this is due to its low dielectric constant, 7.58 as seen in Table 1. The polar atmosphere 
necessary to push reactions to completion is not applicable in THF, however attempts to aid in this 
effort with the incorporation of solvents with higher dielectric constants were applied. Acetonitrile 
(ACN), is a prime solvent for MW synthesis as it holds a dielectric constant of 37.5, which is 5-
fold higher than that seen with THF. Conversely, the adaptation of ACN as the solvent during MW 
synthesis of BODIPY 3-3 still did not produce an increase in BODIPY formation as no product 
was found. This could be partially due to solubility issues of anhydride 3-1 in ACN.  
Several efforts to increase the yields of BODIPY 3-3 and 3-4.were attempted, such as 
changing solvent and temperature conditions, however neither alteration was able to yield BODIPY 
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3-4, or cause a true increase in yield of BODIPY 3-3 were found (Table 1).  
Table 1: Synthesis of Carboxylic BODIPYs from 2,4-dimethylpyrrole 
BODIPY METHOD TEMP (oC) SOLVENT % YIELD 
3-3 BT 77 THF 3.3 
3-3 MW 110 THF 1.7 
3-3 MW 110 ACN - 
3-4 BT 60 ACN 2.4 
3-4 MW 100 ACN 4.8 
  
3.2.2 Optimization of BODIPY Synthesis 
 
Several attempts to rectify downfalls associated with carboxylic BODIPY dye synthesis 
led to an evaluation of anhydrides 3-1 and 3-2, and the premise for BODIPY formation. 
Condensation of anhydride 3-1 with 2,4-dimethylpyrrole releases a very short alkyl chain between 
the core of the BODIPY dye and the point of attachment at the meso-position. This short alkyl 
chain is beneficial for allowing each entity to extend in a preferred conformation, away from the 
core (Figure 1). Anhydride 3-2 condensation with 2,4-dimethylpyrrole source would yield a more 
sterically hindered carboxylic BODIPY however the possibility of a more fluorescent probe due to 
the restriction of rotation of the phenyl substituent at the meso position containing the carboxylic 
acid allowing for an increased quantum yield. 23 
Ultimately, the disadvantage of using either anhydride is the reactivity of the anhydride 
toward the addition of 2,4-dimethylpyrrole during the formation of the dipyrromethene. To counter 
this issue, increased nucleophilicity of the pyrrole, in the reaction is strongly desired. To achieve 
this goal, a Grignard of the desired 2, 4-dimethylpyrrole was considered to increase the reactivity 
and push the reaction toward BODIPY formation.  
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To form th desired Grignard pyrrole, 2,4-Dimethylpyrrole was allowed to react with methyl 
magnesium chloride in 3M diethyl ether and refluxed for  one hour. The resulting Grignard pyrrole 
was then condensed with anhydride 3-1 and 3-2 in THF at room temperature for 12 hours. The 
more nucleophilic pyrrole was still engaged with boron trifluoride source to coordinate with 
anhydrides in solution to provide the optimal conditions for condensation of the two entities.  The 
consequential dipyrromethene was then coordinated as seen before using TEA and BF3OEt2 to yield 
BODIPY 3-3 and 3-4 in improved yields (Scheme 5). 
 
Scheme 5. Synthesis of carboxylic BODIPYs 3-3 and 3-4 Grignard pyrroles. 
The one pot two step carboxylic BODIPY dye concept was expelled and used as a one pot 
reaction, but now requiring three steps producing yields that showed a considerable increase over 
10-fold as shown in Table 2. The development of BODIPY dyes with a carboxylic acid as a point 
of attachment identified several disadvantages such as poor yields, multiple impurities, and various 
complications. However, instituting a more reactive pyrrole has resulted in the increase the yields 
of product formation considerably, and also assist with limiting the amount of side products formed. 
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The reactions were purified in the same manner as Peng’s method, and were readied for 
conjugation. 
 
Table 2: Synthesis of Carboxylic BODIPYs from 2,4-dimethylpyrrole 
 under Grignard Conditions 
BODIPY Equiv of Grignard % YIELD 
3-3 None 3.3% 
3-3 1.1 50% 
3-4 None 2.4% 
3-4 1.1 70% 
 
3.2.3 Activation of BODIPY dye   
 
Conjugation of fluorescent dyes and peptide/amino acids is most frequently performed 
using peptide chemistry via SPPS or solution phase. Of these techniques, SPPS provides a cleaner 
reaction and is considered most convenient for peptide synthesis, however, there are several factors 
of SPPS that deems this method unfavorable for some fluorophore conjugation procedures. Normal 
SPPS solvents used, such as DMF, are not favored due to possible solubility issues for fluorophores. 
Another prominent issue is the adsorption of the fluorophore to the resin beads, making it almost 
impossible to retrieve conjugates after cleavage.24 Lastly, the conditions of cleavage of product 
from the resin may be harsh for certain fluorophores, especially BODIPY dyes.19 The TFA cocktail 
used can potentially degrade the core of the BODIPY dye.  For these reasons conjugation methods 
tend to lean toward solution phase protocols for amide bond formation. 
 Solution phase protocols to connect dyes to biomolecules have shown to be mostly low 
yielding; thus, activating dyes prior to interaction with biomolecules have been employed to combat 
these issues. Activation of BODIPY dyes with N-hydroxysuccinimide (NHS) or another coupling 
agent that is most prominent in peptide building are routes to create a highly active BODIPY dye 
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that is more reactive than its carboxylic counterpart to interact with free amino group on desired 
peptides 2-1 and 2-2.20, 25-26  
Activation of BODIPYs 3-3 and 3-4 were first completed using dicyclohexylcarbodiimide 
(DCC) to create an electrophile that is then attacked by N-hydroxyl succinimide (NHS) in 
anhydrous acetonitrile (ACN). These reactions should yield  stable active NHS-BODIPY ester 
intermediates BODIPY 3-5 and 3-6. However the desired product was an intermediate to the actual 
product isolated BODIPY 3-7 using microwave-assistance (Scheme 6).  
 
Scheme 6. Activation of carboxylic BODIPYs 3-3 and 3-4 using N-hydroxysuccinimide using 
MW. 
 A side product with comparable molecular weight was formed, and was determined 
through X-ray crystallography to be an undesired product 3-7 (Figure 1). Activation of BODIPY 
3-4 was more promising and product 3-6 was formed in 84% yield (Table 3), however including a 
method to improve the yield of reaction is also preferred.  
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Figure 1. Crystal Structure of undesired BODIPY 3-7 of activated Glutaric BODIPY. 
To counter the formation of BODIPY 3-7 and bids to increase the yield of BODIPY 3-5, a 
second method for producing NHS-activated BODIPY dye was investigated. BODIPY 3 and 4 
were reacted with triethylamine to activate the carboxylic acid in the presence of N,N’-
disuccinimidyl carbonate in anhydrous DMF (Scheme 7). 
 
Scheme 7. Activation of carboxylic BODIPYs 3-3 and 3-4 using N,N’-disuccinimidyl carbonate. 
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Activated BODIPY 3-3 and 3-4 varied depending on the method used to activate them as 
shown in Table 3, as well as the product created. BODIPY 3-5 was synthesized from method 2 in 
higher yield where N’N,-disuccinimidyl carbonate was the source to create the ester. BODIPY 3-6 
was produced from method 1 in higher yield using NHS. BODIPY 3-6 preference of NHS may be 
due to a steric interaction involving N’N-disuccinimidyl carbonate and the methyl groups located 
at C1 and C7 positions of the BODIPY core. BODIPY 3-5 and 3-6 were purified on silica gel using 
dichloromethane (DCM) and ethyl acetate (EtOAc)  in a 12:1 ratio . 
Table 3: Activation of Carboxylic BODIPY dyes 3-3 and 3-4  
 
Method Product SUCCINIMIDE TEMP 
(oC) 
SOLVENT %YIELD 
1 3-5 NHS 110 ACN trace 
1 3-6 NHS 100 ACN 84.1 
2 3-5 N,N’-DISUCCINIMIDYL 
CARBONATE 
77 DMF 76.3 
2 3-6 N,N’-DISUCCINIMIDYL 
CARBONATE 
60 DMF 25.3 
 
3.2.4 Conjugation of  BODIPY dyes to Peptide Ligands  
Compounds 3-5 and 3-6 were first introduced to peptides 2-1 and 2-2 using microwave-
assistance to form the desired conjugates. Compounds 3-5 and 3-6 were activated using TEA  and 
coupled to each peptide in DMF. The resulting compounds were then removed from the resin using 
the aforementioned TFA cocktail, and lyophilized, which should have produced conjugates 3-8, -
9, -10, and -11 (Scheme 8). 
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Scheme 8. Coupling of activated BODIPYs 3-5 and 3-6 to peptide. 
Of the four conjugates, conjugate 3-11 was the only compound not to show any molecular 
ion through MALDI mass spectrometry (Table 4). Conjugate 3-10 did show product, however, the 
product was produced only in trace amounts. These two compounds are believed to have larger 
steric interaction preventing full conjugation of the peptide to the BODIPY dye. Conjugates 3-8 
and 3-9 were synthesized, but after purification, conjugate 3-8 no longer fluoresced which was 
confirmed by mass spectrometry to be missing the BF2 chelation. In an attempt to restore the BF2 
complex the dipyrromethene product of conjugate 3-8 was subjected to complexation with boron 
trifluoroetherate and TEA, which was unsuccessful. Conjugate 3-9 synthesis did not yield enough 
compound for further studies, and as seen with conjugate 8 the BF2 complex was also removed 
after a while.  
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Each successful conjugate was purified using RP-HPLC, and identified by mass 
spectrometry. Overall, all conjugates were confirmed in very low yields, therefore, indicating the 
need for optimization of reaction conditions and purifications for conjugates in Table 4. Of the 
products, conjugates containing peptide EGFR-L1 proved to be more promising for the conjugation 
via NHS activation.    
Although studies suggested SPPS is unfavorable in conjugation procedures for peptides 
and fluorophores, an attempt to confirm these findings were performed. SPPS chemistry was 
investigated with peptide 2-1 and activated BODIPYs 3-5 and 3-6.  Each activated dye was allowed 
to stir with TEA for one hour, followed by introduction to EGFR-L1 and allowed to react for 36 to 
72 hours (Scheme 9).   
After 72 hours the anticipated conjugates were cleaved from resin beads and investigated 
via Mass Spectrometry, however no product was determined. While minimal fluorescence was 
noted on resin beads, the desired conjugates 3-8, 3-9, 3-10, or 3-11 were also not returned as 
expected. This observation confirmed the previously mentioned rigorous cleavage cocktails, 
possibly degrading any possible conjugates. To ensure activated BODIPY 3-5 and 3-6 were not the 
issues regarding the conjugation, BODIPYs 1 and 2 were further investigated.  
 
Table 4: Results of Solution Phase Conjugation of BODIPY-peptide Conjugates 
Compound Molecular Weight % Yield 
3-8 1001.62 5.8 
3-9 1855.88 .6 
3-10 1035.06 .13 
3-11 1889.89 - 
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Scheme 9. Coupling of activated BODIPYs 3-5 and 3-6 to resin bound peptides 2-1 or 2-2. 
Overall, activated BODIPY dyes 3-5 and 3-6 interaction with either peptide returned very 
little to no compound, and SPPS strategies showed no alleviation to conjugation issues, thus 
requiring the return to carboxylic BODIPY dyes 3-3 and 3-4 to strategize the next step. The 
determination of the more beneficial dye for synthesis of Peptide-BODIPY conjugates was vital. 
Carboxylic BODIPY 3-4 would have a stronger steric interaction with either peptide during 
conjugation, leading to a decrease in percent yields. Alternatively, BODIPY 3-3 has a short alkyl 
chain, distancing the core of the BODIPY dye from the point of attachment making conjugation 
through the meso-position quite easier from this scaffold. For this reason, further efforts toward 
BODIPY-peptide conjugation procedure with BODIPY 3-3 were sustained.  
Solution phase coupling provided minimal product using activated BODIPY dyes, and 
prompting the need for an alternative-coupling agent that would possibly push each reaction to 
completion. Choosing the appropriate coupling agent depends on the chemical properties of every 
component. These properties consist of items such as reactivity, sterics, and stability to name a 
few.27 Various coupling agents are available for peptide synthesis with different advantages for 
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synthesis, however, three coupling agents were investigated for these fluorophore-peptide 
conjugations TBTU, TSTU, and DEPBT (Figure 2).  
 
 
 
 
 
 
 
 
 
 
Figure 2.Coupling reagents TBTU, TSTU, and DEPBT interaction with BODIPY 3-3. 
The first coupling agent considered was TBTU that was used in Chapter 2 for peptide 
synthesis. TBTU was introduced to the carboxylic acid of BODIPY 3-3 in a similar manner. The 
carboxylic acid was allowed to stir for one hour in the presence of TEA followed by the addition 
of a mixture of coupling agent TBTU, additive HOBT, and free peptide 2-1.  Conjugation of peptide 
2-1 and BODIPY 3-3 was successfully, however in 12% yield, slightly higher than what was 
obtained with the NHS activated BODIPY (Scheme 10).  
 
Scheme 10. Coupling of BODIPY 3-3 solution phase to peptide 2-1. 
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Coupling agents TSTU and DEPBT were then investigated under different procedures. 
Unlike TBTU, coupling agents TSTU and DEPBT do not require an additive to assist with 
coupling.28 BODIPY 3-3 was allowed to activate, with either coupling agent TSTU or DEPBT, for 
one hour in the presence of diisopropylethylamine (DIPEA) in DMF. After each reaction showed 
activation by mass spectrometry, each activated BODIPY was added slowly to a solution of .2M 
sodium bicarbonate (NaHCO3) at pH 8.2 containing peptide 2-1 at 0°C. The solution was then 
allowed to stir at 8°C overnight (Scheme 11). Each reaction showed successful conjugation by MS, 
which was purified by RP-HPLC.  
The yield for this reaction was noted at 18% yield, with TSTU proving to be a better 
coupling agent. This increase in percent yield could be explained by the structure of the coupling 
agents (Figure 2).  Comparing TSTU to DEPBT and TBTU the NHS-activated BODIPY formed is 
a smaller intermediate than what is formed in the other cases, furthermore possibly allowing for 
more of the activated intermediate to be formed. The reactivity of TSTU compared to NHS during 
the in situ activation maybe a driving force for conjugate formation.   
Scheme 11. Coupling of BODIPY 3-3 solution phase to peptide 2-1 using TSTU or DEPBT 
coupling agents. 
Although 18% yield was the highest percent yield obtained, further expansion on the 
conjugation platform was necessary. However, an expansion on the peptides utilized was 
considered to assist in increasing the percent yields of the reaction.  Two peptide derivatives of 
parent peptide 2-1 were considered, which have amino acids present that can behave as a small 
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linker between BODIPY 3-3 and the core sequence of the peptides. Peptides 2-6 (GLARLLT) and 
2-7 (KLARLLT) from Chapter 2 were investigated for their potential as targeting molecules with 
BODIPY 3-3. As a comparison peptide 2-3 (GYHWYGYTPQNVI) was also investigated.  
The new peptides were first tested with coupling agents TSTU and DEPBT to identify any 
difference in reaction yields.  Under the conditions seen with peptide 2-1, BODIPY 3-3 was allowed 
to activate, with either coupling agent, for one hour in the presence of diisopropylethylamine 
(DIPEA) in DMF. Each activated BODIPY was added slowly to a solution of the peptide and stirred 
overnight (Scheme 12). 
Scheme 12. Coupling of BODIPY 3-3 solution phase to peptide 2-3, 2-6, 2-7 using TSTU or 
DEPBT coupling agents. 
 It was determined that TSTU was the ideal coupling agent needed to continue synthesis as 
for all peptide derivatives produced as summarized in Table 5. For conjugates 3-12 and 3-13, no 
product was obtained, which was probably due to the steric interaction at the N-terminus of each 
conjugate when trying to activate with coupling agent DEPBT. A longer linker/amino acid is 
necessary, similar to that of conjugate 3-12. When also comparing conjugate 3-12 and conjugate 
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3-8, the small linker seems to have played a positive role in increasing the yield of desired BODIPY 
conjugates to up to 22% yield.   
The effect of the amount of compound solubilized during activation has the potential to 
increase the amount of conjugate returned, and minimize the amount of side products formed.  
 The stability of each reaction was tested in two well-known peptide solvents DMF and 
NMP. Both solvents have similar properties and belong to a class of solvents noted as dipolar 
aprotic solvents that will not interfere with the synthesis of conjugates, but provide good solvency 
of the organic BODIPY dyes.  BODIPY 3-3 was dissolved in either DMF or NMP and allowed to 
activate using TSTU coupling agent for 1 hour in the presence of DIPEA. After one hour the 
activated dye was added in a drop wise manner to each peptide in .2M NaHCO3 at pH 8.2.   
Overall, the most efficient solvent for amide bond conjugation remained as DMF for 
conjugates 3-12, 3-13, 3-14 as shown in Table 6. The solubility of each BODIPY in either solvent 
was good; however, when the coupling agent was added to NMP solvation proved to be quite 
difficult, as extra solvent was necessary to dissolve the coupling agent. This measure possibly 
diluted the agent causing for a less effective synthesis of activated BODIPY 3-3 and 3-4. To 
Table 5: Results of Coupling Agent Studies for Synthesis of Peptide-BODIPY 
conjugates 
Compound Molecular Weight 
7.5 equiv of  
Coupling Agent 
% Yield 
3-12 1058.64 TSTU 22 
3-12 1058.64 DEPBT 0 
3-13 1911.91 TSTU 26 
3-13 1911.91 DEPBT 0 
3-14 1129.72 TSTU 21 
3-14 1129.72 DEPBT 10 
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maintain the efficiency of the reaction thus far, DMF was considered the most viable solvent, and 
carried forward for more optimizing. Next, the conjugates reactions were optimized by  
varying the temperature.   
 
Conjugate 3-12 peptide solution was allowed to sit at 0°C longer than the other solutions 
due to the slow addition of activated BODIPY dyes. After purification, an increase in the amount 
of compound returned, and an ease of purification was noted. To determine if allowing peptide 
solutions in .2M NaHCO3 to stir longer at 0°C will have a positive effect on all conjugates, all 
reactions were studied. This time before addition of activated BODIPY 3-3, all solutions were 
allowed to stir at 0°C for 30 minutes.  
Reaching the optimal temperature for peptides before interacting with the reactive 
BODIPY dyes is indeed a vital component as observed in Table 7. The lower reaction temperatures 
minimize the reactivity of the peptide and allow the reaction to push the desired products to 
complete formation, thus, an increase of each conjugate was afforded.  
The final strategy was to determine the effects of the reactions pH on the percent yield. The 
method previously utilized had allowed the reaction to maintain a pH of 8.2. Considering the 
environment of our peptides that were not previously desalted to remove any residual triflate salts, 
Table 6: Results of Solvent Studies for Synthesis of BODIPY-peptide 
Conjugates 
Compound Solvent % Yield 
3-12 DMF 30% 
3-12 NMP 12% 
3-13 DMF 26% 
3-13 NMP 18% 
3-14 DMF 21% 
3-14 NMP 13% 
 87   
 
the pH of the reaction mixture could possibly be slightly more acidic than desired. To counter this 
issue, increasing the pH of the reaction mixture to a pH of 9.2 was performed. The activation of 
BODIPY 3-3 was performed as previously mentioned, and the solubilizing of each peptide in the 
.2M NaHCO3 now at 9.2 pH was carried out (Scheme 13).  
 
  
 
 
 
 
 
 
 
 
 
The results for each conjugation nearly doubled allowing more anticipated yields to be 
attained as seen in Table 8. Controlling the reaction environment was found to be promising, 
allowing for ideal conjugation procedures under slightly more basic conditions. This effect showed 
that reactions mixtures were cleaner during purification by minimizing the quantity of side products 
allowing for higher percent yields. All conjugates were purified by RP-HPLC to a purity of 95% 
or higher and prepared for characterization.  
 
Table 7: Results of Temerature Studies of Peptide-BODIPY Conjugates 
Compound Temperature % Yield 
3-12 RT 22% 
3-12 0C 30% 
3-13 RT 26% 
3-13 0C 46% 
3-14 RT 21% 
3-14 0C 49% 
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Scheme 13. Coupling of BODIPY 3 -3 solution phase to peptides 2-2, 2-6, and 2-7 using pH 9.2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.3 Characterization of BODIPY-Peptide Conjugates 
3.3.1 NMR Studies 
 
Proton NMR (1H-NMR) and HSQC were used to characterize all conjugates. 1H-NMR was 
used to test BODIPY 3-3. From the 1H-NMR spectra of BODIPY 3-3 the methyl groups present at 
the 1,7- and 3,5- positions of the dyes scaffold yield a single peak (Appendix B). These singlets are 
Table 8: Results of pH Studies of Peptide-BODIPY Conjugates 
Compound Molecular Weight pH % Yield 
3-12 1058.64 8.2 30% 
3-12 1058.64 9.2 71% 
3-13 1911.91 8.2 46% 
3-13 1911.91 9.2 65% 
3-14 1129.72 8.2 49% 
3-14 1129.72 9.2 73% 
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typically observed in each conjugate approximately around 2.5 and 2.3 ppm respectively. These 
significant peaks, representing the scaffold of the BODIPY’s core, were essential in investigating 
the proton NMR due to various overlaps of the BODIPY,s alkyl chain present at the meso-positons’ 
protons,and the  methyl protons at the side chains of each peptide sequence were observed around 
1.5-1.8 ppm. Furthermore the backbone of the peptides sequence were also used to analyze the 1H-
NMR as the protons of each amide linkage are noted as one multiplet near approximately .86 ppm.  
3.3.2 Photophysical Studies 
UV-Vis spectroscopy and fluorescence were used to investigate the absorption and 
emission properties of BODIPY conjugates 3-12, 3-13, and 3-14. All studies were recorded in 
dimethylsulfoxide (DMSO ) at room temperature, and the conjugates were then compared to the 
carboxylic precursor BODIPY 3-3 Particular emphasis on  spectroscopic properties such as: the 
maximum absorption (λabs) and emission (λem) wavelengths, Stokes’ shifts, and molar 
extinction coefficients (log ε), were studied and the results are summarized in Table 9  and 
Figure 3. 
Figure 3 shows the normalized absorption and emission spectra for BODIPY 3-3 
and the corresponding conjugates 3-12, 3-13, and 3-14. As reported in literature carboxyl 
BODIPY 3-3 showed characteristic strong absorption band at 500 nm with a log ε value of 
3.97 with an emission at 509 nm.  
 All BODIPY-peptide conjugates have parallel absorption and emission spectra, due 
to their similar BODIPY cores which is slightly blue shifted from the parent compound 
BODIPY 3-3 as shown in Table 9 and Figure 3. 
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Table 9. Spectroscopic properties of BODIPYs in DMSO at room temperature 
Compound λabs λem Stokes shift Logε 
3-3 500 nm 509nm 9 nm 3.97 
3-12 499 nm 508 nm  9 nm 4.40 
3-13 499 nm 508 nm  9 nm 4.30 
3-14 499 nm 508 nm 9 nm 4.21 
 
 
Figure 3. Normalized UV-Vis and fluorescence spectra of BODIPY 3-3 (Blue), BODIPY 
peptide conjugates 3-12 (Red), 3-13 (Green), and 3-14 (Purple) in DMSO at room 
temperature. 
 
This instance is also noted in the emission of all conjugates as they all exhibit a 
band at 508 nm. The similarity in absorbance and emission may be an indication that 
conjugation through a short alkyl chain at the meso position of the BODIPYs core will 
result in negligible blue-shifts of the compounds spectroscopic properties. The Stokes shifts 
for all BODIPY dyes, precursor and conjugates, exhibit in the range of (~9 nm). Determination of 
Quantum Yields are still underway. 
3.3.2 SPR of BODIPY-Peptide  Conjugates 
SPR of all BODIPY-Peptide conjugates and precursor were tested in a concentration 
manner from .25 uM to 250 uM. The results found are shown in Figures (3-6).  BODIPY 3-3  and 
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conjugates 3-12, 3-13, and 3-14 were diluted to desired concentrations with a  solution of running 
buffer HBS-EP+ used in Chapter 2, however this time containing 4%  of DMSO. The association 
and disassociation rates of the compounds with EGFR are constant and were further assessed.  
 
Figure 4. SPR sensogram for BODIPY 3-3 at concentrations up to 250 μM. 250 μM (burgundy), 
200 μM (lime), 100 μM yellow), 50 μM (orange), 25 μM (green), 10 μM (royal blue), 1 μM 
(navy blue), .5 μM (purple), blank (mint).  
 
BODIPY 3-3 showed a linear increase in response units or binding affinity for the EGFR 
receptor from concentrations 50 to 200 μM, however at 250 μM the response units begin to decrease 
indicating at concentrations above 200 μM a non-specific binding may occur (Figure 4).  
 
Figure 5. SPR sensogram for conjugate 3-12 at concentrations up to 250 μM. 250 μM (burgundy), 
200 μM (lime), 100 μM yellow), 50 μM (orange), 25 μM (green), 10 μM (royal blue), 1 μM 
(navy blue), .5 μM (purple), blank (mint). 
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The SPR sensograms of all conjugates showed a higher binding affinity for EGFR than 
BODIPY 3-3 (Figures 4). The binding affinity of conjugates 3-12 and 3-13 behaved similar to 
BODIPY 3-3, however conjugate 3-13 plateaued much earlier than BODIPY 3-3 and conjugate 3-
12 (Figure 5).  
 
 
Figure 6. SPR sensogram for conjugate 3-13 at concentrations up to 250 μM. 250 μM (burgundy), 
200 μM (lime), 100 μM yellow), 50 μM (orange), 25 μM (green), 10 μM (royal blue), 1 μM 
(navy blue), .5 μM (purple), blank (mint). 
 
 
 
Figure 7. SPR sensogram for conjugate 3-14 at concentrations up to 250 mM. 250 μM. 250 μM 
(burgundy), 200 μM (lime), 100 μM yellow), 50 μM (orange), 25 μM (green), 10 μM (royal 
blue), 1 μM (navy blue), .5 μM (purple), blank (mint). 
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Conjugate 3-13   starts to exhibit non-specific binding at the 50 uM concentration (Figure 
6). Conjugate 3-14, conversely demonstrated a continual linear increase in the binding affinity from 
concentration .25 to 250 uM (Figure 7) when compared to the other conjugates demonstrating a 
stronger affinity for EGFR.  
 
The kinetics of binding of the conjugates to EGFR were analyzed assuming Langmuir 1:1 
binding and the sensograms were fit using the Langmuir equation to provide the KD values. Of all 
the conjugates, conjugate 3-14  displayed the higher dissociation conjugate as seen in Table 10 at 
2.85 nM followed by conjugate 3-12 at 6.06 nM indicating a higher affinity for EGFR.  
3.3.3 In vitro studies  
In vitro cellular studies were conducted by Mrs. Zehua Zhou and examined against 
human carcinoma HEp2 cell lines including cellular uptake and cytotoxicity (phototoxicity and 
dark toxicity), in Cell Titer Blue (CTB) Assay a fluorescence-based assay used to measure 
toxicity of various substrates.  
3.3.3.1 Cytotoxicity. The phototoxic effect of BODIPY 3-3 and conjugates 3-12, 3-13, and 3-14 
were tested under a low dose of light irradiated at 1.5 J/cm2.  The dose-dependent survival curves 
of each compound over a course of 24 hours in the dark or after light irradiation are shown in 
Table 10: Molecular Weight and KD Values of BODIPY and BODIPY-
peptide Conjugates 
Compound Molecular Weight KD Value 
(nM) 
BODIPY 3 334.16 35.13 
12 1058.64 6.06 
13 1911.91 19.29  
14 1129.72 2.85 
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Figures 8 and 9. The results of this test is then expressed in values of IC50, the concentration of dye 
in units of micromolar necessary to kill 50% of the cells.  
In the absence of light the cell viability using CTB was determined to possess a IC50 value 
of greater than 200 μM proving to be non-toxic in the dark.  All compounds proved non- toxic in 
the presence of light with IC50 values greater than 100 μM. Table 11 summarizes the cell 
viability of conjugates 3-12, 3-13, and 3-14 and BODIPY 3-3 in HEp2 cells.  
 
Figure 8. Dark Toxicity of BOIDPY 3-3 (black), conjugate 3-13 (green), conjugate 3-14 (pink), 
conjugate 3-15 (purple) using a CTB assay. 
 
 
Figure 9. Phototoxicity  (1.5 J/cm2) of BOIDPY 3-3 (black), conjugate 3-13 (green), conjugate 3-
14 (pink), conjugate 3-15 (purple) using a CTB assay. 
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3.3.3.2 Time Dependent Cellular Uptake.  Measurements of time-dependent cellular uptake for 
all four compounds were performed at a 10 μM concentration in HEp2 cells, and the results 
are indicated in Figure 10. After 24 h, conjugates 3-13 accrued more than BODIPY 3-3 
and all other conjugates in the HEp2 cell line. Additionally, BODIPY 3-3 and the other 
conjugates accrued in cells at similar rates. This was particularly surprising as all other 
reports obtained with EGFR-L1 or EGFR-L2 sequences show a reverse result with the 
short charged peptide sequence accruing more and at a faster rate into cells.29-30 This 
occurrence may be due to the smaller core structure of BODIPY 3-3. The smaller size of 
the BODIPY dye may allow for more of the peptide to reach the binding pocket of EGFR.  
 
Figure 10. Cellular Uptake of BOIDPY 3-3 (black), conjugate 3-13 (green), conjugate 3-14 
(pink), conjugate 3-15 (purple). 
Table 11. Cytotoxicity in HEp2 cell (Cell Titer Blue assay, 1.5 J/cm2) 
Compound Dark toxicity (IC50  Phototoxicity (IC50  
   
BODIPY 3 > 200 >100 
Conjugate 12 > 200 >100 
Conjugate 13 > 200 >100 
Conjugate 14 > 200 >100 
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3.3.3.3. Subcellular Distribution. To determine the intracellular localization of all compounds 
within cells fluorescence microscopy was used. To clearly determine the localization of conjugates 
various organelle specific fluorescent trackers were used such as ER (endoplasmic reticulum) 
Tracker Blue/white, LysoSensor Green (lysosomes), MitoTracker Green (mitochondria), and 
BODIPY FL C5 ceramide (Golgi).  The fluorescent patterns of HEp2 cell lines containing localized 
BODIPY 3-3 and conjugates 3-12, 3-13, and 3-14 were investigated and the results are shown in 
Figures 10-13. All compounds were found to preferably localize in the cell mitochondria, 
unlike BODIPY 3-3, all conjugates were also found to localize in the lysosomes 
summarized in Table 12. Additionally, small amounts of localization were determined in 
the Golgi apparatus for conjugate 3-14, while conjugates 3-13 and BODIPY 3-3 were found 
to also localize in the ER.  
Table 12. Subcellular localization of BODIPY 3 and Conjugates 12-14  
Compound Major sites of localization 
3-3 ER, Mito 
3-12 Mito, Lyso 
3-13 ER, Mito, Lyso 
3-14 Golgi,Mito, Lyso 
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Figure 10. Subcellular fluorescence of BODIPY 3-3 in HEp2 cells at 10 μM for 6 h. (a) Phase 
contrast; (b) overlay of BODIPY 3-3 fluorescence and phase contrast; (c) ER tracker Blue/White 
fluorescence; (d) overlay of BODIPY 3-3 fluorescence and ER Tracker; (e) BODIPY ceramide; (f) 
overlay of BODIPY 3-3 fluorescence and BODIPY ceramide; (g) MitoTracker Green fluorescence; 
(h) overlay of BODIPY 3-3 fluorescence and MitoTracker; (i) LysoSensor Green fluorescence; (j) 
overlay of BODIPY 3-3 fluorescence and LysoSensor. Scale bar: 10 μm. 
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Figure 11. Subcellular fluorescence of conjugate 3-12 in HEp2 cells at 10 μM for 6 h. (a) Phase 
contrast; (b) overlay of conjugate 3-12  fluorescence and phase contrast; (c) ER tracker Blue/White 
fluorescence; (d) overlay of conjugate 12 fluorescence and ER Tracker; (e) BODIPY ceramide; (f) 
overlay of conjugate 3-12  fluorescence and BODIPY ceramide; (g) MitoTracker Green 
fluorescence; (h) overlay of conjugate 3-12 fluorescence and MitoTracker; (i) LysoSensor Green 
fluorescence; (j) overlay of conjugate 3-12 fluorescence and LysoSensor. Scale bar: 10 μm. 
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Figure 12. Subcellular fluorescence of conjugate 13 in HEp2 cells at 10 μM for 6 h. (a) Phase 
contrast; (b) overlay of conjugate 13  fluorescence and phase contrast; (c) ER tracker Blue/White 
fluorescence; (d) overlay of conjugate 13 fluorescence and ER Tracker; (e) BODIPY ceramide; (f) 
overlay of conjugate 13  fluorescence and BODIPY ceramide; (g) MitoTracker Green fluorescence; 
(h) overlay of conjugate 13 fluorescence and MitoTracker; (i) LysoSensor Green fluorescence; (j) 
overlay of conjugate 13 fluorescence and LysoSensor. Scale bar: 10 μm. 
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Figure 13. Subcellular fluorescence of conjugate 3-14 in HEp2 cells at 10 μM for 6 h. (a) Phase 
contrast; (b) overlay of conjugate 3-14 fluorescence and phase contrast; (c) ER tracker Blue/White 
fluorescence; (d) overlay of conjugate 3-14 fluorescence and ER Tracker; (e) BODIPY ceramide; 
(f) overlay of conjugate 3-14  fluorescence and BODIPY ceramide; (g) MitoTracker Green 
fluorescence; (h) overlay of conjugate 3-14 fluorescence and MitoTracker; (i) LysoSensor Green 
fluorescence; (j) overlay of conjugate 3-14 fluorescence and LysoSensor. Scale bar: 10 μm 
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3.3 Conclusion 
In conclusion, two carboxylic BODIPY dyes were synthesized in a one-pot three step 
fashion similar to previous studies, however with enhanced reactivity, less impurities, and higher 
yields. Activation of the carboxylic BODIPY dyes 3-3 and 3-4 were successful, however 
conjugation with peptides 2-1 and 2-2 were unsuccessful.  Strategies to enhance the methods of 
conjugation were performed, and optimal conditions found were activation of BODIPY 3-3 with 
TSTU and slow addition of the activated dye to a solution of peptides 2-2, 2-6, and 2-7 in .2M 
NaHCO3 pH 9.2 at 0C. Conjugates 3-12, 3-13, and 3-14 were synthesized over 24 hours in percent 
yields of 60-75%  .All new conjugates were fully characterized using 1H NMR, HSQC NMR, mass 
spectrometry (MALDI-TOF and MALDI-TOF MSMS), UV-Vis/fluorescence spectroscopy 
(Appendix A.3).  Spatial Plasmon Resonance was used to determine the affinity of each conjugate 
for EGFR. Conjugate 3-14 afforded a linear increase in binding affinity for EGFR from 0 to 250 
uM concentrations. While conjugates 3-12 and 3-13 showed portions of non-specific binding. 
Conjugate 3-12 showed a linear increase in affinity up to 200uM and non-specific binding at 250 
uM concentration. While conjugate 3-13 showed a linear increase in affinity up to 100uM and non-
specific binding at 200 to 250 uM concentration.  
Studies in human HEp2 cell lines revealed that all conjugates and precursor dyes were non-
toxic to cells in the absence of light (IC50 > 200 uM). Once cells were treated with 1.5 J/cm2 
irradiation of light, conjugates were still non-toxic to cells (IC50 > 100 uM) making these beneficial 
probes for imaging CRC.  
Studies in human HEp2 cell lines revealed that all conjugates and precursor dyes were non-
toxic to cells in the absence of light (IC50 > 200 uM). Once cells were treated with 1.5 J/cm2 
irradiation of light, conjugates were still non-toxic to cells (IC50 > 100 uM) making these beneficial 
probes for imaging CRC.  
With much surprise conjugate 3-13 showed the highest cellular uptake followed by 
conjugate 3-14. Conjugate 3-12 had extremely low cellular uptake that followed the uptake noted 
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in BODIPY 3-3. Future analyses of the efficacy of these amide conjugates will be determined so 
that the optimal conjugate is chosen for in vivo studies.  
3.4 Experimental 
3.4.1 General Information 
 
Commercial available chemicals were purchased from VWR or Sigma-Aldrich and used 
without further purifications for the reactions and purifications. Thin layer chromatography (TLC) 
was performed on the precoated silica gel plates (0.2 mm, 254 indicator, polyester backed, 60Å, 
Sorbent Technologies) to monitor the reactions. Preparative TLC plates (60G, VWR) and silica gel 
(60Å, 230-400 mesh, Sorbent Technologies) were used for liquid chromatography and column 
chromatography. 1H NMR and 13C NMR spectra were collected on a Bruker AV-400 liquid, or AV-
500 spectrometer at 308K. All the chemical shifts (δ) are provided in parts per million (ppm) in 
CDCl3 (7.27 ppm for 1H NMR and 77.0 ppm for 13C NMR) and DMSO (2.54 ppm for 1H NMR). 
The coupling constants (J) are reported in Hz. High-resolution mass spectra (HRMS) and MALDI 
(TOF) spectra were obtained on a 6210 ESI-TOF Mass Spectrometer (Agilent Technologies) under 
positive or negative mode and Applied Biosystems QSTAR at the LSU Mass Spectrometry Facility. 
Reverse-phase HPLC analysis was performed with a Waters 2485 Quaternary Gradient Module, 
Waters Sample Injector, and 2489 UV/Visible Detector which are controlled by Waters Empower 
2 software. Separations were completed on an X-Bridge BEH300 Prep C18 (5 um, 10 x 250 mm) 
with a X-Bridge BEH300 Prep Guard cartridge 300 Å (5 um, 10 x 10 mm) at a 4 mL/min flow rate 
with UV detection for peptides at 220 nm, and for BODIPY conjugates at 580 nm. Fractions of 
HPLC purity (> 95%) with the anticipated mass were combined and lyophilized.   
 
3.4.2 General Procedure for Synthesis of Carboxylic BODIPYs  
 
 In an oven dried flask containing a stir bar and/or reflux condenser, 2,4-dimethylpyrrole 
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 (1.67 eq) and anhydride (1 eq) were dissolved in appropriate solvent. Boron trifluoride diethyl 
etherate may be added to the solution. The reaction is then refluxed/irritated under nitrogen 
atmosphere for a certain timeframe. The reaction was then allowed to cool to room temperature, 
and triethylamine (6.7 eq) was added to the solution followed by Boron trifluoride diethyl etherate 
(6.7 eq).  The reaction was then allowed to stir until complexing was complete. The mixture was 
washed with water three times and extracted with CH2Cl2 three times. The organic layer was dried 
over MgSO4 and evaporated under nitrogen gas overnight. 
3.4.3 Method 1: Conventional Bench-top of BODIPY 3 and 4 
BODIPY 3-3: In an oven dried flask containing a stirrer and reflux condenser, 2,4-dimethylpyrrole 
(.856 g, 9 mmol) and glutaric anhydride (.800 g, 5.4 mmol) were dissolved in anhydrous THF (90 
mL). Boron trifluoride diethyl etherate (1.53 g, 10.8 mmol) was added drop wise to the solution. 
The reaction was then refluxed under nitrogen atmosphere for eight hours. The reaction was then 
allowed to cool to room temperature, and triethylamine (3.64 g, 36 mmol) was added to the solution 
followed by Boron trifluoride diethyl etherate (3.83 g, 27 mmol).  The reaction was then allowed 
to stir at 50°C for four hours. The mixture was washed with water (3 x 15 mL) and extracted with 
CH2Cl2 (3 x 100 mL). The organic layer was dried over MgSO4 and evaporated under nitrogen gas 
overnight. The resulting oil was purified by running a short plug using CH2Cl2 as the eluent. The 
resulting residue was purified by silica gel (hexane/EtOAc/HOAc, 80:40:1) and gave 50.8 mg of 
dye as a red solid. Yield: 3.39% 1H-NMR (400MHz, CDCl3) δ 6.06 (s, 2H, β-pyrrole H), 3.21 (m, 
2H, -CH2, 6.9 Hz), 3.02 (m, 2H, -CH2), 2.53 (s, 6H, -CH3), 2.42 (s, 6H, -CH3), 1.97 (m, 2H, -CH2); 
MS (ESI-TOF) m/z Calculated for C17H21BF2N2O2:  334.1664, found 7 357.1566 
BODIPY 3-4: In an oven dried flask containing a stirrer and reflux condenser, 2,4-dimethylpyrrole 
(2.85 g, 30 mmol) and phthalic anhydride (2.22 g, 15 mmol) were dissolved in anhydrous ACN 
(150 mL). The reaction was then refluxed under nitrogen atmosphere overnight. The reaction was 
then allowed to cool to room temperature, and triethylamine (9.11 g, 90 mmol) was added to the 
solution followed by Boron trifluoride diethyl etherate (17.03 g, 120 mmol).  The reaction was then 
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allowed to stir at 50°C for four hours. The mixture was washed with water (3 x 30 mL) and extracted 
with CH2Cl2 (3 x 100 mL). The organic layer was dried over MgSO4 and evaporated under nitrogen 
gas overnight. The resulting oil was purified by running a short plug using CH2Cl2 as the eluent. 
The resulting residue was purified by silica gel (hexane/EtOAc/MeOH 100:30:3) and gave 23.0 mg 
of dye as a deep red solid. Yield: 0.42% 1H-NMR (400MHz, CDCl3) δ 8.10 (dd, 1H, 7.9 Hz), 7.59 
(dd, 1H, 7.4 Hz), 7.50 (d, 1H, 7.7 Hz) 7.23 (d, 1H, 7.7 Hz), 5.86 (s, 2H, β-pyrrole H), 2.45 (s, 6H, 
-CH3), 1.24 (s, 6H, -CH3),MS (ESI-TOF) m/z Calculated for C20H19BF2N2O2:  368.1508, found 
[M-H] 367.1435. 
3.4.4 Method 2: Microwave Syntheses of BODIPY 3 and 4 
BODIPY 3-3: In an oven dried flask containing a stirrer, 2,4-dimethylpyrrole (.142 g, 1.5 mmol) 
and glutaric anhydride (.133 g, 0.9 mmol) were dissolved in anhydrous THF (15 mL). Boron 
trifluoride diethyl etherate (.255 g, 1.8 mmol) was added drop wise to the solution. The reaction 
was set to ramp to temperature 110°C at 340 W of power for 5 minutes and held at 340 W and 
110°C for 15 minutes. The reaction was cooled to room temperature for 5 minutes. Triethylamine 
(0.607 g, 6 mmol) was added to the solution followed by Boron trifluoride diethyl etherate (0.638 
g, 4.5 mmol).  The reaction was then subjected to microwave under a ramp to temperature settings 
at 70°C 340 W for one minute, and held at these settings for 10 minutes. The reaction was allowed 
to cool to room temperature for 5 minutes. The mixture was washed with water (3 x 15 mL) and 
extracted with CH2Cl2 (3 x 100 mL). The organic layer was dried over MgSO4 and evaporated 
under nitrogen gas overnight. The resulting oil was purified by running a short plug using CH2Cl2 
as the eluent. The resulting residue was purified by thin layer preparative chromatography 
(hexane/EtOAc/HOAc, 80:40:1) and gave 4.2 mg of the dye as a red solid. Yield: 1.7%  
BODIPY 3-4: In an oven dried flask containing a stirrer, 2,4-dimethylpyrrole (.190 g, 2 mmol) and 
phthalic anhydride (.148 g, 1 mmol) were dissolved in anhydrous THF (15 mL). The reaction was 
subjected to microwave-assistance and set to ramp to temperature 110°C at 340 W of power for 5 
minutes and held at 340 W and 110°C for 15 minutes. The reaction was cooled to room temperature 
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for 5 minutes. Triethylamine (0.607 g, 6 mmol) was added to the solution followed by Boron 
trifluoride diethyl etherate (0.136 g, 8 mmol).  The reaction was then subjected to microwave under 
a ramp to temperature settings at 70°C 340 W for one minute, and held at these settings for 10 
minutes. The reaction was allowed to cool to room temperature for 5 minutes. The mixture was 
washed with water (3 x 15 mL) and extracted with CH2Cl2 (3 x 100 mL). The organic layer was 
dried over MgSO4 and evaporated under nitrogen gas overnight. The resulting oil was purified by 
running a short plug using CH2Cl2 as the eluent. The resulting residue was purified by thin layer 
preparative chromatography (hexane/EtOAc/MeOH, 100:30:3) and gave 4.2 mg of dye as a deep 
red solid. Yield: 1.7%  
3.4.5 Method 3: Grignard Syntheses of BODIPY 3-3 and 3-4 
BODIPY 3-3: In an oven dried flask containing a stirrer, 2,4-dimethylpyrrole (.171 g, 1.8 mmol) 
in  THF (4ml) and a solution of methyl magnesium chloride in 3M diethyl ether (,237g, 1.98 mmol) 
were stirred under reflux for 30 minutes. Resulting mixture was allowed to cool to room 
temperature followed by the addition of glutaric anhydride (.128 g, 1.12 mmol) dissolved in 
anhydrous THF (1 mL). To this mixture boron trifluoride diethyl etherate (.459 g, 3.24 mmol) was 
added drop wise over the course of 5 minutes, and allowed to stir at room temperature for 12 hours. 
Triethylamine (1.122 g, 12 mmol) and  Boron trifluoride diethyl etherate (1.27 g, 9 mmol) was 
added and allowed to stir at 50C for 4 hours. The reaction was quenched with Ammonium chloride. 
Remaining precipitate dissolved in DCM and added to the aqueous solution. The mixture was 
washed with water (3 x 15 mL) and extracted with CH2Cl2 (3 x 100 mL). The organic layer was 
dried over MgSO4 and evaporated under nitrogen gas overnight. The resulting oil was purified by 
running a short plug using CH2Cl2 as the eluent. The resulting residue was purified by thin layer 
preparative chromatography (hexane/EtOAc/HOAc, 80:40:1) and gave 151 mg of the dye as a red 
solid. Yield: 50.1% 1H-NMR (400MHz, CDCl3).  
BODIPY 3-4: In an oven dried flask containing a stirrer, 2,4-dimethylpyrrole (.171 g, 1.8 mmol) 
in THF (4 ml) and a solution of methyl magnesium chloride in 3M diethyl ether (,237g, 1.98 mmol) 
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were stirred under reflux for 30 minutes. Resulting mixture was allowed to cool to room 
temperature followed by the addition of phthalic anhydride (.167 g, 1.125 mmol) dissolved in 
anhydrous THF (1 mL). To this mixture boron trifluoride diethyl etherate (.459 g, 3.24 mmol) was 
added drop wise over the course of 5 minutes, and allowed to stir at room temperature for 12 hours. 
Triethylamine (1.09 g, 10.8 mmol) and BF3OEt2 (2.04 g, 14.4 mmol) was added and allowed to stir 
at 50C for 4 hours. The reaction was quenched with Ammonium chloride. Remaining precipitate 
dissolved in DCM and added to the aqueous solution. The mixture was washed with water (3 x 15 
mL) and extracted with CH2Cl2 (3 x 100 mL). The organic layer was dried over MgSO4 and 
evaporated under nitrogen gas overnight. The resulting residue was purified by thin layer 
preparative chromatography (hexane/EtOAc/MeOH, 100:30:3) and gave 232 mg of dye as a deep 
red solid. Yield: 1.7% 1H-NMR (400MHz, CDCl3)  
3.4.6 Procedure for Activation using N-hydroxylsuccinimide 
Compound 3-5: In an oven dried flask with stirrer compound 3 (1.37 g, 4 mmol) is dissolved in 
anhydrous CH3CN  (130 mL). To this mixture N-hydroxylsuccinimide (.552 g, 4.8 mmol) and 
dicyclohexylcarbodiimide (2.06 g, 10 mmol) were added and stirred in microwave at 340 W 
ramped to temperature 60°C for 2 minutes and held at temperature for 15 minutes. The reaction 
was allowed to cool to room temperature for 5 minutes, and washed with water (3 x 30 mL) and 
extracted using CH2Cl2 ( 3 x 75 mL). The solution was dried over MgSO4 and under nitrogen gas 
overnight. The remaining red solid was then purified using thin layer preparative chromatography 
(DCM/EtOAc 12:1). And gave 18.7 mg of dye as a red-orange solid. Yield: 10.9% MS (ESI-TOF) 
m/z Calculated for C21H24BF2N3O4:  431.18, found [M-H] 430.1756. 
Compound 3-6: In an oven dried flask with stirrer compound 4 (0.029 g, .011 mmol) is dissolved 
in anhydrous CH3CN (2 mL). To this mixture N-hydroxylsuccinimide (.004 g, .0355 mmol) and 
dicyclohexylcarbodiimide (.0153 g, .0740 mmol) were added and stirred in microwave at 340 W 
ramped to temperature 60°C for 2 minutes and held at temperature for 15 minutes. The reaction 
was allowed to cool to room temperature for 5 minutes, and washed with water (3 x 15 mL) and 
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extracted using CH2Cl2 ( 3 x 50 mL). The solution was dried over MgSO4 and under nitrogen gas 
overnight. The remaining red solid was then purified using thin layer preparative chromatography 
(DCM/EtOAc 12:1). And gave 13.8 mg of dye as a red-orange solid. Yield: 84.1 % 1H-nmr 
(400MHz, CDCl3), δ 7.12 (d, 2H, 8.3 Hz), 6.81 (d, 2H, 8.0 Hz), 6.06 (s, 2H, β-pyrrole H), 2.53 (s, 
6H, -CH3), 2.43 (s, 4H, -CH2), 1.25 (s, 6H, -CH3); MS (MALDI-TOF) m/z Calculated for 
C25H23BF2N2O4:  464.17, found [M-H]  
3.4.7 Procedure for Activation using N,N’ -disuccinimidyl carbonate 
Compound 3-5: In an oven dried flask with stirrer compound 3 (.039 g, .117 mmol) is dissolved 
in anhydrous DMF (4 mL). To this mixture N,N’-disuccinimidyl carbonate (.045 g, .1757 mmol) 
and triethylamine (.0889 g, .8784 mmol) were added and stirred in microwave at 340 W ramped to 
temperature 60°C for 2 minutes and held at temperature for 15 minutes. The reaction was allowed 
to cool to room temperature for 5 minutes, and washed with water (3 x 15 mL) and extracted using 
CH2Cl2 (3 x 50 mL). The solution was dried over MgSO4 and under nitrogen gas overnight. The 
remaining orange solid was then purified using thin layer preparative chromatography 
(DCM/EtOAc 12:1). And gave 33.5 mg of dye as a red-orange solid. Yield: 76.3 % 1H-nmr 
(400MHz, CDCl3) δ 6.06 (s, 2H, β-pyrrole H), 3.09 (m, 2H, -CH2), 2.80 (m, 2H, -CH2), 2.51 (s, 
6H, -CH3), 2.41 (s, 4H, -CH2), 2.16 (s, 6H, -CH3), 2.07 (dd, 2H, -CH2, 8.62 Hz); MS (ESI-TOF) 
m/z Calculated for C21H24BF2N3O4:  431.18, found [M-H] 430.1754. 
Compound 3-6: In an oven dried flask with stirrer compound 4 (.0636 g, .0231 mmol) is dissolved 
in anhydrous DMF (3 mL). To this mixture N,N’-disuccinimidyl carbonate (.024 g, .095 mmol) 
and triethylamine (.048 g, .477 mmol) were added and stirred in microwave at 340 W ramped to 
temperature 60°C for 2 minutes and held at temperature for 15 minutes. The reaction was allowed 
to cool to room temperature for 5 minutes, and washed with water (3 x 15 mL) and extracted using 
CH2Cl2 (3 x 50 mL). The solution was dried over MgSO4 and under nitrogen gas overnight. The 
remaining orange solid was then purified using thin layer preparative chromatography 
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(DCM/EtOAc 12:1). And gave 7.5 mg of dye as a red-orange solid. Yield: 25.34 % MS (ESI-TOF) 
m/z Calculated for C21H24BF2N3O4:  464.17, found [M+H] 465.656. 
3.4.8 General Procedure for Conjugation  
To a solution of carboxylic BODIPY dye (1.5 eq) an addition of TSTU (7.5 eq), DIEA (4 eq)  were 
added and stirred for 1 hour, and confirmed by MS for activated BODIPY dye. BODIPY solution 
was then added drop wise to a vessel containing deprotected peptide in a solution of .2 M NaHCO3 
pH 9.2 buffer previously cooled to 0C for 30 minutes. The combined solution was allowed to come 
up to 4C in the refrigerator and continual stirring at 4C was permitted for 24 hours.  The resulting 
mixture was then immediately purified using RV-HPLC in varying gradients of acetonitrile 
(solvent A) and water (solvent B) containing .1% TFA.  
Conjugate 3-12 (BOIDPY-GLARLLT-CONH2): This conjugate was obtained as a red orange 
solid (6.75 mg, 71%). HPLC (50% A for 1 min, 10% A to 0% A over 18 min, 10% A to 50% A 
over 2 min at a flow rate of 1 mL/min) and tR = 18.02 min. 1H NMR (500 MHz, DMSO-d6) δ 8.03 
(m, 4H), 7.84 (m, 3H), 7.41 (d, J = 8.6 Hz, 3H), 7.06 (d, J = 19.2 Hz, 5H), 6.48 (s, 3H), 6.23 (s, 
3H), 4.86 (d, J = 4.8 Hz, 2H), 4.28 (m, 4H), 4.07 (m, 3H), 3.75 (m, 2H), 3.67 (t, J = 6.4 Hz, 2H), 
2.82 (s, 6H), 2.41 (s, 7H), 1.48 (m, 9H), 1.25 (m, 10H), 1.00 (d, J = 6.2 Hz, 4H), 0.86 (m, 18H). 
MS (MALDI-TOF): m/z calcd for C40H78N11O11  [M]+ 888.588; found 888.542. 
Conjugate 3-13 (BOIDPY-YHWYGYTPQNVI-CONH2): This conjugate was obtained as a red 
orange solid (8.6 mg, 65 %). HPLC (50% A for 1 min, 10% A to 0% A over 18 min, 10% A to 50% 
A over 2 min at a flow rate of 1 mL/min) and tR = 18.02 min.1H NMR (500 MHz, DMSO-d6) δ 8.09 
(s, 5H), 7.64 (m, 4H), 7.21 (m, 14H), 6.98 (d, J = 34.8 Hz, 10H), 6.75 (s, 2H), 6.56 (d, J = 65.7 Hz, 
6H), 6.24 (s, 4H), 4.48 (d, J = 86.2 Hz, 10H), 4.05 (m, 7H), 3.67 (t, J = 6.4 Hz, 5H), 2.92 (d, J = 
19.8 Hz, 10H), 2.74 (s, 9H), 2.40 (s, 8H), 1.75 (m, 9H), 1.44 (s, 3H), 1.25 (s, 8H), 1.12 (s, 7H), 
0.83 (m, 18H). MS(MALDI-TOF): m/z calcd for C40H78N11O11  [M]+ 888.588; found 888.542. 
Conjugate 3-14 (BOIDPY-KLARLLT-CONH2): This conjugate was obtained as a dark red solid 
(6.5 mg, 73%). HPLC (50% A for 1 min, 10% A to 0% A over 18 min, 10% A to 50% A over 2 
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min at a flow rate of 1 mL/min) and tR = 18.02 min 1H NMR (500 MHz, DMSO-d6) δ 8.27 (t, J = 
5.9 Hz, 2H), 7.93 (m, 10H), 7.42 (d, J = 8.8 Hz, 2H), 7.06 (s, 2H), 6.49 (s, 5H), 6.23 (s, 3H), 4.27 
(m, 5H), 4.06 (m, 6H), 3.67 (t, J = 6.4 Hz, 4H), 3.52 (s, 4H), 2.80 (m, 6H), 2.41 (s, 7H), 1.75 (m, 
5H), 1.42 (s, 6H), 1.25 (s, 5H), 1.00 (d, J = 6.3 Hz, 4H), 0.86 (m, 18H). 
MS (MALDI-TOF): m/z calcd for C40H78N11O11  [M]+ 888.588; found 888.542. 
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CHAPTER 4. Design and Synthetic Strageties for BODIPY-Peptidic Conjugates for 
Diagnosis of CRC via Isothiocyanate Chemistry 
 
4.1  Introduction 
 
Amide chemistry discussed in chapter 3 demonstrates a “traditional” approach to peptide 
BODIPY conjugates via amide bond formation reactions. However, conjugation measures using 
traditional coupling reagents such as TSTU required an additional activation step for at least one 
hour. Normal amidation procedures of solution phase conjugation proceed for longer reaction times 
and often yield low amounts of desired compound. However, our approach did proceed for lengthy 
time periods, but in moderate yields. This increase in percent yield was due to heavy optimization 
of reaction conditions.  
The key component of increasing the yield of peptide-BODIPY conjugates via amidation 
was determining the best activation component. 1 For amidation the coupling agent TSTU was 
found to aid in formation of three conjugates. However, the BODIPY scaffold is interestingly 
tunable and allows for addition of a component that will increase the reactivity of the BODIPY dye 
before interaction with the biomolecule. One method of tuning the core structure is the introduction 
of an isothiocyanate moiety on the BODIPY framework as an amino reactive group for conjugation 
to biomolecules, represents an attractive alternative for the conjugation of BODIPYs to peptides1, 
proteins2-5, and other molecules6-12 as a result of their short reaction times and high product yields.13-
14  
                                                        
 
a This Chapter originally appeared as Zhao, N.; Williams, T. M.; Zhou, Z.; Fronczek, F. R.; 
Sibrian-Vazquez, M.; Jois, S. D.; Vicente, M. G. H., Synthesis of BODIPY-Peptide Conjugates 
for Fluorescence Labeling of EGFR Overexpressing Cells. Bioconjugate Chemistry 2017, 28 (5), 
1566-1579.Reprinted with permission from [22] Copyright (2017) American Cancer Society. 
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 Isothiocyanates are natural products that occur widely in nature and are of interest in food 
science and medicine. The naturally occurring compound belongs to the “cabbage” family  or 
cruciferous vegetable group.15-16 Vegetables such as broccoli, cauliflower, kale, turnips, collards, 
bok choy, and horseradish, to name a few, are grouped under the cruciferous class.  Most of these 
vegetables are used in households daily and are eaten raw or cooked. These vegetables tend to be 
a bit bitter compared to other vegetables.16-17  Furthermore, naturally occurring isothiocyanates 
have been found to aid in protection of the body from carcinogens. Isothiocyanates assist the fight 
against certain cancers, such as lung and esophageal, in three manners: 1) Inhibiting the carcinogens 
activation  by way of enzymes; 2) They promote detoxification of carcinogens from the body; and 
3) They neutralize the toxic assets and speed up the elimination  of these carcinogens from the 
body. 15, 18-19Overall, Isothiocyanates are valued functional groups that are naturally occurring, and 
possess a wide use of applications in various areas of chemistry including bioconjugation20, 
heterocyclic21 chemistry, and medicinal chemistry. For these reasons, much effort has been devoted 
to develop efficient routes for the synthesis of these classes of compounds and attaching 
biomolecules for further studies.  
In this chapter, a description of the effects of conjugating a BODIPY dye bearing a mono 
NCS moiety is investigated. The mono NCS-BODIPY reactivity towards the addition of pegylated 
peptides 3PEG-EGFR-L1 (2-4) and 3PEG-EGFR-L2-Gly (2-5) from chapter 2 is investigated. The 
effects of each NCS linkage are explored for its efficacy for EGFR binding by way of SPR and 
docking studies.22 Finally the performance of each conjugate in human carcinoma HEp2 cells over-
expressing EGFR is studied to determine the levels of cellular uptake and cytotoxicity. 
4.2 Results and Discussion 
4.2.1 BODIPY Synthesis 
We have previously reported the synthesis of flexible polyhalogenated BODIPY platforms, 
and an investigation of their reactivity under various reaction conditions.23-26 BODIPY platforms 
containing halogen moieties with different reactivity, accepting regioselective functionalization of 
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the BODIPY core using several Pd(0)-catalyzed coupling or nucleophilic elimination/addition 
reactions. The order of reactivity for the chloro groups in pentachloro-BODIPY 4-1, was shown to 
be: 8-Cl > 3,5-Cl > 2,6-Cl, which permits the regioselective functionalization of the 8-position, 
followed by the 3 and/or 5 positions, and finally the 2 and/or 6 positions of this BODIPY platform 
in a step-wise manner.26-27  
This study was determined previously by another colleague of the Vicente group Ning 
Zhao. Ning  was able to modify starting material 2,3,5,6,8-pentachloro-BODIPY 4-1 26 in four 
steps. As shown in Scheme 1, Ning was able to tune the BODIPY scaffold through a series of 
Suzuki-type coupling reactions to give the precursor BODIPY 4-3 bearing a nitro phenyl group. 
BODIPY 3 was then reduced and treated with 1,1’-thiocarbonyldi-2(1H)-pyridone to yield the 
desired isothiocyanato-BODIPY 4-5 in 88% yield. After purification and characterization of 
BODIPY 4-5 by MS and NMR studies, Ning contributed the desired starting material for 
conjugation.  
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Scheme 1: Synthesis of NCS-BODIPY 4-5. 
A crystal structure of BODIPY 4-5 was obtained and revealed the BODIPY core is 
reasonably planar, exhibiting a mean deviation of 0.061 Å (Figure 1).  The 8-methoxyphenyl 
substituent is turned out of the 
 
Figure 1. X-ray structure of BODIPY 4-5. 
 BODIPY plane, where it forms a dihedral angle of 47.4° with the BODIPY core. This 
behavior is typical of 8-aryl substituents on 1,7-unsubstituted BODIPY dyes. Conversley, the 
substituents at the 3 and 5 positions exhibit slightly larger dihedral angles with the BODIPY core, 
the NCS-phenyl has an angle of 54.5° while the OMe-phenyl bears a 62.9° angle.  While the 
average C-Cl distance is 1.706 Å, the NCS group possesses an angle 174(2)° which is nearly linear, 
however the phenyl group forces the NCS to bend slightly, the angle about N being 168(2)°. This 
instance causes the NCS to tilt slightly away from the plane of the phenyl group, with the N atom 
0.08 Å out of plane, the C atom 0.30 Å and the S atom 0.68 Å.  
4.2.2 Conjugation of BODIPY dyes to Peptide Ligands  
To establish proof of concept, BODIPY 4-5 was first tested with peptides 2-1 and 2-3 to 
ensure the reactivity of the peptides amino group would proceed. BODIPY 4-5 was first dissolved 
in anhydrous DMF followed by the addition of peptide in the presence of triethylamine (TEA). The 
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reaction was allowed to stir at room temperature for 18 hours in expectation of achieving conjugates 
4-6 and 4-7 (Scheme 2). After 18 hours the reactions were checked via MS to determine their 
progression.  Conjugate 4-7 was present via MALDI-TOF, however no product was confirmed for 
conjugate 4-6 only starting material of both BODIPY and peptide were returned. This may be due 
to the N-terminus amine being sterically hindered from the  isopropyl group present at the side 
chain of  leucine, and peptide 2-3 having the small amino acid glycine at the N-terminus. To counter 
these issues incorporation of a small liner or amino acid was considered.  
 
Scheme 2. Synthesis of conjugates 4-6 and 4-7. 
Previous reports from the Vicente group suggests that conjugates of EGFR-L1 and EGFR-
L2 to a porphyrin28 and a phthalocyanine29 macrocycles, using both short (up to 5-atom) and long 
(up to 20-atom) linkers (Scheme 3) are favorable compound formations. PEG linkers were shown 
to enhance the solubility and increase the cellular uptake of the conjugates, all while preserving the 
fluorescent properties of the dye by mediating a distance between the targeting peptides and the 
fluorescent molecules. This was observed especially in cases where low molecular weight 
triethylene glycol linkers were used. This phenomenon is mainly due to their relatively low 
flexibility compared with higher molecular weight PEG groups. Furthermore, PEG linkers have 
also presented an increase in specificity for affinity based molecules for surface sites.30 In addition, 
the triethylene glycol linker is expected to alleviate the steric effects of the leucine at the N-terminus 
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of the peptide with the BODIPY-NCS 4-5, leading to higher yields of the targeted conjugates. 
Incorporating a small linker could also afford the conjugates with extended conformation resulting 
in an enhanced EGFR binding affinity.29, 31-32   
 
Scheme 3. Synthesis of conjugate 4-8 and 4-9. 
The pegylated peptides PEG3-EGFR-L1,  (2-4) and PEG3-EGFR-L2 (2-5) reacted with 
BODIPY-NCS 4-5 in anhydrous DMF and in the presence of TEA, at room temperature for 18 
hours (Scheme 3).   MS showed evidence of compounds and the solvents were removed under 
vacuum and the blue solid was then purified using RP- HPLC. Conjugates 4-8 and 4-9 were purified 
and determined to yield 20 and 28 percent, respectively. Although both reactions were able to 
produce the desired products, further investigation was necessary to optimize the reaction yields. 
NCS reactions are typically high yielding reactions in the presence of amino groups, however the 
yields were very low. To determine the effects of reaction time, each desired conjugate was allowed 
to react at various time points and the results are listed in Table 1.  
All studies pointed to reaction conditions of 30 min being the optimal timeframe  to provide 
the corresponding conjugates 8 and 9 in 80 and 50% yields, respectively. Longer reaction times led 
to lower product yields, required purification of conjugate 8 without the usual .1% TFA normally 
used in HPLC solvents. The desired molecular weight (MW) of the compound was found as well 
as two other distinctive molecular weights. Purification using solvents inclusive of TFA showed a 
continual presence of nagging side products that were difficult to remove. 
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Table 1: Results of Time Study of synthesis of Conjugates 8 and 9 
Conjugate Peptide Reaction Time % YIELD 
4-8 2-4 12 h 20 
4-8 2-4 2 h 49 
4-8 2-4 30 min 80 
4-9 2-5 12 h 28 
4-9 2-5 2 h 45 
4-9 2-5 30 min 50 
  
 
Figure 2. Structure of side products 4-10 and 4-11. 
The hypothesized side products 4-10 and 4-11 were both reminiscent of the desired 
product, however, they both were missing one chloro group. However HPLC purification without 
the .1%TFA gave cleaner separation and isolation of the desired conjugate 4-8, and one peak with 
the corresponding mass for compound 4-10 was able to be isolated (Figure 2). Throughout these 
reaction conditions the BODIPY platform was preserved, as confirmed by 11B-NMR, which 
showed triplets for the BF2 group at δ = 0.368 and 0.374 ppm for 4-8 and 4-9, respectively (see 
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Appendix D). The BODIPY-peptide conjugates were further characterized by 1H NMR, HSQC, 
and MALDI-TOF.  
4.3 Characterization of BODIPY-Peptide Conjugates 
4.3.1 Photophysical Studies 
The spectroscopic properties were identified for BODIPY 4-5, and for peptide conjugates 
4-8 and 4-9 in DMSO. Specifically, the maximum absorption (λabs) and emission (λem) wavelengths, 
Stokes shifts, fluorescence quantum yields (Φf), and molar extinction coefficients (log ε), were 
studied and the results are shown below. Figure 2 shows the normalized absorption and emission 
spectra for BODIPY 4-5 and the corresponding conjugates. BODIPY 4-5 showed a characteristic 
strong absorption band and a log ε value of 4.5 with an emission at 623 nm in DMSO. This is 
because of the S0-S1 (π-π*) transition, and the weaker absorption band centered at around 450 nm 
is due to S0-Sn (n ≥ 2) transition.  
Table 2. Spectroscopic properties of BODIPYs in DMSO at room temperature 
Compound λabs λem Stokes shift Фf[a] log ε 
4-5 575 nm 623 nm 48 nm 0.16 4.5 
4-8 588 nm 634 nm 46 nm 0.033 4.3 
4-9 586 nm 634 nm 48 nm 0.014 4.5 
[a] Cresyl violet (0.5 in ethanol)33 was used as the standard for compounds 4-5, 4-8, and 4-9. 
 
 BODIPY-peptide conjugates 4-8 and 4-9 have similar absorption and emission spectra as 
their precursor NCS-BODIPY 4-5, due to their similar BODIPY cores as shown in Table 2 and 
Figure 3. Small red-shifts (11-13 nm) were observed in the spectra of conjugates 4-8 and 4-9, 
compared with BODIPY 4-5. This may possibly be due to decreased dihedral angles between the 
BODIPY core and the α-phenyl groups due to the presence of the peptide group on the para position 
of α-phenyl group. Both conjugates 4-8 and 4-9 emit closely in the NIR region of the optical 
spectrum, with minor autofluorescence and absorption by tissues, and with better light penetration, 
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which makes these two compounds suitable for imaging applications.34 However, conjugates 4-8 
and 4-9 exhibit a 5- and 10-fold decrease in quantum yield from BODIPY 4-5.   
 
Figure 3. Normalized UV-Vis and fluorescence spectra of BODIPY 4-5 (yellow), 
BODIPY-peptide conjugate 4-8 (blue), and BODIPY-peptide conjugate 4-9 (red) in DMSO at room 
temperature.  
 
The difference in quantum yield is thought to be due to the introduced flexibility of the 
conjugates by way of the small PEG3 linker. Both peptide conjugates have an enhanced interaction 
between the core of the BODIPY dye and peptides that could possibly lead to increased non-
radioactive decay.  
4.3.2 SPR of BODIPY-Peptide Conjugates 
Compounds 4-8 and 4-9 and NCS-BODIPY 4-5 were evaluated by SPR for their binding 
affinity for EGFR in a concentration study from 0 to 250 M. Pegylated peptides 2-4 and 2-5 
exhibited binding to EGFR with fast kinetics of association and dissociation are shown in Appendix 
B. For peptide 2-4 at 100 M the response was observed at approximately 20 units, however for 
peptide 2-5 at the same concentration the response was about 150 units, suggesting a significantly 
higher binding affinity for peptide 2-5 compared to the affinity observed with peptide 2-4.  
In the case of binding affinity for conjugates 4-8 and 4-9, 4% DMSO was used to dissolve 
the conjugates and diluted with running buffer inclusive of 4% DMSO. Conjugate 4-8 exposed two 
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methods of binding at concentrations lower than 100 M, the first observation was an increase in 
response units were observed by 400 units followed by a level of saturation being met. 
 
Figure 4. SPR sensogram for conjugate 4-8 at concentrations up to 250 μM. 250uM(burgundy), 
200 μM (lime), 100 μM (yellow), 50 μM (orange), 25 μM (green), 10uM (royal blue), 1 μM 
(navy blue), .5 μM (purple), Blank (mint). 
 
Yet, further addition of compound 4-8 at concentrations above 100 M resulted in a drastic 
increase of the SPR signal (nearly 2000 units), as seen in Figure 4. At higher concentrations, the 
kinetics of association and dissociation suggest specific binding of 4-8 to EGFR, as seen by a slow 
increase in the SPR signal.  
However, in the case of conjugate 4-9, the SPR signal showed signs of saturation at the 10 
M concentration, and the relative increase in response was less than 10 units (Figure 5). This 
sluggish change in response units suggested weak or non-specific binding of conjugate 4-9 to 
EGFR. As a comparison, BODIPY 4-5 was also used as an analyte in SPR studies to determine if 
any specificity was pertinent. BODIPY 4-5 also indicated binding similar to conjugate 4-9 (Figure 
6), showing slow-moving increases in response, and suggesting that the core of the BODIPY dye 
probably binds to EGFR non-specifically, together with peptide 2-5. Conversely, peptide 2-5 
showed specific binding as shown in Appendix B.  
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Figure 5. SPR sensogram for conjugate 4-9 at concentrations up to 250 μM. 250uM(burgundy), 
200 μM (lime), 100 μM (yellow), 50 μM (orange), 25 μM (green), 10uM (royal blue), 1 μM 
(navy blue), .5 μM (purple), Blank (mint). 
 
Hence, the addition of BODIPY 5 to the hydrophobic sequence of peptide 2-5 appears to 
reduce the specificity of binding to EGFR.  
 
Figure 6. SPR sensograms for BODIPY 4-5 at concentrations up to 250 μM. 250uM(burgundy), 
200 μM (lime), 100 μM (yellow), 50 μM (orange), 25 μM (green), 10uM (royal blue), 1 μM 
(navy blue), .5 μM (purple), Blank (mint). 
 
4.3.3 In vitro studies 
In vitro cellular studies were examined against human carcinoma HEp2 cell lines 
including cellular uptake and cytotoxicity (phototoxicity and dark toxicity), using a Cell Titer 
Blue (CTB) Assay, a fluorescence-based assay used to measure toxicity of BODIPY 4-5 and 
BODIPY-peptide conjugates 4-8 and 4-9 which was conducted by Mrs. Zehua Zhou. 
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4.3.3.1 Cytotoxicity 
 The phototoxic effect of BODIPY 4-5 and conjugates 4-8 and 4-9 were tested under a 
low dose of light irradiated at 1.5 J/cm2.  The dose-dependent survival curves of each compound 
over a course of 24 hours are shown in Figures 7 and 8. The results of this test is then expressed 
in values of IC50, the concentration of dye in units of micromolar necessary to kill 50% of the 
cells as summarized in Table 3.  
 The dark- and photo-cytotoxicity (using light dose of 1.5 J/cm2) for BODIPY 4-5 and 
BODIPY-peptide conjugates 4-8 and 9 using HEp2 cell line at concentrations up to 200 μM. Table 
3 and Figures 7 and 8 indicate the cytotoxicity results. Dose−response curves of all three 
compounds were plotted for the determination of IC50. BODIPY 4-5 and its peptide conjugates 4-
8 and 4-9 were found to be nontoxic in the dark with IC50 values  ≥ 98 μM (Figure 7).  
 
 
Moreover, our results showed that there was no photocytotoxic effects of BODIPY 4-5 
and BODIPY-peptide conjugate 4-9, while BODIPY-peptide conjugate 4-8 showed a slightly 
higher photocytotoxicity with an IC50 of 74 μM as shown in Figure 8.This increased phototoxicity 
may be due to the cationic charge of EGFR-L1 that induces a higher cellular uptake of conjugate 
4-8, compared with BODIPY-peptide conjugate 4-9 and BODIPY 4-5.29 This instance was also 
previously noticed with Pc-PEG-EGFRL1 and Pc-PEG-EGFRL2 conjugates. The observed low 
cytotoxic effects are good qualities for BODIPY-peptide conjugates use as imaging agents of 
colorectal cancer cells.  
Table 3. Cytotoxicity results for compounds 5, 8 and 9  
Compound Dark toxicity (IC50, μM) Phototoxicity (IC50, μM) 
4-5 >200 > 100 
4-8 98  74  
4-9 180 > 100 
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Figure 7. Dark toxicity of BODIPYs 4-5 (blue), 4-8 (green) and 4-9 (purple) in HEp2 cells using 
the CTB assay. 
 
 
  
 Figure 8. Photo toxicity  (~ 1.5 J/cm2) of BODIPYs 4-5 (blue), 4-8 (green) and 4-9 (purple) in 
HEp2 cells using a CTB assay. 
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4.3.3.2 Time Dependent Cellular Uptake. 
The time-dependent cellular uptakes for all three compounds were performed at the 10 μM 
concentration in HEp2 cells, and the results are indicated in Figure 9. After 24 h, conjugates 4-8 
and 4-9 accrued ∼30-fold more than BODIPY 4-5 in the HEp2 cell line. Additionally, each 
conjugate accumulated much faster than BODIPY 4-5. As observed in Table 4, conjugates 4-8 and 
4-9 accumulated approximately 90- and 60-fold more than the precursor 4-5 at 1h, and 
approximately 55- and 35-fold more at 2 h, respectively. Various factors may cause an enhanced 
uptake of conjugates at a rapid speed: (1)  enhanced aqueous solubility from PEG linker, and (2) 
the potential EGFR targeting effect from EGFR-peptides, as previously observed.35   
On the other hand, BODIPY-peptide conjugate 4-8 accumulated around 2-fold faster than 
conjugate 9, which can be due to the charged arginine amino acid of the peptide sequence of 
conjugate 4-8. The charged amino acid may also aid the PEG3 linker with increasing the solubility. 
 
Table 4. Cellular Uptake for Compounds at Various Timeframes 
Compound Cellular 
uptake at 1 h 
(nM/cell) 
cellular 
uptake at 2 h 
(nM/cell) 
cellular 
uptake at 4 h 
(nM/cell) 
cellular 
uptake at 8 
h (nM/cell) 
cellular 
uptake at 24 
h (nM/cell) 
      
4-5 0.00028 0.00063 0.00073 0.00090 0.0016 
4-8 0.0254 0.0344 0.0398 0.0424 0.0431 
4-9 0.016 0.0224 0.0287 0.036 0.0485 
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Figure 9. Time-dependent cellular uptake of BODIPYs 4-5 (blue), 4-8 (green) and 4-9 (purple) at 
10 μM in human HEp2 cells. 
 
4.3.3.3 Fluorescence Microscopy 
 To determine the subcellular sites of localization of BODIPY 4-5 and conjugates 4-8 and 
4-9 in the HEp2 cell line, fluorescence microscopy was used. The results are summarized in Table 
5 as well as Figures 10-12. During co-localization experiments, organelle-specific probes were 
used, including ER Tracker Blue/White (ER), BODIPY Ceramide (Golgi), MitoTracker Green 
(mitochondria), and LysoSensor Green (lysosomes).  All compounds were found to preferably 
localize in the cell ER, as identified in Figures 10-12, which is confirmed within previous studies.36-
37 Additionally, small amounts of localization were determined in the Golgi apparatus, while 
conjugates 4-8 and 4-9 were also found in the lysosomes to a moderate extent. However, very trace 
localization of the conjugates was observed in the mitochondria.  
 
 128   
 
 
Figure 10. Subcellular fluorescence of BODIPY 4-5 in HEp2 cells at 10 μM for 6 h. (a) Phase 
contrast; (b) overlay of BODIPY 4-5 fluorescence and phase contrast; (c) ER tracker Blue/White 
fluorescence; (d) overlay of BODIPY 4-5 fluorescence and ER Tracker; (e) BODIPY ceramide; (f) 
overlay of BODIPY 4-5 fluorescence and BODIPY ceramide; (g) MitoTracker Green fluorescence; 
(h) overlay of BODIPY 4-5 fluorescence and MitoTracker; (i) LysoSensor Green fluorescence; (j) 
overlay of BODIPY 4-5 fluorescence and LysoSensor. Scale bar: 10 μm.  
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Figure 11. Subcellular fluorescence of conjugate 4-8 in HEp2 cells at 10 μM for 6 h. (a) Phase 
contrast; (b) overlay of conjugate 4-8 fluorescence and phase contrast; (c) ER tracker Blue/White 
fluorescence; (d) overlay of conjugate 4-8 fluorescence and ER Tracker; (e) BODIPY ceramide; 
(f) overlay of conjugate 4-4-8 fluorescence and BODIPY ceramide; (g) MitoTracker Green 
fluorescence; (h) overlay of conjugate 4-8 fluorescence and MitoTracker; (i) LysoSensor Green 
fluorescence; (j) overlay of conjugate 4-8 fluorescence and LysoSensor. Scale bar: 10 μm.  
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Figure 12. Subcellular fluorescence of conjugate 4-9 in HEp2 cells at 10 μM for 6 h. (a) Phase 
contrast; (b) overlay of conjugate 4-9 fluorescence and phase contrast; (c) ER tracker Blue/White 
fluorescence; (d) overlay of conjugate 4-9 fluorescence and ER Tracker; (e) BODIPY ceramide; 
(f) overlay of conjugate 4-4-9 fluorescence and BODIPY ceramide; (g) MitoTracker Green 
fluorescence; (h) overlay of conjugate 4-9 fluorescence and MitoTracker; (i) LysoSensor Green 
fluorescence; (j) overlay of conjugate 4-9 fluorescence and LysoSensor. Scale bar: 10 μm.  
 
 
 
 
 
 
 
 
 131   
 
Table 5. Subcellular localization of BODIPY 4-5 and Conjugates 4-8 and 4-9 
Compound Major sites of localization 
4-5 ER 
4-8 ER, Golgi 
4-9 ER, Golgi, Lyso 
 
4.3.3.4 Modeling and Docking 
 To accurately account for the binding interaction of conjugates 4-8 and 4-9 with EGFR, 
three-dimensional structures of the compounds were pursued using InsightII molecular modeling 
software  by collaborater Dr. Seetharama Jois .The 3D structures of each conjugate was docked to 
the EGFR structure using Autodock software (Figure 13).38 The parent peptide sequence 
(LARLLT) of conjugate 4-8 is known to bind to EGFR near domain I, as observed in previous 
studies.29, 39 The lowest energy docked structure of conjugate 4-8 is found in Figure 13A with 
docking energy of -4.19 kcal/mol. In the docked structure three interactions of hydrogen bonding 
can be observed: the -NH of L5 of the peptide sequence hydrogen bonded with the carbonyl group 
of Ser222 from EGFR; -NH of L1 hydrogen bonds with carbonyl group of Gln59; and oxygen of 
the 3PEG bonded with Asn119 of EGFR.  The core of the BODIPY dye formed a hydrophobic 
interaction with Leu186, Pro171, Lys185 side chain, Ile189 and 190 of EGFR. The conjugate 
exhibited an extended confirmation with the  BODIPY dye pointing away from the peptide 
sequence. This confirmation allowed for the BODIPY and binding pocket to form a non-specific 
hydrophobic interaction with the surface of EGFR. 
In figure 13B the binding of conjugate 4-9 with EGFR near the EGF binding pocket was 
observed.40 Compound 4-9 was found to bind at the lower side of the binding pocket with a docking 
energy of -6.07 kcal/mol  equipped with three hydrogen bonding interactions as well. The side 
chains of G6 and T8 of the peptide sequence of conjugate 4-9 formed hydrogen-bonding 
interactions with the side chain of Arg310 from EGFR. Y2 of the hydrogen bonded with Val312 of 
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EGFR. Conjugate 4-9 did not exhibit a hydrogen bond with the 3PEG moiety. This insantace is due 
to the folded loop structure of the PEG group to block any and ydrogen bonding interaction with 
the receptor. The BODIPY scaffold of conjugate 4-9 was suppressed in the hydrophobic pocket 
near Phe335 and His334 of EGFR. One of the methoxy phenyl groups of the dye was also found 
buried in the hydrophobic pocket of EGFR. This immersion into the hydrophobic pocket leads to 
stabilizing the compound in binding pocket of EGFR. Still, the BODIPY core was extended out of 
the pocket with the peptide part buried in the inside of EGF binding site.  
 
Figure 13. Proposed model of interaction of EGFR with A) conjugate 4-8 and B) conjugate 4-9. 
BODIPY is highlighted. Amino acids from peptide are represented by single letter code and 
amino acids from the protein are represented with three-letter code. EGFR is shown in surface 
representation. Reprinted with permission from [22] Copyright (2017) American Cancer Society. 
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From SPR and docking studies it is clear the conjugate 4-8 binds specifically to EGFR 
away from the EGF binding pocket. However, conjugate 4-9 binds near EGF binding pocket with 
BODIPY buried in the hydrophobic pocket. Previous studies by Li et al.,40 suggest that peptide 
YHWYGYTPQNVI binds near EGF binding pocket,  and the EGF binding pocket is partially 
overlapped with the peptide binding pocket. Dr. Jois’ docking studies demonstrate that conjugate 
4-9 binds to the lower side of EGFR in the EGF pocket. Furthermore, SPR studies indicated that 
compound 4-5 binds to EGFR non-specifically (Figure 6) and conjugate 4-9  (Figure 5) binding 
seems to be non-specific at higher concentration. This may be due to the binding of BODIPY to 
the hydrophobic pocket near EGF binding pocket. Furthermore, modeling studies indicated that in 
the case of conjugate 4-8, PEG and BODIPY part of the molecule did not block the efficient groups 
(amino acid side chains) of the peptide needed for bonding interactions, whereas in compound 4-9 
the 3PEG moiety twisted structure onto the peptide surface covering some of the side chains in the 
peptide (Figures 13 A and B). Consequently, looking at specific binding to EGFR, conjugate 4-8 
may be a better choice for EGFR binding. 
4.4 Conclusion 
 
In conclusion, NCS-BODIPY 4-5 was designed and successfully synthesized from 
pentachloro-BODIPY 4-1 in several steps. BODIPY 4-5 was confirmed by 1H, 13C, and 11B NMR, 
HRMS, and X-ray analysis. The quick and clean conjugation reactions between isothiocyanate 
group of BODIPY 4-5 and EGFR-peptides 2-4 and 2-5 were investigated for the first time, and 
each conjugation exhibits percent yields up to 80%. The formation of BODIPY-peptide conjugates 
4-8 and 4-9 was confirmed using 1H and 11B NMR, HSQC, and MALDI-TOF. Each conjugate was 
further characterized by spectroscopic studies, which showed that conjugates 4-8 and 4-9 observed 
similar spectroscopic properties, both emitting > 630 nm in DMSO.  BODIPY 4-5 and conjugate 
4-9 (at higher concentrations) showed a non-specific binding to EGFR, while conjugate 4-8 
displayed an apparent specific binding to EGFR. Computational studies were conducted by Dr. 
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Seetharama Jois to further reveal the binding ways of conjugates 8-9 to EGFR. Cell studies 
conducted by Mrs. Zehua Zhou results, compared with precursor 4-5, conjugates 4-8 and 4-9 
showed faster (> 50 fold) accumulation in the human HEp2 cells; conjugates 4-8 and 4-9 also 
showed low dark toxicity (IC50 ≥ 98 μM) and phototoxicity (IC50 ≥ 74). Those properties above 
suggest BODIPY-peptide conjugates 4-8 and 4-9 are suitable EGFR targeting agents for imaging 
CRC.   
4.5 Experimental 
4.5.1 General Information 
 Commercially available chemicals were purchased from VWR or Sigma-Aldrich and used 
without further purifications for the reactions and purifications. Thin layer chromatography (TLC) 
was performed on the precoated silica gel plates (0.2 mm, 254 indicator, polyester backed, 60Å, 
Sorbent Technologies) to monitor the reactions. Preparative TLC plates (60G, VWR) and silica gel 
(60Å, 230-400 mesh, Sorbent Technologies) were used for liquid chromatography and column 
chromatography. 1H NMR and 13C NMR spectra were collected on a Bruker AV-400 liquid, or AV-
500 spectrometer at 300K. All the chemical shifts (δ) are provided in parts per million (ppm) in 
CDCl3 (7.27 ppm for 1H NMR and 77.0 ppm for 13C NMR) and DMSO (2.54 ppm for 1H NMR). 
The coupling constants (J) are reported in Hz. High-resolution mass spectra (HRMS) and MALDI 
(TOF) spectra were obtained on a 6210 ESI-TOF Mass Spectrometer (Agilent Technologies) under 
negative mode and Applied Biosystems QSTAR at the LSU Mass Spectrometry Facility. Normal-
phase HPLC was performed on Dionex system (organics system) including a P680 pump with a 
UVD 340 detector and a fraction collector III. This system is connected to a Dynamax axial 
compression column in the packing of irregular silica gel (Rainin 60 Å).  Reverse-phase HPLC 
analysis was performed with a Waters 2485 Quaternary Gradient Module, Waters Sample Injector, 
and 2489 UV/Visible Detector, which are controlled by Waters Empower 2 software. Separations 
were completed on an X-Bridge BEH300 Prep C18 (5 um, 10 x 250 mm) with a X-Bridge BEH300 
Prep Guard cartridge 300 Å (5 um, 10 x 10 mm) at a 4 mL/min flow rate with UV detection for 
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peptides at 220 nm, and for BODIPY conjugates at 580 nm. Fractions of HPLC purity (> 95%) 
with the anticipated mass were combined and lyophilized.   
4.5.2 Synthesis of NCS BODIPY 4-5  
BODIPY 4-5 
 Into a 25 mL round-bottomed flask were added BODIPY 4-4 (10.2 mg, 0.018 mmol), 1,1’-
thiocarbonyldi-2(1H)-pyridone (20.9 mg, 0.09 mmol), and dichloromethane (2 mL). The mixture 
was stirred at room temperature for 2 h. The reaction was stopped when the starting material was 
completely consumed, according to TLC. The organic solvent was removed, and the residue was 
subjected to prep TLC using ethyl acetate/hexanes 1:2 for elution to provide the desired product 5 
(9.6 mg, 88%). mp 247-249 oC; 1H NMR (400 MHz, CDCl3) δ 7.64-7.69 (m, 4H), 7.54-7.56 (d, J 
= 8.7 Hz, 2H), 7.27-7.29 (s, 2H), 7.09-7.11 (d, J = 8.7 Hz, 1H), 6.96-6.98 (m, 3H), 6.90 (s, 1H), 
3.95 (s, 1H), 3.86 (s, 1H); 13C NMR (125 MHz, CDCl3) δ 162.2, 161.1, 155.8, 151.0, 144.1, 136.7, 
133.3, 132.8, 132.4, 132.3, 131.9, 131.7, 129.2, 128.6, 127.4, 125.8, 125.3, 123.6, 121.7, 121.3, 
114.3, 113.6, 55.6, 55.2; 11B NMR (128 MHz, CDCl3) δ 0.518 (t, J = 30.3 Hz); HRMS (ESI-TOF) 
m/z calcd for C30H20BCl2F2N3O2S [M]- 604.0756; found 604.0734. 
4.5.3 Procedure for peptide conjugation  
 Into a 4 mL vial were added the pegylated peptides (1.5eq) and triethylamine (7.5 eq). The 
mixture was stirred at room temperature for 5 min. BODIPY 4-5 (1 eq) was added into the vial, 
and the final mixture was stirred at room temperature for 30 min. TLC was used to monitor the 
reaction. H2O (0.5 mL) was added to quench the reaction, and the solvent was removed using 
pressure. The residue was then subjected to HPLC (CH3CN/H2O as the eluents for conjugate 4-8; 
CH3CN and H20 including 0.1% TFA as the eluents for conjugate 9) to afford the desired BODIPY-
peptide conjugates 4-8 and 4-9.  
Conjugate 4-8 (BODIPY-3PEG-LARLLT-NH2): Yield: 5.91 mg, 80%. HPLC (50% A for 5 min, 
10% A to 0% A over 13 minutes, 0% A to 50% A over 2 min at a flow rate of 4 mL/min) and tR = 
11.00 min. 1H NMR (500 MHz, DMSO) δ 9.87 (s, 2H), 8.16 (s, 2H), 8.03 (s, 4H), 7.91 (d, J = 8.1 
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Hz, 1H), 7.72 (d, J = 8.7 Hz, 2H), 7.68 (d, J = 8.6 Hz, 2H), 7.51 (dd, J = 14.9, 8.7 Hz, 4H), 7.40 
(d, J = 7.8 Hz, 2H), 7.19 (dd, J = 23.7, 9.7 Hz, 5H), 7.05 (m, 4H), 6.48 (s, 1H), 4.27 (m, 5H), 4.05 
(m, 2H), 3.92 (s, 3H), 3.82 (s, 3H), 3.67 (s, 2H), 3.52 (m, 14H), 3.09 (d, J = 6.0 Hz, 2H), 1.58 (m, 
4H), 1.48 (m, 8H), 1.21 (m, 7H), 1.00 (d, J = 6.3 Hz, 3H), 0.87 (m, 18H); 11B NMR (128 MHz, 
DMSO) δ 0.368 (t, J = 30.2 Hz); MS (MALDI-TOF): m/z calcd for C70H98BCl2F2N14O11S [M]+ 
1493.659; found 1493.726. 
Conjugate 4-9 (BODIPY-3PEG-GYHWYGYTPQNVI-NH2): Yield: 5.95 mg, 50%. HPLC (50% 
A for 5 min, 10% A to 0% A over 13 minutes, 0% A to 50% A over 2 min at a flow rate of 4 
mL/min) and tR = 11.99 min. 1H NMR (500 MHz, DMSO) δ 13.99 (s, 1H), 10.74 (s, 1H), 9.89 (s, 
2H), 9.15 (s, 3H), 8.90 (s, 1H), 8.09 (m, 12H), 7.70 (dd, J = 26.4, 8.5 Hz, 5H), 7.51 (dd, J = 14.2, 
8.7 Hz, 4H), 7.43 (s, 1H), 7.22 (m, 6H), 7.03 (m, 8H), 6.79 (s, 1H), 6.62 (d, J = 4.2 Hz, 5H), 6.54 
(s, 3H), 4.58 (dd, J = 12.0, 5.6 Hz, 4H), 4.38 (t, J = 7.0 Hz, 5H), 4.16 (m, 2H), 4.08 (t, J = 7.8 Hz, 
2H), 3.92 (s, 4H), 3.81 (s, 3H), 3.59 (m, 16H), 3.13 (m, 3H), 2.90 (s, 4H), 2.67 (m, 3H), 2.37 (m, 
2H), 1.99 (m, 11H), 1.45 (m, 3H), 1.16 (m, 14H), 0.83 (m, 9H);11B NMR (128 MHz, DMSO) δ 
0.374 (t, J = 30.2 Hz); MS (MALDI-TOF): m/z. calcd for C116H139BCl2F2N23O25S+  [M+H]+ 
2405.950; found 2406.018. 
4.5.4 Spectroscopic Studies 
A Varian Cary spectrophotometer and a Perkin Elmer LS55 spectrophotometer were used 
to determine the UV-Visible and emission spectra at room temperature. Quartz cuvettes (1 cm path 
length) were used for both measurements. The plots of integrated absorbance vs. the corresponding 
solution concentrations were used to determine the extinction coefficients (ε) at the maximum 
absorption. Different dilute BODIPY solutions with absorbance values between 0.03-0.1 at λ = 550 
nm or 580 nm were selected and used for the determination of the relative fluorescence quantum 
yields. Crystal violet perchlorate (0.50 in ethanol) and methylene blue (0.03 in methanol) were used 
as the external standards.33 Relative fluorescence quantum yields (Φf) were calculated using the 
following equation:41  
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Φx = Φstd × (Gradx/Gradstd) × (nx2/nstd2) 
 Where Φ refers to the fluorescence quantum yields; n represents the refractive indexes of 
the solvents used for the measurement; Grad refers to the gradient of integrated fluorescence 
intensity vs. the corresponding absorbance; subscript x and std represent the tested samples and the 
external standards, respectively.  
4.5.5 Surface Plasmon Resonance 
SPR was achieved using Biacore X100 from GE Health Sciences. Pure recombinant protein 
EGFR was obtained from Leinco Technologies (St. Louis, MO). HBS-EP+ buffer and 100 mM 
glycine at pH 4, 4.5, 5, 5.5 were purchased from GE Health Science. The extracellular domain of 
EGFR protein was immobilized on a CM5 sensor chip (GE Healthcare Biosciences) at a rate of 10 
μL/min using a customary amine coupling procedure. The carboxyl groups on the CM5 chip were 
initiated using a solution containing 0.2 M N-ethyl N-(dimethylaminopropyl) carbodiimide (EDC) 
and 0.05 M N-hydroxysuccinimide (NHS) (35μL solution, with a flow rate of 5 μL/min). The 
running buffer for peptides was HBS-EP+ buffer diluted 10 times, including 0.01 M HEPES, 0.15 
M NaCl, 3 mM EDTA, and 0.005% surfactant P20 at pH 7.5. Peptides dissolved in buffer were 
used as analytes. The running buffer for the BODIPY conjugates was HBS-EP+ buffer diluted 10 
times, also containing 0.01 M HEPES, 0.15 M NaCl, 3mM EDTA, 0.005% surfactant P20 at pH 
7.5, but brought to a 4% DMSO concentration. BODIPY 5 and conjugates 8 and 9 were dissolved 
in 4% DMSO buffer solutions and used as the analytes. SPR sensorgrams were attained and the 
association and dissociation rates were obtained from 0 to 250 μM concentrations.  
4.5.6 Cell Studies 
 The human HEp2 cell line was purchased from ATCC, and maintained in a 
DMEM/AMEM (50:50) mixture supplemented with FBS (5%) and Primocin antibiotic. All other 
commercial available reagents used in the cell studies were purchased from Life Technologies. 
4.5.6.1 Dark Cytotoxicity 
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 A Stock solution (32 mM) of BODIPYs 4-5 and conjugates 8 and 9 was prepared using 
100% DMSO. Working solutions with concentrations of 0, 6.25, 12.5, 25, 50, and 100 μM were 
prepared from the stock solutions. The HEp2 cells were exposed to each of the solutions of desired 
compounds up to 100 μM and incubated overnight (5% CO2, 95% humidity, 37 °C). The loading 
medium solution was removed, and the cells were washed with PBS solution. Medium (20% Cell 
Titer Blue from Promega) was added and the cells incubated for another 4 h. BMG FLUOstar 
Optima microplate reader was used to measure the dark toxicity by reading the medium 
fluorescence at 570/615 nm. The fluorescence intensity of the untreated cells was normalized to 
100%. 
4.5.6.2 Phototoxicity 
 The HEp2 cells were exposed to the different working solutions of BODIPYs 4-5, 4-8 and 
4-9 up to 100 μM and incubated overnight (5% CO2, 95% humidity, 37 °C). The loading medium 
solution was removed, and the cells were washed with PBS solution. New medium was added and 
the cells were then exposed to a halogen lamp (600 W) as the light source, prepared with a water 
filter (transmits radiation 250−950 nm) and a beam turning mirror (200 nm to 30 μm spectral range, 
Newport), for 20 min. The total light dose used was ≈ 1.5 J/cm2. The cells were then incubated for 
another 24 h, followed by the measurement of cell viability as previously described. 
4.5.6.3 Time-Dependent Cellular Uptake 
 The HEp2 cells were exposed to 10 μM concentration solutions of BODIPYs 4-5, 4-8 and 
4-9 for different periods of time (0, 1, 2, 4, 8, and 24 h). The loading medium solution was removed, 
and the cells were washed with PBS solution. The cells were then dissolved in 0.25% Triton X-100 
in PBS solution. BODIPY solutions with concentrations of 10, 5, 2.5, 1.25, 0.625, and 0.3125 μM 
were prepared by diluting 400 μM of each compound with 0.25% Triton X-100 (Sigma-Aldrich) 
in PBS solution, and used to obtain the standard curves. The concentration of the compounds was 
determined using a BMG FLUOstar Optima microplate reader at 570/615 nm.   
4.5.6.4 Microscopy 
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 The human HEp2 cells were incubated in a six-well plate (MatTek), and allowed to grow 
overnight. The cells were exposed to each compound at a concentration of 10 μM, and incubated 
for 6 h (5% CO2, 95% humidity, 37 °C). The following organelle trackers (Invitrogen) were added 
to the cells: ER Tracker Blue/White (100 nM), BODIPY FL C5 Ceramide (50 nM), MitoTracker 
Green (250 nM), LysoSensor Green (50 nM). The cells were incubated with each compound and 
trackers for half an hour, and washed with PBS solution three times before imaging. A Leica 
DMRXA2 upright microscope equipped with a water immersion objective, and DAPI, GFP, and 
Texas Red filter cubes (Chroma Technologies) was used to acquire the images.  
4.5.7 Computational Modeling 
 The 3D structures of conjugates 4-8 and 4-9 were built using InsightII (BIOVIA San Diego, 
CA) molecular modeling software. The BODIPY structure was obtained from the coordinates of 
the crystal structure of 5 described above. For the EGFR receptor 3D structure, the pdb file 1nql42 
that represents EGFR in a closed conformation was downloaded from the protein data bank. 
Conjugates 4-8 and 4-9 contain a boron atom in the BODIPY core and forcefield parameters were 
not defined in the Autodock default parameters file. Parameters for boron can be obtained from the 
literature,43 however, for docking calculations the boron atom was replaced with a carbon atom, as 
boron atom is not calibrated in docking studies using Autodoc. Docking was performed using 
Autodock 4.38 The lowest energy docked structure was represented using PyMol software 
(Schrodinger LLC, Portland, OR). 
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CHAPTER 5. Design and Synthetic Strageties for BODIPY-Peptidic Conjugates for 
Diagnosis of CRC via Click Chemistry 
5.1  Introduction 
 
Nobel Laureate Dr. Barry Sharpless first introduced a novel 1,3-dipolar cycloaddition 
between a terminal alkyne and an azide in 2001. This cycloaddition also known as the azide/alkyne- 
“Click”-reaction or “CuAAC reaction” is a very unique reaction that has gained popularity due to 
its varied utility in diverse fields. Click chemistry consists of a group of reactions that are clean, 
fast, and efficient. Click chemistry can be very versatile in the method of connecting two 
compounds, as well as providing a regiospecific manner during connection1. There are several 
reaction types that use this concept such as the mentioned cycloadditions, nucleophilic ring 
opening, non-aldol carbonyl chemistry, and addition to carbon-carbon multiple bonds to name a 
few. Of those mentioned reactions, cycloadditions in particular the copper-catalyzed Huisgen 1,3-
dipolar cycloaddition of azides and terminal alkynes, abbreviated as CuAAC (Copper-catalyzed 
azide alkyne cycloaddition) is the best known click reaction.2  Rolf Huisgen contribution to the 
azide/alkyne cycloadditions required the alkyne to behave as a dipolarphile ready for the addition 
of an azide moiety or 1,3-dipole in concerted fashions3 by heating, to produce a mixture of 1,4- and 
1,5-triazoles (Scheme 1).  
  
Scheme 1. 1,3-Dipolar cycloaddition of an 1,3-dipole and dipolarphile discovered by Rolf 
Huisgen.3 
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The heating of these reactions to induce cycloaddition was considered harsh reaction 
conditions requiring improvements. The desired changes were considerably moderated by the use 
of a copper catalyst, which accelerates the rate of the reaction by 7 orders of magnitude.4 This 
phenomenon was revealed by Sharpless and Meldal groups opposing Huisgen’s uncatalyzed 
conditions, where the addition of copper (I) salts safeguards the restricted 1,2,3-triazole 
regioselective formation of the 1,4- regioisomer (Scheme 2).4 
 
Scheme 2. Copper catalyzed 1,3-dipolar cycloaddition by Sharpless/Meldal.  
 Copper (I) catalyzed cycloaddition reactions have a multitude of desirable characteristics 
including simple reaction conditions, short reaction time, simple purification, and robust under 
various reaction conditions, such as air and moisture.  These benefits have allowed this 1,3-dipolar 
cycloaddition to catch the eye of researchers in biomolecule conjugation for use in multiple areas 
such as photodynamic therapy and imaging. This cycloaddition is especially suitable for gentle 
components such as peptides, carbohydrates, and nucleotides.2  The continual attraction of the click 
chemistry is ingrained in its selectivity, productivity, and adaptability.5 The click reaction is often 
quantitativeand highly desirable due to its robust behavior and insensitivity to various 
environments.6 The triazole formed is a strong entity that is stable to conditions such as acid and 
base hydrolysis, reductive and oxidative environments, and is quite resistant to proteolytic 
cleavages.7 
 Thus, cycloadditions have been used in various conjugation attempts in probe 
developments including BODIPY dyes as the fluorophore of choice, and a targeting moiety for 
appreciation in in vivo imaging. Wolfbeis et al.8 reported in vivo cellular labeling of biomolecules 
by way of copper free and copper-mediated click chemistry. Clickable BODIPY fluorophores were 
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designed for labeling of the azide modified surface glycans of CHO cells. Akkaya et al.9 reported 
the use of click chemistry in the synthesis of a bay region BODIPY dye appended to a 
perylenediimide (PDI). The molecule is suited for light-harvesting and allows a large cross-section 
for the absorption of light in the visible range. The excitation energy was shown to efficiently 
channel the perylenediimide core structures.9 Overkleeft et al.10 synthesized three acetylene 
functionalized BODIPY dyes that are used to identify an azido- bearing epoxomicin analogue by 
fluorescence. This identification was performed through the Huisgen 1,3-dipolar cycloaddition, 
which resulted in a collection of fluorescent epoxomicin derived proteasome probes.10  
The growing success of the CuAAC reaction is ingrained in its selectivity, efficiency and 
versatility. The CuAAC reaction is a virtually quantitative, very robust, insensitive to the 
environment, and with the orthogonal ligation reaction, suitable for various bimolecular pairing 
and in vivo labeling. The triazole formed is stable to acid and base hydrolysis, reductive and 
oxidative environments, and is quite resilient to metabolic degradation.2 Several other 
functionalized BODIPYs were conjugated to peptides or proteins for imaging applications using 
“click” reactions.11-14 
As a result, this chapter will focus on utilizing click chemistry as the desired method for 
conjugating peptides to alkynyl BODIPY dyes. The use of click chemistry is not only due to the 
facile synthetic processes surrounding the methodology, but also due to the: (1) resourcefulness of 
the reaction (2) moderate reaction conditions that could be well endured by the BODIPY and 
peptide scaffolds, and (3) ease of purification.15 15-16 
5.2  Results and Discussion 
The drive of this work was to make use of the versatile cycloaddition reactions to design 
and synthesize a sequence of new fluorescent bioconjugates appended to L1 peptide derivatives. 
This group of bioconjugates would consist of a BODIPY fluorophore bearing a durable 1,2,3- 
triazole ring, linked to a peptide moiety that targets EGFR for a specific accumulation of fluorescent 
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dye at the site of CRC. Furthermore, the ultimate goal would not be complete unless the entire 
probe possessed moieties that would promote a red-shift of the emission wavelength into the red 
and NIR region through a classical Knovenagel condensation approach, along with useful Sharpless 
alkyne/azide cycloaddition potentials. 
The strategies employed for development of the desired BODIPY-peptide conjugates, has 
been formerly investigated on different fluorophores including porphryrins and related 
macrocycles.17-20 However, similar work has been noted with identical BODIPY dyes that were 
conjugated to biomolecule moieties PEG (for linkage to biomolecules) and carbohydrates (as a 
targeting moiety) (Scheme 3).21 This work was noted by a former member of the Vicente’s group 
Timsy Uppal.  
         
Scheme 3. Copper catalyzed 1,3-dipolar cycloaddition of BODIPY dyes with PEG and 
carbohydrates moiety.21     
 
 
A thorough study of BODIPY-conjugates generated via click chemistry implied that the 
1,3-cycloaddition labeling of biomolecules is generally completed on the functionalized 
macrocycle.2  Thus, a comparable practice was implemented for the work described hereon. Vicente 
et al. mentioned the most important stage as the development of the terminal alkyne “handle” on 
the BODIPY fluorophore, to generate the so-called “clickable BODIPY fluorophores”.22 To 
,Glucose, lactose 
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replicate Timsy’s work of installing this alkyne arm while creating the BODIPYs core, a literature 
procedure was followed that used p-hydroxy benzaldehyde which then could be O-alkylated 
through a Williamson reaction, using propargyl bromide and potassium carbonate in acetone to 
generate p-propargyloxy-benzaldehyde 5-1 in a near quantitative manner (Scheme 4.4).23 This 
starting material is greatly desired due to the establishment of the desired alkyne arm very early on 
in the BODIPY synthesis. To develop the meso-phenyl-BODIPY 5-2 bearing the desired alkyne, a 
cascade of reactions took place in a classical one-pot, three-step approach.  This synthesis began 
with the p-propargyloxy-benzaldehyde 5-1 and two equivalents of 3-ethyl-2,4-dimethyl pyrrole, in 
the presence of a catalytic amount of BF3OEt2 and dry dichloromethane as solvent (Scheme 4).  
 
Scheme 4. Synthetic route to desired BODIPY 5-2. 
 
The final reaction mixture was allowed to stir under inert conditions while being monitored 
by TLC until completion. The resulting mixture was allowed to cool down to 0 °C in an ice bath, 
and treated with 1.2 equiv. of DDQ oxidant to form the dipyrromethene component. After stirring 
for 20 min., triethylamine was added in a dropwise manner while remaining at 0 °C. After 20 min. 
stirring, the reaction mixture was treated with BF3OEt2 and the resulting reaction mixture was 
stirred at room temperature under nitrogen. The progress of the reaction was closely monitored by 
TLC until completion. To remove the majority of oxidized dipyrromethene, unwanted side 
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products, and residual DDQ, the reaction mixture was then filtered through a short plug of silica 
gel to separate the desired product and byproducts. The solvent was removed under vacuum to 
afford the crude mixture of BODIPY 5-2. This residue was then dissolved in a mixture of 
dichloromethane and water and stirred overnight to decompose any unreacted BF3OEt2. The 
consequent reaction mixture in DCM was then extracted with .1M HCl to ensure all DDQ is 
removed. The organic layers are then combined and dried over sodium sulfate and the solvent 
removed under vacuum. 
The crude result was purified on a silica gel column with a solvent mixture of 
dichloromethane/hexane in a 1:1 ratio as the eluting solvent. The desired product is an orange-
green fluorescent band, and is the first compound to elute off the column. The product was collected 
and the solvent was evaporated to afford the desired BODIPY 5-2 in 40% overall yield over three 
steps. Unlike the high yields received in the previous work of our group, the yield was moderate. 
This is could be in part due to the purity of the 3-ethyl-2,4-dimethyl pyrrole used. The pyrrole was 
slightly discolored hinting at possible oxidized products inclusive in the mixture. Nevertheless, 
BODIPY 5-2 was then confirmed by H-NMR and MS (MALDI) . 
BODIPY 5-2 possesses acidic methyl groups at the 3- and 5- positions on the BODIPY 
core, and an attempt to create a BODIPY dye with the desired alkyne while red shifting the 
abostiopn and emission of the molecule was investigated using Knovenagel condensation. It is 
known that styryl-derived BODIPY compounds display red-shifted fluorescence emissions due to 
extension of the π-conjugation, and their emission wavelengths vary according to the styryl 
moieties.24 The insertion of one or two styryl groups on BODIPY 5-2 was accomplished with 
electron-rich indole-3-carbaldehyde 5-3 by classical Knoevenagel condensation, using piperidine 
and acetic acid while refluxing in toluene. The use of a Dean-Stark apparatus was essential in 
previous work for removing any water formed during the reaction to push the reaction towards 
double condensation;25 however, in this work the desired product was mono conjugation and no 
significant difference was noted for the production of mono condensation when using the Dean-
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Stark apparatus. The key component for pushing the reaction forward for mono condensation was 
noted at the concentration of the reagents. The more concentrated the reaction mixture was the 
more product was achieved, and the less double condensation was noted. The use of indole-3-
carbaldehyde 5-3 for the integration of styryl groups was based on results previously published in 
our group.21 Additionally, the incorporation of “indole” moieties have been admired for their 
biological inorporation with tryptophan.26 Tryptophan is a naturally occurring amino acid and an 
important component of many enzymes, peptides, and proteins, such as EGFR-L2 found in chapter 
2.27-28  It is expected that by attaching the styryl group on the BODIPYs’ core the product will not 
only exhibit the desired bathochromic shift, but have further increased biological efficacy for our 
desired receptor EGFR.  
BODIPY 5-2 was added to a mixture of dry toluene, glacial acetic acid and piperidine 
followed by the addition of compound 5-3 in a 1:3 ratio. The advancement of the reaction was 
monitored by TLC analysis, a slightly blue spot corresponding to the monostyryl-BODIPY 
derivative 5-4 was noticeable as early as 4 hours (Scheme 5).  However, a larger spot on TLC 
indicated the presence of starting material, therefore the reaction was left to stir overnight. Although 
starting material was still present, the reaction was stopped after 14 hours to minimize the amount 
of distyryl compound formed. The reaction mixture was then allowed to cool to room temperature 
and removal of the solvent was performed under vacuum. The crude material was purified by silica 
gel chromatography using an eluent mixture of dichloromethane/hexane in 2:1. In this purification, 
three distinct bands were obtained. The orange-green band corresponding to starting material 
BODIPY 5-2 was the first to elute, followed by the blue-red band of the desired mono- styryl 
BODIPY 5-4, and finally a dark green band is eluted corresponding to the  di-styryl BODIPY 5-5. 
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Scheme 5. Synthetic route to BODIPYs 5-4 and 5-5. 
Each band was collected and the solvent was removed under vacuum. The starting material 
BODIPY 5-2 was then reused to develop more of BODIPY 5-4. The desired product 5-4 was 
isolated in 28% yield. Mass spectrometry MALDI-TOF and proton NMR were used to characterize 
BODIPYs 5-2 and 5-4. 
Two peptides previously discussed in chapter 2 with azide functionalities were ideal for 
cycloaddition to BODIPYs 5-2 and 5-4.  Peptide 2-9 has a linear sequence that displayed good 
binding affinity to EGFR; however, it may be prone to proteolytic cleaveage in vivo due to its linear 
structure. While peptide cycloL1.1 is a cyclic peptide, it also exhibited high binding affinity for 
EGFR, and it is less likely to undego enzymatic cleavage due to the cyclic structure of the backbone 
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of the sequence. With these two azido peptides and alkynyl BODIPY dyes 5-2 and 5-4, 1,3-
cycloaddition reactions were studied.  
 
Figure 1. Azido peptides cycloL1.1 and 2-9 .  
To employ “click chemistry,” the reaction was performed in the presence of CuSO4 H2O, 
Cu (0) , and ascorbic acid in THF/water (3:1), as shown in Scheme 5.6. The meso-alkynylphenyl-
BODIPY 5-2 was dissolved in THF/water, and to this solution azido-peptide 2-9 (1.5 equiv) 
dissolved in DMSO was added. A catalytic amount of Cu (0) (1 equiv) was added to the resulting 
mixture followed by the addition of CuSO4.5H2O (1 eqiv) and L- ascorbic acid (1 equiv.) in distilled 
water. A catalytic amount of the essential copper metal was added as a suitable reductant for Cu(II) 
in an aqueous solution to produce Cu(I), which is a potent stimulus for the formation of 1,2,3-
triazoles.29 The reaction mixture was allowed to stir for 24 hours and monitored by MALDI-TOF 
for the desired product. Once the reaction was complete, the mixture was then quenched with water. 
To purify the resulting conjugate a molecular weight cut off (MWCO) of 1,000 Da was used to 
retain the conjugate, as the molecular weight for this conjugate was 1273.91, and remove any 
starting materials remaining in the mixture.  
2-9 cycloL1.1 
O
N
H
O
H
N
O
HN
HN
NH2H2N
O
HN
OH
N
O
HN
OH
O
N3
N
H
O
HN
O
H
N
O
N
H
NH
H2N NH2
O
H
N
O
N
H
O
H
N
HO
NH2
N3
O
H2N
 154   
 
   
                     
 
Scheme 6. Generic synthetic route to BODIPY conjugates 5-6 ,5-7, and 5-8. 
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After removal of solvents the mixtures were purified using RP-HPLC, eluting with a 
gradient of 10:90 to 0:100 .1% TFA in H2O/ .1% TfA in CH3CN to afford 1,2,3-triazole cycloadduct 
5-6 in 82% yield. The reaction conditions used with BODIPY 5-2 and azido-peptide 2-9 were 
repeated to determine the efficacy of peptide 2-9 in the click reaction with BODIPY 5-4. The meso-
alkynylphenyl-BODIPY 5-4 was dissolved in THF/water, to this solution azido-peptide 2-9 (1.5 
equiv) dissolved in DMSO was added. A catalytic amount of Cu (0) (1.0 eq) was added to the 
resulting mixture, followed by the addition of CuSO4 .5H2O (1 equiv) and L- ascorbic acid (1 equiv) 
in distilled water (Scheme 4-7). This reaction yielded the desired cycloadduct 5-7 in 70% yield. 
Thus, the most bulky azido peptide cycloL1.1 was then subjected to cycloaddition with the reddest 
shifted BODIPY dye 5-4 under the same conditions with peptide cycloL1.1 to produce conjugate 
5-89 in a percent yield of 80% as shown in Scheme 5.6. 
All cycloaadducts were formed in good yields as hoswn in Table 1. Compound 5-6 was 
synthesized in the highest percent yield of 82%. Cycloadduct 5-8 was isolated in a percent yield of 
80% which is an excellent yield, considering the bulkiness of the cyclic backbone structure of the 
peptide cycloL1.1, and the larger size of BODIPY 5-4, however this is one of the attractive features 
of click chemistry.  
 
 
 
 
 
 
Table 1:  Results of  Peptide BODIPY Conjugates via Click Chemistry 
Compound Molecular Weight (g/mol) Peptide Percent Yield 
4-6 1273.79 2-9 82% 
4-7 1400.89 2-9 70% 
4-8 1383.81 cycloL1.1 80% 
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5.2.1 In Vitro Studies  
Preliminary in vitro cellular studies, including photo cytotoxicity and cellular uptake were 
investigated against human carcinoma HEp2 cell lines in order to determine the biological efficacy 
of the peptide-functionalized BODIPY-conjugates.  
5.2.1.1Time Dependent Cellular Uptake. The cellular uptake of all compounds were obtained by 
Mrs. Zehua Zhou in a time-dependent manner. At a 10 μM concentration against HEp2 cells 
cellular uptake was determined over a 24 hour period. The results are shown in Figure 2. To 
compare the uptake of the conjugates, BODIPYs 5-2 and 5-4 were also investigated.  At the 10 μM 
concentration, both BODIPYs were found to be nontoxic under a CTB assasy, and displayed a 
similar cellular uptake. The kinetics showed a rapid accululation of the dyes at short time points of 
less than 4 hours, after the addition of BODIPY to the cells. The addition of one indole moiety to 
the core of the BODIPY 5-4 dye gave a faster uptake into cells. However, when compared to the 
conjugates, there is a significant difference in the cellular uptake observed. Conjugates with linear 
peptide sequences cycloadducts 5-6 and 5-7 showed a significant difference in the behavior of 
uptake into the cells. Cycloadduct 5-7 was not only taken up in to the cells faster than cycloadduct 
5-6, but more of the compound was taken into the cells. Essentially, cycloadduct 5-6 was taken up 
into the HEp2 cell line with the least amount when compared to all compounds. This may be due 
to the lack of styryl components that may aid in increasing the amount of conjugate taken up into 
HEp2 cells. Cycloadduct 5-8 surprisingly accrued in cells slower than all of the other conjugates; 
however, between 4 and 8 hours an increase in the amount of compound taken up into cells was 
observed. This instance may be noted by the increased stability of the cyclic structure allowing for 
a sustained conjugate uptake within cells, but entering at a slower rate when compared to the linear 
sequences.  
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Figure 2. Time dependent cellular uptake of BODIPYs 5-2 (Black), 5-4 (Green), 5-6 (Pink), 5-7 
(Purple), 5-8 (Blue). 
 
5.2.1.2 Phototoxicity. The phototoxic effect of BODIPYs and conjugates were tested under a low 
dose of light irradiated at 1 J/cm2.  The dose-dependent survival curves of each compound over a 
course of 24 hours are shown in Figure 3. All compounds proved nontoxic in the presence of light 
with IC50 values greater than 100 μM. It is observed that all BODIPY dyes are indeed nontoxic in 
the presence of light. The cycloadduct 5-6 follows strongly in suit with the BODIPY dyes. 
However, conjugates 5-7 and 5-8 show a slight increase in phototoxicity when compared to the 
other conjugate, but overall, the conjugates are non-toxic to the cells. This slight increase in 
phototoxicity is probably due to the increase in cellular uptake that was noted for the compounds 
against the HEp2 cell line still less than BODIPYs 5-2 and 5-4. The increase in cellular uptake 
paired with the charge observed in the sequence of both peptides might explain the results observed.  
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Figure 3. Phototoxicity of BODIPYs 5-2 (Black), 5-4 (Green), 5-6 (Pink), 5-7 (Purple), 5-8 
(Blue). 
 
5.3 Conclusion and Future Work 
 
Two BODIPY dyes 5-2 and 5-4 were synthesized, one bearing one indolyl styryl arm 
inclusive of a meso-alkynyl functionalization point for click chemistry. These BODIPY dyes were 
characterized by 1H-NMR and mass spectrometry (MALDI-TOF). Cu(I)-catalyzed azide-alkyne 
Huisgen cycloaddition (also referred to as “click chemistry”) was used to successfully synthesized 
conjugates 5-6, 5-7 and 5-8 in a convenient, quick and proficient method to offer percent yields of 
70-80 %. Of the conjugates, compounds 5-7 and 5-8 bearing an additional mono-styrl group, and 
conjugate 5-8 was the only conjugate to bear a cyclic peptide cycloL1.1. Preliminary in vitro studies 
using human carcinoma HEp2 cells indicated all the BODIPYconjugates were cell permeable, non-
cytotoxic with high cellular uptake. The monoindolyl styryl-BODIPY conjugate (5-7) conjugated 
to the linear peptide 2-9 was the most efficiently taken up by the HEp2 cells, accumulating more 
than the other conjugates, but less than what was seen for the BODIPY dyes alone. This supple 
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versatile synthetic strategy is anticipated to provide a resourceful platform for vast arrays of 
functionalized BODIPYs possessing potential utility in in vivo imaging for conjugation of various 
biomolecules. 
5.4 Experimental 
5.4.1: General Information 
All reagents are commercially available were purchased from Sigma-Aldrich Co. Canada 
and VWR International. All solvents and reagents used in the synthesis of conjugates were 
performed with reagents purchased from Sigma Aldrich peptide synthesis grade. Required amino 
acids were purchased from either Anaspec, AAPPTec or Applied Biosystems.All reactions were 
performed under argon atmosphere in oven-dried glassware unless otherwise noted. Analytical 
thin-layer-chromatography (TLC) was performed on polyester backed TLC plates 254 (pre-coated, 
200 µm, Sorbent Technologies). Column chromatography was performed on silica gel (Sorbent 
Technologies, 60 Å, 40-63 µm). 1H NMR and HSQC spectra were recorded using a Bruker AVIII-
500 spectrometer (operating at 500MHz for 1H NMR and HSQC) in DMSO-d6. All chemical shifts 
are given in parts per millions (ppm) relative to tetramethylsilane (TMS, 0 ppm); multiplicities are 
indicated as br (broad), s (singlet), d (doublet), t (triplet), q (quartet) and m (multiplet). All spectra 
were recorded at 308 K and coupling constants (J values) are given in Hz. High resolution mass 
spectra were obtained at the LSU Department of Chemistry Mass Spectrometry Facility using 
Bruker Omniflex MALDI Time-of-Flight Mass Spectrometer. The absorption measurements were 
carried out on a Varian 212 Cary 50 UV/Vis spectrophotometer and the steady-state fluorescence 
spectroscopic studies were performed on a PTI Quantum Master4/2006SE spectrofluorometer. All 
spectras were recorded at 298 K using non-degassed samples, spectroscopic grade solvents and a 
10 mm quartz cuvette. 
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5.4.2: Synthesis of 4-(prop-2-ynyloxy)-benzaldehyde (5-1) 
 4-hydroxybenzaldehyde, 1, (2.00 g, 16.38 mmol) and propargyl bromide (7.79 g, 65.51 
mmol,) were added to a solution of potassium carbonate (13.58 g, 98.3 mmol) in 100 mL acetone. 
The reaction mixture was heated to reflux overnight and then cooled to room temperature. The 
heterogeneous solution was filtered off to remove solid potassium carbonate and the solvent was 
removed under vaccum. The crude product was dissolved in dichloromethane (20 mL) and washed 
successively with water twice (20 mL), 5% NaHCO3 (20 mL) and brine (20 mL) once each. The 
organic extracts were combined, dried over Na2SO4 and concentrated under vacuum. The resulting 
crude product was purified by column chromatography using pure dichloromethane as the eluent 
to afford 2.28 g of the compound 2 as pale yellow solid (quantitative). 1H NMR (500 MHz, 
Chloroform-d) δ 9.92 (d, J = 1.4 Hz, 1H), 7.87 (d, J = 8.8 Hz, 2H), 7.11 (d, J = 8.8 Hz, 2H), 4.80 
(d, J = 2.4 Hz, 2H), 2.59 (t, J = 2.4 Hz, 1H).MALDI-TOF m/z 161.059; calcd. for C10H8O2: 
160.52. 
 5.4.3: Synthesis of BODIPY 5-2 
Compound 5-1 (0.6490 g, 4.0584 mmol, 1 equiv.) and 3-ethyl-2,4-dimethyl pyrrole (3.51 
g, 28.47 mmole) were dissolved in dry dichloromethane (281 mL) under the inert gas atmosphere. 
Two drops of BF3OEt2 were added and the reaction mixture was stirred overnight at room 
temperature. When the aldehyde was consumed (monitored by TLC), a solution of DDQ (3.88 g, 
17.08 mmole) in dry dichloromethane (35 mL) was added via syringe at 0°C. 213 After stirring for 
20 min at room temperature, triethylamine (13.89 mL, 7 equiv.) was added dropwise and the 
reaction mixture was stirred for another 30 min at room temperature. Further, BF3OET2 (19.32 mL, 
11 equiv.) was added dropwise at 0°C and the mixture was stirred for 10h at room temperature. 
Once TLC indicated reaction completion, the reaction mixture was passed through a short plug of 
silica gel to get rid of the oxidized dipyrromethene derivatives and starting materials. The solvent 
was removed under reduced pressure and the residue was taken up in dichloromethane (100 mL) 
and kept for overnight stirring at room temperature to decompose any unreacted BF3OET2. The 
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subsequent reaction mixture was extracted with 0.1M HCl (2 x 100mL) to remove excess DDQ, 
brine (1 x 100 mL). The organic extracts were collected, dried over Na2SO4 and the solvent was 
evaporated. The crude product was purified by column chromatography using 
Hexane/dichloromethane (1/1, v/v) as eluent. The orange-green fluorescent fraction containing the 
desired BODIPY 4 was collected and recrystallized from dichloromethane/hexane mixtures to yield 
the title compound as lustrous orange-red solid. Yield: 2.41 g, 39%. 1H NMR (400 MHz, 
Chloroform-d) δ 7.22 (d, J = 8.7 Hz, 2H), 7.11 (d, J = 8.7 Hz, 2H), 4.79 (d, J = 2.4 Hz, 2H), 2.58 
(t, J = 2.4 Hz, 1H), 2.55 (s, 5H), 2.33 (q, J = 7.6 Hz, 4H), 1.35 (s, 5H), 1.28 (s, 2H), 1.01 (t, J = 7.6 
Hz, 5H), 0.91 (t, J = 13.6 Hz, 1H). MALDI-TOF m/z 434.10; calcd. for C26H29BF2N2O: 434.23.  
 
5.4.4: Synthesis of BODPY 5-4 
BODIPY 5-2 (0.0122 g, 0.02809 mmol) and indole-3-carbaldehyde (0.01223 g, .08427 
mmol) were added to a 150 mL triple necked round bottom flask containing a mixture of dry toluene 
(20 ml), piperidine (0.032 ml) and glacial acetic acid (0.019 ml). The mixture was refluxed 
overnight. After completion of the reaction (monitored via thin-layer chromatography), the mixture 
was cooled to room temperature and the solvent was removed under vacuum. The residue was 
purified by silica gel column chromatography using dichloromethane/hexane (2/1, v/v) as eluent. 
(BODIPY 5-4): The first fraction with red fluorescence was dried in vacuo, affording (BODIPY 5-
4): The first fraction with red fluorescence was dried in vacuo, affording BODIPY 5-4 as a red-
blue solid (4.4 mg, yield 28%). 1H NMR (400 MHz, (CD3)2CO): δ; 10.72 (s, NH), 8.16 (m, 1H), 
7.91 (d, J = 8.1 Hz, 1H), 7.74 (d, 1H), 7.65 (d, J = 8.1 Hz, 1H), 7.49–7.51 (m, 2H), 7.20-7.32 (m, 
6H), 4.89 (d, J = 2.0 Hz, 2H), 3.13 (t, J = 2.0 Hz, 1H), 2.69 (q, J = 7.6 Hz, 2H), 2.56 (s, 3H), 2.36 
(q, J = 7.6 Hz, 2H), 1.41 (s, 3H), 1.38 (s, 3H), 1.19 (t, J = 7.6 Hz, 3H), 0.99 (t, J = 7.6 Hz, 3H); 13C 
NMR (100MHz, (CD3)2CO): δ; 158.3, 152.1, 151.4, 129.8, 128.7, 128.2, 125.3, 122.5, 120.9, 
120.7, 120.2, 115.8, 115.7, 115.6, 112.0, 78.5, 76.4 55.7, 18.0, 16.6, 14.1, 13.5, 11.8, 11.1, 10.9; 
MALDI-TOF m/z 561.28; calc. for C35H34BF2N3O: 561.35. 
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5.4.5: General Procedure for 1,3 cycloaddition 
Meso-alkynylphenyl-BODIPY 5-2 and azido-peptide (1.5 equiv) were dissolved in a 
mixture of THF:H2 0 (1.8 mL, 3:1), followed by addition of Cu (0) (1.0 equiv). Next, a solution of 
CuSO4 .5H2O (1 equiv) and L-ascorbic acid (1 equiv.) in H20 was added to the reaction mixture. 
The solition was allowed to stir at room temperature for 24 hours. Once the  reaction was complete, 
the mixture was quenched with water and lyophilized. The fluffy product was then purified by RP-
HPLC under varying gradients of  water (with .1%TFA) and Acetonitrile (with .1%TFA). 
Conjugate 5-6 (BOIDPY-K(N3)LARLLT-CONH2): This conjugate was obtained as a redish 
orange solid (4.8 mg, 82%). MALDI-TOF m/z 1274.59; calc. for C63H100BF2N16O9+: 1273.79. 
Conjugate 5-7 (BOIDPY-K(N3)LARLLT-CONH2): This conjugate was obtained as a dark blue 
solid (3.49 mg, 70%). MALDI-TOF m/z 1274.59; calc. for C73H106BF2N16O9+: 1399.93. 
Conjugate 5-8 (BOIDPY-K(N3)LARLLT-CONH2): This conjugate was obtained as a deep blue 
solid (6.1 mg, 80%). MALDI-TOF m/z 1367.497; calc. for C72H102BF2N16O9+: 1383.80. 
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APPENDIX A: Characterization of Chapter 2 Compounds 
 
HPLC of  Compounds in Chapter 2 
 
 
 
Figure A.1: The gradient used for chromatogram of 2-1 using RP-HPLC with a C18 column is 
listed below. 
 
Table 1 HPLC Gradient for peptide 2-1 
# 
Time 
(minutes) 
Flow %A (H20) %B (ACN) 
0 0 4.0 ml/min 90 10 
1 5 4.0 ml/min 90 10 
2 8 4.0 ml/min 30 70 
3 18 4.0 ml/min 10 90 
4 25 4.0 ml/min 90 10 
5 30 4.0 ml/min 90 10 
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Figure A.2: The gradient used for chromatogram of 2-3 using RP-HPLC with a C18 column is 
listed below. 
  
Table 1 HPLC Gradient for peptide 2-3 
# 
Time 
(minutes) 
Flow %A (H20) %B (ACN) 
0 0 4.0 ml/min 90 10 
1 5 4.0 ml/min 90 10 
2 8 4.0 ml/min 30 70 
3 16 4.0 ml/min 10 90 
4 18 4.0 ml/min 90 10 
5 22 4.0 ml/min 90 10 
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Figure A.3: The gradient used for chromatogram of 2-4 using RP-HPLC with a C18 column is 
listed below. 
 
Table 1 HPLC Gradient for peptide 2-4 
# 
Time 
(minutes) 
Flow %A (H20) %B (ACN) 
0 0 4.0 ml/min 90 10 
1 5  4.0 ml/min 90 10 
2 8  4.0 ml/min 30 70 
3 18 4.0 ml/min 10 90 
4 20 4.0 ml/min 90 10 
5 25 4.0 ml/min 90 10 
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Figure A.4: The gradient used for chromatogram of 2-5 using RP-HPLC with a C18 column is 
listed below. 
 
Table 1 HPLC Gradient for peptide 2-5 
# 
Time 
(minutes) 
Flow %A (H20) %B (ACN) 
0 0 4.0 ml/min 90 10 
1 5  4.0 ml/min 90 10 
2 8  4.0 ml/min 30 70 
3 18 4.0 ml/min 10 90 
4 20 4.0 ml/min 90 10 
5 25 4.0 ml/min 90 10 
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Figure A.5: The gradient used for chromatogram of 2-6 using RP-HPLC with a C18 column is 
listed below. 
 
 
 
 
Table 1 HPLC Gradient for peptide 2-6 
# 
Time 
(minutes) 
Flow %A (H20) %B (ACN) 
0 0 4.0 ml/min 90 10 
1 5  4.0 ml/min 90 10 
2 8  4.0 ml/min 30 70 
3 18 4.0 ml/min 10 90 
4 20 4.0 ml/min 90 10 
5 25 4.0 ml/min 90 10 
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Figure A.6:The gradient used for chromatogram of 2-7 using RP-HPLC with a C18 column is 
listed below. 
 
Table 1 HPLC Gradient for peptide 2-7 
# 
Time 
(minutes) 
Flow %A (H20) %B (ACN) 
0 0 4.0 ml/min 90 10 
1 5  4.0 ml/min 90 10 
2 8  4.0 ml/min 30 70 
3 18 4.0 ml/min 10 90 
4 20 4.0 ml/min 90 10 
5 25 4.0 ml/min 90 10 
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Figure A.7: The gradient used for chromatogram of 2-8 using RP-HPLC with a C18 column is 
listed below. 
 
Table 1 HPLC Gradient for peptide 2-8 
# 
Time 
(minutes) 
Flow %A (H20) %B (ACN) 
0 0 4.0 ml/min 90 10 
1 5  4.0 ml/min 90 10 
2 8  4.0 ml/min 30 70 
3 18 4.0 ml/min 10 90 
4 20 4.0 ml/min 90 10 
5 25 4.0 ml/min 90 10 
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Figure A.8: The gradient used for chromatogram of 2-9 using RP-HPLC with a C18 column is 
listed below. 
 
Table 1 HPLC Gradient for peptide 2-9 
# 
Time 
(minutes) 
Flow %A (H20) %B (ACN) 
0 0 4.0 ml/min 90 10 
1 5  4.0 ml/min 90 10 
2 8  4.0 ml/min 30 70 
3 18 4.0 ml/min 10 90 
4 20 4.0 ml/min 90 10 
5 25 4.0 ml/min 90 10 
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Proton NMR of Compounds in Chapter 2   
 F
ig
u
re
 A
.2
5
. M
A
L
D
I-
T
O
F
 o
f 
p
ep
ti
d
e 
2
-1
 
  191   
 
  
F
ig
u
re
 A
.2
6
. M
A
L
D
I-
T
O
F
 o
f 
p
ep
ti
d
e 
2
-3
 
  192   
 
 
  
F
ig
u
re
 A
.2
7
. M
A
L
D
I-
T
O
F
 o
f 
p
ep
ti
d
e 
2
-4
 
  193   
 
F
ig
u
re
 A
.2
8
. M
A
L
D
I-
T
O
F
 o
f 
p
ep
ti
d
e 
2
-5
 
  194   
 
F
ig
u
re
 A
.2
9
. 1
H
N
M
R
 s
p
ec
tr
u
m
 f
o
r 
p
ep
ti
d
e 
2
-6
 
 
 
  195   
 
 
Fig
ur
e 
A.3
1. 
1H
NM
R 
spe
ctr
um 
for 
pe
pti
de 
2-8 
 
  
 
F
ig
u
re
 A
.3
0
. 1
H
N
M
R
 s
p
ec
tr
u
m
 f
o
r 
p
ep
ti
d
e 
2
-7
 
 
  196   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
F
ig
u
re
 A
.3
1
. 1
H
N
M
R
 s
p
ec
tr
u
m
 f
o
r 
p
ep
ti
d
e 
2
-8
 
 
 
  197   
 
  
 F
ig
u
re
 A
.3
2
. 1
H
N
M
R
 s
p
ec
tr
u
m
 f
o
r 
p
ep
ti
d
e 
2
-9
. 
 
  198   
 
HSQC NMR of Compounds in Chapter 2  
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SPR Sensograms of Compounds in Chapter 2  
 
 
Figure A.37. SPR sensogram of peptide 2-1 
 
 
 
 
 
 
Figure A.38. SPR sensogram of peptide 2-3 
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Figure A.39. SPR sensogram of peptide 2-4 
 
 
 
 
Figure A.40. SPR sensogram of peptide 2-5 
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Figure A.41. SPR sensogram of peptide 2-6 
 
 
 
 
 
 
Figure A.42. SPR sensogram of peptide 2-7 
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Figure A.43. SPR sensogram of peptide 2-8 
 
 
 
 
Figure A.44. SPR sensogram of peptide 2-9 
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Figure A.45. SPR sensogram of peptide cycloL1.1 
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APPENDIX B: Characterization of Chapter 3 Compounds 
 
HPLC of Compounds in Chapter 3  
 
Figure B.1: The gradient used for chromatogram of 3-3 using RP-HPLC with a C18 column is 
listed below. 
 
Table 1 HPLC Gradient for BODIPY 3-3 
# 
Time 
(minutes) 
Flow %A (H20) %B (ACN) 
0 0 4.0 ml/min 50 50 
1 5 4.0 ml/min 50 50 
2 8 4.0 ml/min 10 90 
3 18 4.0 ml/min 0 100 
4 20 4.0 ml/min 50 50 
5 25 4.0 ml/min 50 50 
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Figure B.2: The gradient used for chromatogram of 3-12 using RP-HPLC with a C18 column is 
listed below. 
 
Table 1 HPLC Gradient for Conjugate 3-12 
# 
Time 
(minutes) 
Flow %A (H20) %B (ACN) 
0 0 4.0 ml/min 50 50 
1 5 4.0 ml/min 50 50 
2 8 4.0 ml/min 10 90 
3 18 4.0 ml/min 0 100 
4 20 4.0 ml/min 50 50 
5 25 4.0 ml/min 50 50 
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Figure 
B.3: The gradient used for chromatogram of 3-13 using RP-HPLC with a C18 column is listed 
below. 
 
 
Table 1 HPLC Gradient for Conjugate 3-13 
# 
Time 
(minutes) 
Flow %A (H20) %B (ACN) 
0 0 4.0 ml/min 50 50 
1 5 4.0 ml/min 50 50 
2 8 4.0 ml/min 10 90 
3 18 4.0 ml/min 0 100 
4 20 4.0 ml/min 50 50 
5 25 4.0 ml/min 50 50 
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Figure B.4: The gradient used for chromatogram of 3-14 using RP-HPLC with a C18 column is 
listed below. 
 
 
 
Table 1 HPLC Gradient for Conjugate 3-14 
# 
Time 
(minutes) 
Flow %A (H20) %B (ACN) 
0 0 4.0 ml/min 50 50 
1 5 4.0 ml/min 50 50 
2 8 4.0 ml/min 10 90 
3 18 4.0 ml/min 0 100 
4 20 4.0 ml/min 50 50 
5 25 4.0 ml/min 50 50 
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MALDI of Compounds in Chapter 3  
 
 
 
 
 
Figure B.5. ESI spectrum of  BODIPY 3-3 . 
  212   
 
 
 
 
  
Figure B.6. ESI spectrum of  BODIPY 3-4 . 
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Figure B.7. MALDI-TOF spectrum of  conjugate 3-12 . 
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Figure B.8. MALDI spectrum of  conjugate 3-13 . 
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Figure B.9. MALDI spectrum conjugate  3-14 .
1129.69 
 
1129.69 
1130.72 
1131.72 
1132.92 
1128.70 
  216   
 
MALDI MSMS of Compounds in Chapter 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure B.10. MALDI MSMS spectrum of conjugate 3-12. 
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Figure B.11. MALDI MSMS spectrum of  conjugate 3-13. 
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Figure B.12. MALDI MSMS spectrum of  conjugate 3-14.
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Proton NMR of Compounds in Chapter 3  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure B.14. Proton NMR spectrum of  BODIPY 3-3 . 
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Figure B.15. Proton NMR spectrum of  BODIPY 3-4. 
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Figure B.16. Proton NMR spectrum of  conjugate 3-12. 
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Figure B.17. Proton NMR spectrum of  conjugate 3-13. 
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Figure B.18. Proton NMR spectrum of  conjugate 3-14 . 
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HSQC NMR of Compounds in Chapter 3  
  
Figure B.19. HSQC NMR spectrum of  conjugate 3-12 . 
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Figure B.20. HSQC NMR spectrum of  conjugate 3-13 . 
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Figure B.21. HSQC NMR spectrum of  conjugate 3-14. 
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Boron NMR of Compounds in Chapter 3  
  
Figure B.22. Boron NMR spectrum of  BODIPY 3-3. 
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Figure B.23. Boron NMR spectrum of  conjugate 3-12. 
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Figure B.24. Boron NMR spectrum of  conjugate 3-13. 
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Figure B.25. Boron NMR spectrum of  conjugate 3-14 
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APPENDIX C: Characterization of Chapter 4 Compounds 
HPLC of Compounds in Chapter 4  
 
Figure C.1.The gradient used for chromatogram of 4-8 using RP-HPLC with a C18 column is 
listed below. 
 
Table 1 HPLC Gradient for peptide 4-8 
# 
Time 
(minutes) 
Flow %A (H20) %B (ACN) 
0 0 4.0 ml/min 50 50 
1 5 4.0 ml/min 50 50 
2 8 4.0 ml/min 10 90 
3 18 4.0 ml/min 0 100 
4 20 4.0 ml/min 50 50 
5 25 4.0 ml/min 50 50 
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Figure C.2.The gradient used for chromatogram of 4-9 using RP-HPLC with a C18 column is 
listed below. 
 
 
Table 1 HPLC Gradient for peptide 4-9 
# 
Time 
(minutes) 
Flow %A (H20) %B (ACN) 
0 0 4.0 ml/min 50 50 
1 5 4.0 ml/min 50 50 
2 8 4.0 ml/min 10 90 
3 18 4.0 ml/min 0 100 
4 20 4.0 ml/min 50 50 
5 25 4.0 ml/min 50 50 
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MALDI of Compounds in Chapter 4  
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MALDI MSMS of Compounds in Chapter 4  
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Proton NMR of Compounds in Chapter 4  
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HSQC NMR of Compounds in Chapter 4 
 
 
 
 
 
 
 
 
Figure C.9. HSQC NMR of Conjugate of  4-8. 
Figure C.10. HSQC NMR of Conjugate of  4-9. 
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Boron NMR of Compounds in Chapter 4  
 
 
Figure C.11. Boron NMR of Conjugate of  4-8. 
Figure C.12. Boron NMR of Conjugate of  4-9. 
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APPENDIX D: Characterization of Chapter 5 Compounds 
 
MALDI of Compounds in Chapter 5  
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Figure D.1. MALDI spectrum of  BODIPY 5-2 . 
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Figure D.2. MALDI spectrum of  BODIPY 5-4. 
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Figure D.3. MALDI spectrum of conjugate 5-6. 
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Figure D.4 . MALDI spectrum of   conjguate 5-8. 
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Proton NMR of Compounds in Chapter 5  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure D.5. NMR spectrum of compound 5-1. 
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 Figure D.6. NMR spectrum of compound 5-2. 
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Figure D.7. NMR spectrum of compound 5-4. 
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Boron NMR of Compounds in Chapter 5  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure D.8. Boron NMR spectrum of compound 5-2. 
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Figure D.9. Boron NMR spectrum of compound 5-4. 
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